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ABSTRACT
The Effects of Immune Regulation and Dysregulation: Helper T cell Receptor Affinity,
Systemic Lupus Erythematosus and Cancer Risk, and Vaccine Hesitancy
Deborah K. Johnson
Department of Microbiology & Molecular Biology, BYU
Doctor of Philosophy
Helper T cells direct the immunological response to foreign pathogens and cancer. To become
activated, helper T cells must recognize unique peptides presented on major histocompatibility complex II
(pMHCII) by antigen presenting cells (APCs) with their T cell receptor (TCR). While much is known
about helper T cell activation signaling cascades and the subsequent roles of helper T cell subsets, the
initiation of helper T cell activation by the TCR and other co-receptors is less well understood.
Specifically, the affinity of the TCR for its pMHCII can change helper T cell subset fate, proliferation,
and alter the risk for activation induced cell death. High affinity TCRs are attractive targets for
immunotherapies, but little is known about how helper T cells respond to high affinity TCRs. Here we
describe high affinity TCR activation thresholds for both full length TCRs and chimeric antigen receptor
TCRs both with and without the presence of the coreceptor CD4 and propose a mechanism whereby CD4
inhibits T cell activation via Lck sequestration and a CD4-independent method.
Dysregulated helper T cells play critical roles in the development and perpetuation of systemic
lupus erythematosus (SLE), a systemic autoimmune disease that causes widespread inflammation and
organ damage throughout the body. Chronic inflammation in SLE affects the immune response to viruses
and the risk of developing cancer. However, in SLE patients, it is unclear if viruses initiate the
development of cancer directly or if the effects are non-interacting and concomitant. Here we describe
the interactions between SLE, viruses, and cancer risk revealing that viruses and SLE do interact to
increase the both the overall cancer risk and the risk for hematological malignancies.
Due to vaccine efficacy, vaccine preventable diseases (VPDs) are no longer commonly
experienced or understood by the public. Vaccines are a victim of their own success and according to the
World Health Organization (WHO), vaccine hesitancy (VH) is one of the top threats to global health. VH
is the refusal to accept vaccinations and the reasons for VH vary across time, place, and vaccine.
Refuting VH is difficult as directly confronting false assumptions can cause individuals to become more
entrenched in their position resulting in confirmation bias. Adults with VH attitudes are often motivated
by concerns over personal liberty, harm, independence, and body purity. Here we describe the results of a
VPD interview- and education-based intervention geared towards promoting positive vaccine attitudes for
young adults and demonstrate that education focused on VPDs is more effective than vaccine safety.

Keywords: Helper T cell, CD4+ T cell, CD4, T cell receptor (TCR), Lck, IL-2, T cell activation, TCR single
chain signaling (TCR-SCS), chimeric antigen receptor (CAR), full length TCR (flTCR), high affinity TCRs,
systemic lupus erythematosus (SLE), cancer-risk, viruses, vaccine hesitancy (VH), vaccine preventable
diseases (VPDs), vaccines
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CHAPTER 1: Immune Functions in Immunotherapy and Disease
1.1 Introduction: The role of helper T cells in immune responses
Helper T cells coordinate the immune system’s cellular and humoral response to cancer
or infectious disease [1-3]. Each helper T cell has a unique T cell receptor (TCR) which
recognizes a specific antigen, a short intracellular polypeptide presented on the major
histocompatibility complex II (MHCII) by antigen presenting cells (APC) such as macrophages,
dendritic cells, and B cells [2, 4, 5]. APCs phagocytose, digest and present foreign material,
including mutated cancer cell proteins. This ability to recognize foreign peptides or mutated
intracellular targets makes TCRs important assets for cancer and infectious disease
immunotherapies [3, 5, 6].
T cells originate in bone marrow as hematopoietic stem cells and mature in the thymus.
Similar to B cell antibodies, TCRs are stitched together from several multiple-copy gene
fragments to generate a staggering array of TCR diversity. The mature “classic” TCR is a
heterodimer comprised of an α and a β chain. Once naïve helper T cells display a mature TCR,
they undergo several rounds of selection [7]. To become a circulating peripheral helper T cell,
naïve helper T cells must be able to recognize MHCII while not binding too tightly to selfpeptide-MHCII [8]. If the naïve helper T cell fails either test it will undergo apoptosis, thus
reducing the likelihood of self-reactive helper T cells reaching the periphery and causing
autoimmunity [8]. As such, most peripheral helper T cells that make it through thymic selection
have affinity for foreign pMHC in the low range, with KD values of approximately 5-90 µM [9,
10].
Once activated, helper T cells play a critical role in coordinating immune system cell
function. To respond effectively to unique immunological threats such as viruses, bacteria, and
1

parasites, activated helper T cells can differentiate into distinct effector subtypes (Figure 1).
These subtypes modulate the immune response by secreting specific cytokines (intercellular
immune cell signaling proteins) to stimulate, as needed, innate immune system cells, B cells,
cytotoxic T cells, and non-immune cells, and can even suppress the immune reaction [11].
Helper T cell differentiation into subsets is controlled by a complex network of specific cytokine
signaling, TCR affinity for peptide, and transcription factors, followed by epigenetic
modifications [11].
Two helper T cell subsets, Th1 and Th2, can illustrate this point. Th1 cells organize the
immune response to intracellular pathogens by stimulating cytotoxic T cells, macrophages, and
microglial cells to kill infected body cells [12, 13]. Th2 cells assist the immune response to
extracellular parasites including helminths, by promoting the activation of antibody producing Bcells, and anti-parasite eosinophils, neutrophils, and mast cells [14]. A naïve helper T cell is
stimulated by foreign peptide-MHCII (pMHCII) while simultaneously receiving cytokine signals
from the APC. To stimulate Th1 development, APCs produce cytokines IL-12 and IFN-γ [15],
whereas cytokines IL-4 and IL-2 augment Th2 development [16]. These cytokines induce
activation of exclusive transcription factors in the T cell (Th1: T-bet and STAT4; Th2: STAT6,
GATA3, and STAT5) [17-25], which aid in the upregulation of genes required for each subset
function while actively inhibiting the activation of other subset functions [26]. Th1 and Th2
further differentiate and express their own cytokines, which promote recruitment and activation
of specific immune cell subsets. For example, Th1 produce IFN-γ and IL-2 which respectively
enhances phagocytic activities of macrophages and microglial cells, or promotes killer T cell
proliferation, cytotoxic capacities and memory responses [13, 27, 28]. Contrastingly, Th2
produce a milieu of cytokines (IL-4, IL-5, IL-9, IL-10, IL-13, IL-25 and amphiregulin) that can
2

promote mast cell responses [29], activate eosinophils [30], B cells, neutrophils and airway
epithelial cells [14], and inhibit Th1 responses [31-33]. This complex system of initial inputs
influencing downstream T cell behavior, allows for nuanced control of immune responses.

Figure 1. Naïve helper T cells become unique subsets
Naïve helper T cells receive unique signals upon activation to become unique helper T cell subsets with
distinct immune responses. Cytokines produced by APCs (far left arrows) influence the activation of
master transcription factors in T cells that determine helper T cell subset fate and T cell cytokine
production, which influences the immune response. This includes activating specific immune cell
subsets, influencing behavior of non-immune cells, or suppress the immune response (Treg) [34, 35].

3

1.1.1 TCR signaling
The most crucial step to downstream helper T cell activation behavior is TCR recognition
of pMHCII. TCR molecular architecture must relay information from the TCR-pMHCII
interface to internal signaling molecules that then recruit kinases to interact, initiate and sustain
activation signaling. TCR signaling is crucial throughout the life of the T cell including, T cell
development, survival, cell fate decisions [8], and T cell memory response [36-39]. Despite the
many functions of TCR signaling, the central T cell biology question: “How does TCR signaling
begin?” remains difficult to answer simply [40]. Downstream T cell responses are clearly
modulated by the strength of TCR signaling thru diverse factors including TCR-pMHC affinity,
antigen concentration, the quality of peptide presented, and co-stimulatory molecule signaling
combinations [36], however, it is poorly understood how each unique contribution interacts to
produce helper T cell responses.
To appreciate the complexity of TCR signaling, consider basic T cell activation as it is
currently understood (Figure 2). Each TCR signaling apparatus is a conglomerate of several
proteins including multiple CD3 subunits and coreceptor CD4 with its cytoplasmic partner Srcfamily tyrosine kinase Lck (Lck). TCRs cannot signal directly into the cell and rely on CD3
chains to transmit the transmembrane signal. Once the TCR recognizes its cognate pMHCII,
coreceptor CD4 recognizes MHCII and brings Lck into close proximity with the CD3 subunits.
Lck phosphorylates ITAMs (immunoreceptor tyrosine-based activation motif) on the cytosolic
tails of the CD3 subunits, which then serve as high affinity docking sites for SH2 domains of the
ZAP-70 kinase. Lck also phosphorylates and binds to ZAP-70, which induces full activation
[41]. The ZAP-70/Lck complex recruits LAT adaptor protein and the ZAP-70 substrates LAT
and SLP-76 [42]. Once LAT is phosphorylated by ZAP-70 it forms a signalosome with
4

signaling molecules (SLP-76, Grb2/Sos, PLCγ1, and Vav1) and regulates downstream effector
events required for T cell activation [43]. This downstream signaling is well understood (see Th1
and Th2 discussion), and includes activating MAPK and Ca+2 signaling pathways, cytoskeletal
reorganization, integrin activation, and the eventual activation and translocation to the nucleus of
critical transcription factors NFAT, NFκB, and AP-1 which control IL-2 expression [44, 45].
Other coreceptors like CD28, 4-1BB, and CD5, provide secondary costimulatory signals that
either promote the activation signal or prevent cell death from overstimulation [16] (Figure 2).
To explore further the nuances of helper T cell activation, the next section will discuss the
contributions of coreceptors CD4, CD28, and 4-1BB to promoting or attenuating activation
signals.

5

Figure 2. Helper T cell activation signaling cascade
Following TCR recognition of pMHC, CD4 relays signals to Lck located on its cytoplasmic tail. Lck
then starts a phosphorylation cascade (phosphate groups denoted by small yellow circles) which results in
actin polymerization, translocation of transcription factors and subsequent upregulation of activation
genes, and calcium influx from the intracellular (endoplasmic reticulum (ER)) and extracellular (CRAC
channel) sources [46]. CD28 is also phosphorylated by Lck and provides a secondary set of signals
through PIP2 to further promote calcium influx, cell survival, cytokine production, and upregulation of
other costimulatory receptors such as 4-1BB [47].

1.1.2 T cell coreceptors modulate TCR-activation signaling
Coreceptor CD4 is expressed on helper T cells and subsets of innate immune system cells
including natural killer cells, monocytes and macrophages [11]. CD4 expression is crucial
throughout the life of the T cell from thymic development and antigen recognition in the
periphery [48] to differentiation, migration and cytokine expression [49, 50]. As previously
mentioned, following colocalization to the TCR, CD4 signals via Lck which is associated with
6

the cytoplasmic tail of CD4 (Figure 2) [51, 52]. Lck phosphorylates ITAMs of the CD3 subunits
of the TCR complex, which then initiates other early signaling machinery of the T cell [51, 53].
Interestingly, unlike the cytotoxic T cell cognate receptor CD8, CD4 has negligible effect on
TCR-pMHCII interaction and affinity [54, 55]. However, CD4 enhances T cell sensitivity for
antigen by 30-100 fold [56-59], and reduces the number of antigenic peptides required for
sustained TCR signaling by 10-fold [60]. When CD4 is present, only 10 pMHCII are required
for full T cell activation [61]. In contrast, 30 pMHCII are required to activate helper T cells
when CD4 is blocked from the immunological synapse [61]. This is because when CD4 is not
recruited to the TCR-pMHC synapse it sequesters Lck away from the activation complex,
inhibiting the efficiency of the CD3-mediated activation phosphorylation cascade, which
attenuates T cell activation and IL-2 production [62]. Thus, delayed Lck accumulation reduces T
cell responsiveness [63]. Intriguingly, ligated CD4 can also send an inhibitory signal
independent of Lck, which attenuates IL-2 production, suggesting that CD4 ligation after
activation is inhibitory [64].
Coreceptor CD28 is activated by binding to CD80 or CD86 expressed by the activated
APC [65], and provides crucial co-stimulation to promote T cell proliferation, cytokine
production (via gene transcription and mRNA stability), cell survival and cellular metabolism
(Figure 2) [47]. CD28 early signals may stimulate the expression of other pro-activation
coreceptors such as ICOS, OX40, and 4-1BB, which sustain or prolong an immune response and
assist memory T cell formation [66]. CD28 ligation with CD80/86 leads to multifactorial
downstream effects. First, PI3K associates with CD28 then catalytically converts PIP2 to PIP3.
PIP3 becomes a docking site for PDK1 and its target Akt. Akt phosphorylates multiple proteins
that affect numerous cellular responses such as NFκB, which promotes cell survival and inhibits
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transcription factors responsible for cell cycle arrest [47]. Akt is also responsible for increasing
glucose uptake and glycolysis, critical for proliferation and cytokine expression, by upregulating
cell surface expression of insulin transporter Glut1 [67, 68]. Finally, Akt promotes IL-2
production by optimizing transcription of NFAT regulatory genes [69]. Other proteins that dock
to PIP3, such as Itk, enhance Ca2+ flux critical for activation [70]. Independent of Akt, CD28
induces arginine methylation, which is also correlated with IL-2 production, although a direct
connection is not currently known [47].
4-1BB is induced by CD28 activation. Like CD28, once activated by its APC ligand (41BBL), induces PI3K/Akt, NFκB, JNK, and p38 MAPK [66]. However, unlike CD28, 4-1BB
does not directly associate with protein kinases, instead signaling through TRAF family of
adaptor proteins [71]. The linking proteins between 4-1BB and the adaptor proteins are
unknown [71]. Whereas CD28 creates powerful initial activation signals, 4-1BB promotes T cell
longevity and establishment of memory by upregulating pro-survival genes surviving, Bcl-2,
Bcl-XL, and Bfl-1 while reducing the expression of pro-apoptotic Bim [72-74]. 4-1BB is more
active in killer T cells than helper T cells in vitro [75] and in vivo [76, 77].
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Figure 3. 4-1BB signaling cascade
Stimulatory co-receptor 4-1BB is upregulated by CD28 stimulation and promotes T cell longevity by
decreasing cell cycle regulator Bim, and upregulating cell proliferation and survival genes Bcl-2, Bcl-XL,
Bfl-1 and surviving [78].

1.1.3 TCR affinity effects on activation
In addition to coreceptor modulations, TCR signaling is affected by the affinity of the
TCR for its cognate pMHCII. These interactions maintain high sensitivity and specificity in
spite of their low KD values (~1-100 µM) and short half-lives (3-30s) [79-82]. TCR-pMHC
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interactions are intrinsically low affinity because high-affinity clones are selected against during
T cell development in the thymus, resulting in a self-tolerant population of T cells that can still
recognize and react to foreign pMHC [83] (Figure 4A). Interestingly, the mature T cell repertoire
is skewed towards T cells that are more highly reactive to self-antigen, indicating that T cells
with high affinity for self-antigen are better responders to infection [84]. While the lowestaffinity T cells can induce proliferation, cytokine production, and memory formation, higheraffinity T cells form the bulk of memory responses [84-86] (Figure 4B). Whether high or low
avidity T cells respond to an antigen best may be influenced by the amount of antigen, the mode
of antigen delivery, the kind of antigen presenting cell presenting the antigen, T cell subtype
competition, and the level of TCR expression and its ability to initiate a signaling cascade [87].
As previously discussed, T cell activation is initiated by the TCR-pMHC interaction,
followed by an ordered phosphorylation of ITAMs [88]. Conflicting activation models suggest
different roles for TCR-pMHC affinity from an optimal dwell time for a single pMHC which
facilitates serial interactions to a simpler model that suggests that longer half-lives increase
activation [89-91]. Efforts to find a single affinity parameter that is predictive of T cell
activation has been difficult [92-94], however, several recent studies of helper and killer T cells
report clearer correlations between T cell activation and 2D-acquired affinity and off-rates
compared to 3D-acquired kinetics [93, 95-97]. Using mathematical modeling of the current
affinity data, kinetic proofreading with limited signaling incorporates aspects of both the
occupancy and kinetic proofreading models and was the most predictive [98]. This model
assumes that TCR signaling is limited in response to pMHC stimulation and thus multiple TCRs
must be activated serially for functional T cell response, implying that high-affinity TCRs with
long dissociation times may have impaired signaling [98]. However, engineered TCRs with
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exceptionally long dissociation times have been shown to mediate sensitive T cell responses
[99].

Figure 4. TCR affinity during selection and periphery stimulation
A. Naïve helper T cells are selected in the thymus through TCR binding to self-pMHC. If naïve T cells
bind too tightly, they are negatively selected and die by apoptosis. Conversely, naïve T cells that bind too
weakly to self-pMHC die from neglect. Naïve helper T cells that are within an optimal window of
affinity for TCR-pMHC receive confirmatory signals and are released into the peripheral immune system
and secondary lymphoid organs (spleen, lymph nodes, etc) to await activation by foreign pMHC. T cells
that bind tightly to self-pMHC are likely to become regulatory T cells to prevent autoimmunity, and T
cells that bind less tightly to self-pMHC are fated to become effector T cells responding to foreign pMHC
[100]. B. T cell responses vary within the defined window of affinity. More is known about killer T cell
affinity responses than helper T cell affinity responses. Autoimmunity and T cell propensity for anergy
(stimulated cell death) increases as affinity for TCR-pMHC increases. T cell responsiveness increases as
TCR-pMHC affinity increases, however at a certain high affinity, T cell responsiveness decreases as high
affinity cells are prone to anergy from overstimulation.
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Because T cells have a naturally low affinity for antigen and function in an environment
where there are many copies of the TCR on the cell surface, their affinity is often best measured
through avidity, a multimeric measurement of TCR affinity. Both high-avidity MHCI and
MHCII-specific TCRs have some general and conflicting response trends. In some studies,
higher-avidity T cells responded more sensitively to antigen, produced more cytokines,
proliferated better than their lower-avidity counterparts, and were preferentially selected during
memory formation [85, 101-105]. Conversely, other studies have demonstrated that high-avidity
T cells can also be severely limited in their biological activity and have reduced peptide
specificity [82, 86, 91, 106, 107]. Thus, it is possible that during an immune response
intermediate or low affinity clones are advantageous while the highest affinity clones may be
impaired [82, 108].
Engineered high affinity TCRs have been used to tease out basic T cell functions such as
identifying important conserved pMHC contact residues and investigating the effects of altered
peptide ligands on activation, and have also been used as multimers to locate MHC-specific
peptides [109-113]. Additionally, high affinity TCRs are attractive immunotherapeutics because
TCRs can target intracellular antigens, respond robustly to as few as 1-10 cognate pMHC, and
utilize endogenous T cell signaling machinery [61, 114-116]. Naturally weak TCR-pMHC
interactions have short half-lives which are inadequate for successful therapeutic interactions
[117]. Furthermore, high affinity TCRs can be used to uncover potential safety concerns even if
lower affinity TCRs are used in clinical settings [118, 119]. Taking these considerations into
account, understanding the peptide specificity and functional avidity effects of high-affinity class
II specific TCRs is of great interest not only to better understand basic T cell biology, but also
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because of the potential use of high-affinity class II specific TCRs in diagnostics and
immunotherapies.
1.1.4 TCR signaling in T cell-based immunotherapies
Helper T cells are critical responders to infection and cancer [2]. Recent research
indicates that helper T cells are the most frequent responders to cancer antigens [120]. Tumor
environments suppress immune responders by secreting anti-inflammatory cytokines,
downregulating co-stimulatory molecules and encouraging the development of regulatory T cells
[121, 122]. Tumor-specific T cells may not mount a robust response towards cancerous cells
because the tumor microenvironment has numerous immunosuppressive factors; cancerous cells
also downregulate cell surface co-stimulatory and MHC proteins and upregulate co-inhibitory
proteins, all of which suppress T cell activation [123-127]. Helper T cells directly activate killer
T cells to eradicate tumors and are essential in generating a strong antitumor response alone or in
concert with killer T cells by promoting their activation, infiltration, persistence, and memory
formation (Figure 5) [128-133]. In one study, 70-95% of tumor-specific antigens elicited a
helper T cell response rather than a killer T cell response and were presented by MHC II
significantly better than non-immunogenic antigens [6].
A promising new molecular means of circumventing this suppressive environment is the
recent development of chimeric antigen receptors (CARs). CARs typically consist of antibody
binding domains specific for a cancer antigen connected to T cell signaling molecules such as
CD3, CD28, and 4-1BB. Transfection of CARs into T cells creates high affinity cancer-specific
effector cells [134]. This technology has had some spectacular results. In one study, 90% of
acute lymphoblastic leukemia patients achieved immediate remission and 67% of the patients
had sustained remission after six months [4]. Antibodies generally recognize extracellular
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antigens while TCRs can recognize intracellular antigens presented by MHC. Furthermore,
helper T cell TCR-CARs are advantageous because they can target low density antigens,
maintain polyfunctional responses, and persist in both helper and killer T cells [135]. CAR
immunotherapy can also be designed to use high affinity tumor-directed TCRs which are
truncated to the peptide recognition portions (Vα and Vβ) and fused to the intracellular signaling
proteins CD3 and CD28 to produce a single-chain TCR construct [136]. This prevents TCR
chain mispairing, takes advantage of TCR intracellular targeting, and conveys important
signaling advantages to combat cancer evasion strategies [135], [137]. As such, high affinity
TCRs are attractive targets for immunotherapy development. However, TCR selection in the
thymus results in deletion of high affinity TCRs and a natural mature T cell repertoire with low
TCR affinity [138]. Thus, the functional activity and peptide specificity of high affinity T cells
are unknown. Intriguingly, T cells with the greatest affinity for self-antigen make up the largest
and most active responders to infection. This pattern is seen in killer T cells, Treg cells, and
helper T cells [139-141]. This compellingly suggests that TCR self-antigen affinity is an
important determinant of T cell responsiveness to foreign or cancer pMHC.
To date, almost all clinical trials utilizing TCRs, except one, have focused on killer TCRs
that recognize pMHCI targets [142]. Mounting evidence suggests that helper TCRs targeting
pMHCII may be especially advantageous as they can contribute to indirect effects (activate
innate immune cells) and direct effects (cytotoxicity for MHCII positive tumors) on immune
response [143-145] and may be less toxic against overexpressed tumor associated antigens
(TAA) [146]. Additionally, because CD4 TCRs do not rely on CD4 for enhanced affinity, they
may function without CD8 or CD4 coreceptor in cell lines like cultured natural killer cell lines
[147].
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Figure 5. Helper T cells influence the immune response to cancer both directly and indirectly
Helper T cells can directly kill (arrow with cross) tumors expressing pMHCII (APC-derived cancers).
Indirectly, helper T cells can stimulate natural killer cells and phagocytic cells including neutrophils and
macrophages with cytokines to aggressively attack cancer cells. Helper T cell can also promote killer T
cell activity with IL-2 to attack MHCI+ cancer cells (most body cells).

1.1.5 Summary and questions (LLO118 and LLO56)
There remains much to learn about the role of TCR affinity and co-receptors on T cell
activation. The second chapter of this dissertation entitled “CD4 inhibits helper T cell activation
at lower affinity threshold for full-length T cell receptors than single chain signaling constructs”
asks the following questions: 1. How does helper TCR affinity contribute to helper T cell
activation? 2. What is the contribution of CD4 to high affinity TCR T cell activation? 3. Does
CD4-Lck sequestration affect high affinity TCR T cell activation? 4. How do high affinity TCRs
function in multiple CAR formats such as CD28, 4-1BB, and 3rd generation CARs?
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To answer these questions, we used helper T cell transgenic mouse lines, LLO56 and
LLO118, to generate a panel of low, intermediate, and high affinity TCRs. LLO56 and LLO118
recognize a Listeria monocytogenes peptide from protein listeriolysin O bound to MHCII
molecule I-Ab (I-Ab/LLO190-201 or I-Ab/LLO190-205) [148]. LLO118 and LLO56 TCRs differ by
15 amino acids and have the same affinity for I-Ab/LLO190-201 in vitro but respond very
differently in vivo. LLO118 has a better response to primary infection while LLO56 has a better
response to secondary infection [149]. Comparisons of LLO56 and LLO118 revealed that
LLO56 expresses higher levels of co-receptor CD5 than LLO118 suggesting that LLO56 binds
more strongly to self peptide:MHC [22]. The affinity clones were transfected into T cell
hybridomas with and without CD4 expression as full length TCRs and second and third
generation single chain TCR-CARs to explore the effects of affinity and co-receptor CD4 on
functional activity and binding specificity. While our system specifically targets an infectious
disease peptide, CAR T cell research is strongly informed by early work from HIV-1/AIDs
research [35-38]. Our system is the first known model to explore MHC II-specific TCR CARs
effects on infectious disease and may have direct cancer therapy applications.
1.2 Systemic lupus erythematosus
Systemic Lupus Erythematosus (SLE) afflicts 0.3-241/100,000 people globally [150,
151]. In the United States, SLE incidence is between 20-150 per 100,000 people, and has
increased prevalence in the southern US [152-155]. SLE is more common in urban than rural
areas [153, 156]. SLE prevalence and incidence is greatly influenced by race, ethnicity,
socioeconomic status and sex [157-159]. Compared to Caucasians, non-Caucasian populations
(Hispanics, African descendants, and Asians) develop SLE more frequently and have heightened
disease activity and damage accrual [160]. Additionally, improved survival was correlated with
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increased household income [161]. Furthermore, females are much more likely than males to
develop SLE [162, 163]. This sex ratio ranges from 2:1 [164] to 15:1 [165]. The 15-year
survival rate is approximately 80% [166] and this increased risk for all-cause mortality applies to
SLE patients with cancer [167-170].
Autoimmunity occurs when the immune system mistakes cellular markers or proteins for
foreign antigens and damages healthy tissues. A combination of immunologic, genetic, and
environmental factors (including infectious agents) are required to develop an autoimmune
disorder (Figure 6) [171]. While basic etiology of SLE cause and progression understanding has
improved over the last decade, the underlying triggering events and pathological mechanisms of
symptoms for SLE are still undefined. SLE is a complex autoimmune disease characterized by
defects in cellular apoptotic debris clearance, interferon (IFN) expression signature in peripheral
lymphocytes and autoantibodies produced by a breakdown of peripheral tolerance mechanisms
which produces irreversible damage to tissues and organs through cellular infiltration and local
activation of complement [172, 173]. These autoreactive polyclonal antibodies usually appear
years before disease clinical manifestation [174]. SLE chronically affects multiple body systems
including the skin, joints, central nervous system (CNS), lungs, kidneys, digestive tract, and
hemopoietic system [175]. Because SLE is systemic rather than localized, SLE patients exhibit a
wide diversity of symptoms which makes diagnosing SLE difficult. Symptoms include
cutaneous manifestations (malar rash), photosensitivity, discoid lesions, oral ulcers, joint pain
and swelling, serositis, renal disorders, hemolytic anemia, leukopenia, neuropsychiatric
disorders, and poor vascularization [176]. SLE flares and remission are unpredictable and no
reliable biomarkers have been identified for either phase [177].
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Figure 6. SLE triggers, immunological dysfunction, and systemic effects
SLE development is influenced by genetic, epigenetic, immunoregulatory, hormonal, and environmental
factors working sequentially or simultaneously on the immune system. These factors affect T cell
regulation leading to autoreactive or inflammatory T cells, inflammatory cytokine expression, and the
generation of autoantibodies and immune complexes. This dysregulation, in addition to local factors,
affect multiple organs, leading to systemic SLE damage [173].
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1.2.1 T cell dysregulation in SLE
SLE is a complex autoimmune disorder involving the dysregulation of multiple classes of
immune cells. However, this discussion will focus on T cells as an example of how small
changes to regulation and homeostasis can result in widespread immune dysregulation and tissue
damage. T cells have a critical role in SLE pathogenesis. T cells maintain SLE disease etiology
through the accumulation of autoreactive memory T cells [177], helping activate autoreactive B
cells [178], inappropriately homing lymphocytes to target tissues [173], and amplifying secretion
of pro-inflammatory cytokines (IL-17 and IL-10) [177, 179] while repressing IL-2 production
required to maintain normal T cell activation and proliferation (Figure 7) [180]. The causes of
these activities are intertwined and attributed to altered T cell subset ratios and intensified T cell
activation via aberrant TCR signaling, which will be discussed in depth in later sections.
SLE patient helper T cells fail to raise proper cytotoxic T cell responses to foreign
antigen due to altered T cell subset ratios and function, yet provide excessive help to autoreactive
B cells [177]. Helper T cells and double negative (DN) T cells (CD4-/CD8-/CD3+) are expanded
in SLE patients and provide costimulatory help to B cells that produce anti-dsDNA
autoantibodies [181]. Autoreactive B cells receive excessive costimulatory help via the CD40
pathway as SLE T cells have increased CD40L expression [182, 183]. CD40L expression is
upregulated by two mechanisms: 1) heightened TCR-CD3 engagement which increases
intracytoplasmic Ca2+ levels and NFAT activation via calcineurin [184, 185], and 2) CD40L is
hypomethylated in SLE T cells thereby increasing NFAT binding and CD40L transcription
(Figure 8) [184, 185].
SLE T cells also direct inappropriate lymphocyte homing to tissues. SLE T cells have
increased expression of CD44, a cell surface adhesion molecule which promotes cell migration
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(Figure 8) [186]. In SLE patients, T cells are present in inflamed tissues including the skin and
kidneys [173]. In the kidneys, T cell presence decreases the preservation of renal function [173]
and contributes to tissue damage via inflammation. T cell homing is also affected by increased
IL-17 production [179].
IL-17 is a potent pro-inflammatory cytokine that contributes to inflammation and
autoimmunity [187]. SLE patients have an increased proportion of IL-17 producing CD4 T cells
in their serum and peripheral blood [188]. IL-17 producing CD4 T cell subsets include Th17
[189] and DN T cells [179]. IL-17 levels correlate with the development of lupus-like nephritis
in several mouse models [190] and activate anti-dsDNA antibody production [191]. IL-17
increased transcription and IL-2 reduced transcription is regulated by the same transcription
factor (cAMP responsive element modulator α (CREMα)) which has increased expression in
SLE T cells [192]. CREMα transcription is influenced by hormones like estrogen, which
provides an interesting link to the increased SLE incidence in females [193]. In addition to
CREMα transcription regulation, IL-2 is also affected by transcription factors NF-κB and API,
which have decreased expression in SLE T cells (Figure 8) [194, 195]. Consequently, SLE T
cells have decreased IL-2 mRNA [180]. IL-2 is required for T cell activation, proliferation, and
activation induced cell death (AICD) needed to remove autoreactive cells [196]. IL-2 is also
critical for cell-mediated immunity against foreign agents, and promotes the survival and
maintenance of regulatory T cells (Tregs) [197]. Thus, the dysregulation of both IL-17 and IL-2
explains several facets of SLE disease etiology (Figure 7).
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Figure 7. SLE dysregulates T cell differentiation and cytokine production
SLE naïve helper T cell development is affected by cytokines produced by macrophages, neutrophils,
APCs, and B cells and decreased IL-2 production. This favors the development of Treg, Th17, Tfh, and DN
T cells, and promotes the production of inflammatory cytokines such as IL-17 and TNFα. Taken
together, these unbalanced signaling and cell subpopulations enhance B cell differentiation, autoantibody
and immune complex production, promoting organ damage. Small arrows indicate increased or
decreased cytokines or cell subsets in SLE compared to controls [198].

1.2.2 Altered T cell subsets in SLE
Peripheral blood T cell subpopulations are very complex and include effector, memory
and regulatory subtypes (Figure 1) [199]. SLE patients not only have unique ratios of some T
cell subsets, but the individual subsets function abnormally (Figure 2). These subsets include
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DN T cells, cytotoxic T cells, invariant natural killer T (NKT) cells, and multiple helper T cell
subsets including Th17, extrafollicular (Tfh), and Tregs.
DN T cells have an αβ TCR but lack CD4 or CD8 and may derive from inactivated,
exhausted, autoreactive or continuously stimulated CD8+ killer T cells [200]. DN T cells are
also seen in chronic infections [201, 202]. CD8 loss is mediated by CREMα, which also
enhances IL-17 production [203, 204]. Normally, DN T cells are immunosuppressive by antigen
competition and T cell killing by the Fas-FasL pathway or perforin/granzyme secretion [205,
206]. However, SLE DN T cells accumulate in the kidneys and produce IL-17, which enhances
the pathogenesis of kidney disease via inflammation [179]. Like DN T cells, killer T cells kill
problematic body cells by releasing perforin/granzymes to control infection, malignancy, and
autoreactive immunity. SLE patient killer T cells have dampened cytotoxic function, which
leads to an increased risk of infection and can trigger or exacerbate autoimmunity [207]. As
result, SLE patients are more prone to viral infections, which is the highest cause of death in SLE
patients [173].
Invariant NKT cells have an invariant TCR that recognizes certain glycolipid antigens
presented on a non-classical MHC (CD1-d) [208]. Invariant NKT cells produce cytokines, are
directly cytotoxic, and are implicated in autoimmune development [209]. SLE patients have
reduced numbers of NKT cells in peripheral blood, and fewer the NKT cells are correlated with
increased with disease activity [210]. These NKT cells also have impaired proliferation and
cytokine production capabilities [210, 211].
SLE patients have increased accumulation of effector and memory helper T cells, which
promote autoantibody production and tissue inflammation [212]. Aberrant expression of cell
surface and signaling molecules leads to increased TCR stimulation and circumvents peripheral
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tolerance mechanisms [177]. As previously stated, SLE effector helper T cells produce less IL-2
and more IL-17 than healthy controls [213]. This leads to a downregulation of Th1 and Treg cell
cytokines (IFNγ and TGFβ) and skews the population towards a Th17 subtype [214]. Increased
numbers of Th17 promote kidney disease and autoantibody production by kidney infiltration
[215, 216] and loss of B cell tolerance [217]. B cell activation is also promoted by Tfh cells.
SLE patients have significant increases of Tfh-like phenotype in their peripheral blood [218-221].
Tfh numbers correlate with plasmablast B cells and autoantibody titers, especially anti-DNA
antibodies [222]. Additional evidence supporting Tfh involvement in SLE etiology is that SLE
autoantibodies have undergone somatic hypermutation and are IgG isotype, indicating that the
autoantibody producing B cells were activated in a T cell dependent manner [178]. Interestingly,
Tfh differentiation is blocked by IL-2, which has reduced expression due to decreased Th1
differentiation. Reduced IL-2 production also effects Treg development [223]. Due to studies
using different markers, there are conflicting reports about how Treg numbers are affected by SLE
[224]. However, it is well documented that SLE Treg immune response control is dysregulated
[225]. Loss of Treg function exacerbates poor autoimmunity control in SLE patients.
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Figure 8. SLE T cells have altered TCR signaling apparatus and heightened signaling capabilities
Normal TCR signaling through CD3ζ and ZAP-70 [198]. In healthy naïve T cells, TCR are other
costimulatory molecules are resting in separate lipid rafts on the cell membrane. However, in SLE naïve
T cells, the lipid rafts are pre-aggregated leading to early and enhanced TCR signaling as measured by
calcium flux [177]. Signaling is also enhanced by the replacement of CD3ζ with FcRγ, which signals
through the Syk pathway. Other aberrant signaling pathways include activated pI3K-Akt-mTORC1
pathway, Rho associated protein kinase (ROCK), calcium/calmodulin kinase IC (CaMKIV), and protein
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phosphatase 2a (PP2A). Dysregulated signaling leads to demethylation and acetylation of critical
regulatory and cytokine genes, the increased production of B cell costimulation protein CD40L, enhanced
production of pro-inflammatory cytokine IL-17, and increases Tfh cell fate. SLE cells also have repressed
activation induced cell death (AICD), and impaired regulatory function. Pathways and arrows are
arbitrarily assigned a color for clarity [190].

1.2.3 Altered TCR signaling in SLE
SLE T cells have a unique signaling apparatus compared to healthy T cells. Unlike
healthy T cell where TCR/CD3ζ complex begins the activation cascade, in SLE, the CD3ζ is
replaced by the homologous Fc receptor common g subunit (FcRγ) chain (Figure 8). FcRγ relays
a many-fold stronger signal than CD3ζ/ZAP70 by recruiting spleen tyrosine kinase (Syk) [226].
This results in an early and heightened signaling event, which allows T cells to respond to low
avidity autoantigens [226]. Syk signaling also promotes other downstream pathways that affect
T cell signaling. For example, TLR2 expression is upregulated by the Syk pathway [227]
leading to increased NF-κB activation [228] and chromatin opening at the promoters of IL-17
[229]. Inhibiting Syk in both murine models and SLE patients corrects aberrant TCR signaling
by upregulating CD3ζ and normalizing IL-2 production, and may even reduce signs of
autoimmunity and organ pathology [177, 230]. Additional TCR activation machinery is
downregulated in SLE T cells including Lck [178, 222, 231, 232] and CD3ζ. CD3ζ expression is
decreased through multiple mechanisms including transcription [233], mRNA [234], alternative
splicing [235], proteasome degradation [236], caspase cleavage [237], and mTOR-dependent
degradation [238]. CD3ζ expression is inhibited by protein phosphatase 2A (PP2A) which also
increases FcRγ expression and CREMα [177], and hypomethylates genes associated with SLE
pathogenesis [239], thereby increasing IL-17 production [240].
Physical T cell characteristics also affect TCR activation signaling. In normal T cells,
TCR/CD3ζ complexes and associated signaling molecules are located in lipid rafts rich in
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sphingolipids, cholesterol, and GM1, uniformly distributed across the cell membrane [241]. In
SLE T cells, these lipid rafts are pre-clustered and aggregated, indicative of an activated state
(Figure 8) [241]. Naïve T cells with clustered lipid rafts have early and enhanced calcium flux
(Figure 8) [177]. Dissociating these rafts corrects TCR/CD3ζ mediated signaling [242, 243] and
delays disease onset [242].
T cell activation, differentiation and function, and cell death are regulated by reactive
oxygen intermediates (ROI) and ATP produced by the mitochondria. Mitochondrial
transmembrane potential is a critical regulator of ROI and ATP. In SLE T cells, anomalous,
persistent mitochondrial hyperpolarization, increases ROI production and depletes ATP causing
spontaneous apoptosis but decreases activation induced apoptosis (Figure 8) [177]. mTOR,
responsible for sensing mitochondrial membrane potential and activating downstream substrates,
is abnormally increased in SLE patient T cells [238]. In healthy T cells, mTOR regulates a wide
variety of cellular functions including growth, apoptosis, metabolism, actin reorganization and
ribosome biogenesis by integrating cues from the environment [244, 245]. Without mTOR,
helper T cells fail become effector T cells and skew towards Treg development [246]. Targeting
mTOR restores T cell activation, Ca2+ flux, and results in attenuated inflammation and clinical
improvement [247, 248]. Interestingly, anomalous activation of the PI3K/AKT/mTOR [212,
249] and CaMKIV [250] pathways is also responsible for the dysregulated balance between
effector cells and Treg cells.
1.2.4 SLE and viruses
While the exact etiology of SLE is unknown, infections may act as environmental
primers by inducing or promoting disease onset and exacerbating SLE in genetically predisposed
individuals [251]. Etiology is especially difficult to sift through, as the causative agent is usually
26

gone when SLE is diagnosed [171]. The cumulative effects of repeated infections may trigger
autoimmunity through a cross reactivity or bystander activation [252]. Cross-reactive T and B
cells are activated through “molecular mimicry” when a pathogenic antigen closely resembles a
human self-antigen [253]. Acute rheumatic fever is a common example of molecular mimicryinduced autoimmunity: immune responses against streptococcal M-protein inappropriately target
cardiac myosin and heart-derived peptides, thereby damaging the heart [254]. In bystander
activation, microbial products induce autoimmunity by “epitope spreading” or the enhanced
presentation of autoantigens by activated APCs leading to the expansion of dormant autoreactive
clones [171]. For example, elevated antibodies against Epstein-Barr virus (EBV) can lead to
anti-Ro antibodies that cause skin and joint symptoms in SLE [255].
Due to the dysregulation of T cell activation and differentiation, lupus patients have
increased susceptibility to certain viruses and higher viral loads [253, 256]. Specific viruses are
implicated for certain SLE symptoms and include: Coxsakie virus (2B protein and Ro
autoantigen) [257]; human parovirus B19 (induces short-lived low titers of autoantibodies)
[258]; Cytomegalovirus (anti-CMV IgM antibodies and CMV DNA are sometimes detected at
SLE onset) [259, 260]; human endogenous retroviruses (incite pathogenicity through molecular
mimicry and immune dysregulation) [261]; and hepatitis C virus (infection higher in SLE and
increases liver pathologies while decreasing cutaneous SLE features and anti-dsDNA antibodies)
[262].
SLE is especially associated with EBV. 99% of young SLE patients have EBV infections
compared to 70% of healthy controls [263]. EBV has a bidirectional effect: while SLE patients
have a dysregulated anti-EBV response and abnormal viral latency period, EBV can trigger
autoimmune processes [264]. EBV may cause defects in B cell tolerance checkpoints by
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inducing B cell activating factor (BAFF), a homeostatic cytokine that regulates innate and
adaptive immune responses [265]. As such, EBV infected B cells, acting as APCs, can
proliferate and express viral anti-apoptotic molecules, and then provide T cells at target organs
with survival signals via costimulation, thereby promoting chronic inflammation [266]. EBV
can also lead to an increased antibody response against viral antigens EBNA, VCA, and EA
[267]. Antibodies against EBV nuclear antigens may cross-react with host antigens Ro or Sm
[268]; anti-Ro antibodies are detected in SLE preclinical period [268].
1.2.5 SLE and cancer risk
Abnormal immune cell signaling and viral dysregulation may contribute to SLE-specific
cancer risk. However, there are conflicting reports whether malignancy is increased in SLE
patients [269, 270]. This may be because a significant proportion of SLE patients develop
cardiovascular or infectious disease complications at younger ages, thus do not reach an age
where malignancy would have a greater impact on mortality [271, 272]. Several investigators,
including large, multi-center studies demonstrate increased risk for specific types of cancer in
lupus patients (Figure 9) [273, 274]. The highest increased risk is for non-Hodgkins lymphoma,
where lupus patients have a 4.4-fold to 15-fold increased risk [275-278]. Lupus patients also had
increased risk for leukemia and cancers of the cervix, vulva, lung, liver [276], thyroid [279, 280],
and bladder [277]. Interestingly, breast and ovarian cancers seem to be less prevalent in lupus
patients [276, 281, 282].
For cancers with increased prevalence, the relative contributions of SLE and its
immunosuppressive treatments are unclear [283, 284]. For example, cyclophosphamide and long
term steroid use have been associated with increased cancer risk [277, 283]. However, cancer
diagnosis tend to occur shortly after SLE diagnosis, which suggests a strong role for disease
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effects over medication [285]. Free radicals produced by SLE systemic inflammation may also
promote cancer development [286]. Additionally, poorly controlled viral infections may
contribute to increased cancer risk for SLE patients. For example, SLE T cells response is
dysregulated by Epstein-Barr virus (EBV) [287, 288] and dysregulated immune response to EBV
can lead to increased Burkitt’s lymphoma [289]. EBV infection is also associated with nonHodgkin’s lymphoma and diffuse large B cell lymphoma [290, 291].
The increased risk for hematological cancer development in SLE has been associated
variably with increased disease activity [283, 292], cyclophosphamide and glucocorticoid use,
and EBV activity [274]. Lung malignancy risk is slightly elevated for SLE patients [276, 293,
294] and attributed to local inflammation of lung tissue [295]. In particular, SLE patients who
smoke or have pulmonary manifestations [296] have increased rates of lung cancer. In contrast,
SLE patients have a substantially decreased risk of breast cancer, which may be due to SLE
autoantibodies [297-299]. Cell penetrating anti-dsDNA autoantibodies inhibit DNA repair,
which is often mutated in BRCA2 breast cancers, thus may suppress breast cancer cells with
intrinsic defects in DNA-repair [298]. Additionally, SLE patients have decreased expression of
anti-apoptotic mediator heat shock protein 27 (HSP-27) that may suppress breast cancer
incidence by causing cancer dormancy [300] and increasing susceptibility to treatments [301].
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Figure 9. Factors that increase or decrease SLE patient cancer risk
Various environmental (including infectious disease), SLE immune dysregulation and treatment, and
lifestyle choices increase (red box) or decrease (green box) SLE patient cancer risk. SLE patients have
increased risk for some cancers (yellow box) and decreased risk for others (blue box) [302, 303].

1.2.6 Multiple sclerosis (MS) and cancer risk
EBV is also implicated in development of multiple sclerosis (MS) [304], a chronic
autoimmune inflammatory disease affecting the central nervous system [305]. Like SLE, T and
B cells generate autoantibodies that demyelinate nerve cells causing inflammation [306]. MS
causes fatigue, pain, restricted movement, coordination, and cognitive and visual problems [307].
Also like SLE, MS immunosuppressive treatment may exacerbate cancer development [308]. It
is unclear how MS affects overall cancer risk as studies have found MS patients have raised,
lowered, and similar cancer risk compared to the general population [309]. This confusion
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extends to breast cancer risk [309]. While MS patients have a decreased risk for ovarian and
prostate cancers, hematological cancers are consistently increased again suggesting that poor
viral control may lead to cancer development [310].
1.2.7 Lupus and cancer summary and questions
SLE is a complex systemic autoimmune disease created by inherent immune
dysregulation. In addition to the morbidities caused directly by SLE, immune dysregulation
promotes viral infections. It is unclear how these factors, together with SLE treatment,
individually promote specific malignancies. To tease apart these contributions, MS patient
cancer risk was also assessed.
Questions addressed include: do SLE patients have increased incidence of viruses,
including EBV? Does SLE status, overall viral incidence, or both together best explain overall
cancer incidence? Does SLE status, EBV or both together best explain increased SLE
hematological cancer incidence? And how does MS compare to SLE for all of these factors?
Can we tease apart SLE autoimmune contributions by looking at MS patients? Understanding
the root of cancer incidence in SLE could inform preventative treatment and promote longer
survival rates for SLE patients.
1.3 Vaccine hesitancy
Vaccines are one of the most successful infectious disease interventions [311, 312].
Vaccinations have led to the control or elimination of diseases that were once endemic, often
called “childhood diseases” or vaccine preventable diseases (VPDs) [311]. VPDs include
smallpox, polio, diphtheria, measles, and pertussis. Before vaccines, many more children
became severely ill or died from these diseases. The use of vaccines has successfully eradicated
smallpox worldwide and eliminated endemic poliomyelitis, measles, rubella, and congenital
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rubella syndrome from the Americas [312, 313]. Most developed countries have high rates of
childhood vaccination coverage, which suggests that vaccination is a widely accepted public
health measure [313]. However, as recent outbreaks of VPDs such as measles [314, 315],
poliomyelitis [316], and pertussis [317] suggest, national estimates of high uptake obscure
clusters of under-vaccinated individuals [318]. These outbreaks are mainly linked to undervaccinated or non-vaccinated communities [319].
In response to these outbreaks, in 2019, the World Health Organization (WHO) listed
vaccine hesitancy (VH) as one of its top ten threats to global health along with items like climate
change, limited primary care, and antibiotic resistance [320]. In 2012, the WHO’s Strategic
Advisory Group of Experts (SAGE) on Immunization defined VH as “delay in acceptance or
refusal of vaccination despite availability of vaccination services. VH is complex and context
specific, varying across time, place and vaccines. It is influenced by factors such as
complacency, convenience and confidence” [321]. While vaccines prevent approximately 2-3
million deaths globally every year, another 1.5 million deaths could be prevented yearly if
vaccines were administered in a timely manner to improve global coverage [320].
Many countries and communities have increasing numbers of individuals who are
delaying or refusing vaccinations [322-324]. VH is driven by a complex milieu of factors that
are specific to time, place, and vaccine. These issues include a host of sociodemographic factors,
cultural values, poor public health literacy or communication, public perception of risk, easy
access to conflicting information, and an increased distrust of experts [325-328]. Each country
has unique challenges. Where one country may have a religious group that distrusts porcine
components in vaccines, another country may associate immunizations with female infertility,
and yet another country may observe VH in people of high socio-economic status living in urban
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areas concerned about vaccine safety [324]. Public health officials are scrambling to respond
effectively to VH, yet interventions are not a one-size-fits all solution and must be tailored to
each situation.
1.3.1 What is vaccine hesitancy like in the United States?
To prevent disease outbreaks the WHO recommends at least 95% childhood vaccination
rate to sustain herd immunity [329]. In 2017, (the most up-to-date statistics available), only
70.4% of children aged 19-35 months had complete vaccination coverage in the United States.
Complete vaccination includes seven vaccines (11 diseases) and individual rates vary by vaccine:
Diphtheria/tetanus/pertussis (83.2%), polio (92.7%), measles/mumps/rubella (91.5%),
Haemophilus influenza type b (80.7%), hepatitis B (91.4%), chickenpox (91.0%), and
pneumococcal conjugate vaccine (82.4%) [330]. Overall vaccination rates have improved from
the early 2000s, however there are clear sociodemographic differences by economic and racial
groupings. For example, 74.2% of Caucasians at or above the poverty level compared to 64.0%
of Caucasians below the poverty level fully vaccinated their children [330]. This pattern was
repeated for African American (73.8% vs 61.7%) and Hispanic (71.7% and 61.8%) communities,
suggesting that availability, affordability, convenience or even education may delay vaccination
in lower income populations [330]. Interestingly, for individuals above the poverty line, the
racial divide noted in 2016 between Caucasians (74.6%), African Americans (64.4%) and
Hispanics (68.9%) vastly improved in 2017 where Caucasians (74.2%), African Americans
(73.8%), and Hispanics (71.7%) had roughly the same vaccine uptake [330]. Despite high
vaccine rates for individual vaccines, up to 1.3% of children in the US have not received a single
vaccine by 24 months [331]. This number is significantly higher than the 2001 rate of 0.3%
[331]. Even among parents who vaccinate and do not pursue exemptions, VH ideology is more
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common [331]. For example, in a survey of parents who vaccinated their children in Wisconsin,
US, 23.4% of parents believed that children get more shots than is good for them, 33.7%
believed that vaccines could overwhelm the immune system, and 34.2% supported non-medical
exemption laws that would allow unvaccinated children to attend school [332].
Due to the success of vaccines, many parents of young children in the US do not have
personal experiences with VPDs [333]. As such, it is easier for parents devalue the risk of VPDs
and increasingly perceive the health and safety risks of vaccinations to be the greater threat [334339]. This may partially explain the increase in the number of parents exempting children from
one or more vaccines [340]. For example, while only 12% of parents of children 17 years old or
younger reported refusing a vaccine, 54% of parents expressed concerns about vaccine safety
[341]. The concerns raised by VH parents fall into four broad categories: 1) vaccination may not
be effective, 2) safe, 3) or needed, or 4) that reasonable alternatives to vaccinations might be
available. More specifically, parents worry about whether vaccines will work; that vaccines
might cause permanent injury, including autism; whether loved ones are actually at risk for a
VPD; whether VPDs are actually dangerous; whether vaccines pose religious or moral issues;
and whether they can trust government officials and the pharmaceutical industry [331]. See
Table 1 for more detailed examples.
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Table 1. Detailed examples of concerns of VH parents from Smith, TC 2017 [342]
Examples of Specific VH Concerns
Vaccines are “toxic” and contain antifreeze, mercury, ether, aluminum, human aborted fetal
tissue, antibiotics, and other dangerous chemicals that can lead to autism and an assortment of
chronic health conditions. Slogan: “Green our Vaccines”.
Vaccines are a tool of “Big Pharma;” individuals who promote them are merely profiting off
of harm to children and/or paid off by pharmaceutical companies (“Pharma shills”).
A child’s immune system is too immature to handle vaccines; they are given “too many, too
soon” and the immune system becomes “overwhelmed,” leading to autism and an assortment
of chronic health conditions.
“Natural immunity is better;” most vaccine-preventable diseases are harmless to most children,
and natural exposure provides more long-lasting immunity. eg, “I had the chickenpox as a kid
and I was just fine.” Some individuals may also have the mistaken belief that all “natural”
infections confer life-long immunity, whereas all vaccine-derived immunity is short-lived.
Vaccines have never been tested in a true “vaccinated versus unvaccinated” study; the
vaccines in the current schedule have never been tested collectively.
Diseases declined on their own due to improved hygiene and sanitation; “vaccines didn’t save
us.”
Vaccines “shed” (can be transmitted by vaccinated individuals to others); therefore, cases of
vaccine-preventable diseases in the population are driven by the vaccinated, not the
unvaccinated.
Researchers have grouped parents into three categories: vaccine acceptors who follow
vaccination guidelines, fence sitters who have concerns about vaccines but give their children
some vaccines, and rejecters who reject all vaccines [343]. Vaccine fence sitters and rejecters
exhibit shared moral preferences for liberty (belief in individual rights) and harm (concern about
the wellbeing of others) [343]. In addition to these qualities, vaccine rejecters have a diminished
moral preference for authority (deference to those in positions of power) and a heightened moral
preference for purity (abhorrence of body impurities) [343]. Furthermore, vaccine opposition,
especially in vaccine rejection, may also stem from deep-rooted ideological beliefs [324, 344] or
conspiracist ideational tendencies [345]. Correcting vaccine misinformation can cause some to
become more entrenched in their position, resulting in conformational bias where parents hear
correct information but draw incorrect conclusions supporting their own ideology [346, 347].
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Thus, while corrections about vaccines can diminish, but not eliminate vaccine misinformation,
they can also reduce intention to vaccinate among certain groups [343, 346, 347].
1.3.2 Measles: A case study of consequences of vaccine hesitancy
In 2019, measles resurged by 30% globally and while the reasons for the resurgence are
complex, vaccine hesitancy is an important component [320]. In the US where measles was
declared eradicated in 2000 [348], there were 1249 reported measles cases, the highest number of
cases since 1992 [349]. These outbreaks often occurred in tight-knit communities with shared
belief systems discouraging vaccination; 89% of reported cases were unvaccinated or had
unknown vaccination status [349]. Every outbreak since 2000 was initiated by international
travelers acquiring measles abroad [350]. Assessment of the 2013 measles outbreak in New
York City, revealed that 78% of infected individuals were unvaccinated owing to parental refusal
or intentional delay [351]. The direct costs of this outbreak for the New York City Department of
Health and Mental Hygiene were high: $394,448 and 10,054 working hours [352]. This does not
account for indirect costs experienced throughout the community such as lost wages to care for a
sick child, individual family healthcare costs, and disrupted school attendance. Because measles
is so infectious (9 in 10 unvaccinated individuals exposed to the measles will catch the virus), the
latest studies suggest that effective herd immunity is only reached when >95% of the population
is vaccinated; however most countries don’t quite reach that level and are at or slightly above
90% coverage [353].
As demonstrated by the recent measles outbreaks, vaccine hesitancy poses health risks to
the general public and immunocompromised individuals and causes economic disruption. The
current SARS CoV2 outbreak has resulted in the worst level of unemployment since the great
depression (a 14.8% unemployment rate at the time of writing) and there is no vaccine available
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at this time. VPDs are controllable and therefore preventable disasters. Thus, it is of great
importance to find interventions that effectively resolve vaccine concerns and improve
vaccination rates in individual communities.
1.3.3 Vaccine hesitancy interventions
As VH is a serious threat to global health, research has focused on understanding the
underlying causes and then creating effective interventions. There are two main types of
interventions: 1) interventions that seek to correct erroneous misinformation, and 2) interventions
that focus on directing attention to other issues. Often effective interventions have elements of
both indirect and direct methods.
When deciding whether to vaccinate their children, parents deliberate between the
perceived risks associated with vaccinating and the risks of not vaccinating [354].
Unfortunately, countering erroneous vaccine myths by relaying correct information risks
repetition of the incorrect information leading to familiarization that may strengthen individuals’
memories for the false information [355, 356]. Furthermore, it is difficult to provide convincing
evidence of the absence of risk [357]. Thus, replacing an existing belief with an alternative
belief (indirect method) may be more effective than attempting to counter it directly [355].
Direct interventions operate on the assumption that access to vaccination information will
improve vaccination uptake. These interventions target improving access to vaccination
services, enhancing demand for vaccinations, and health care provider-based or system-based
interventions. There is strong evidence from numerous randomized controlled trials and quasiexperimental studies that show that these interventions have effectively improved vaccination
rates [358]. These interventions include standing orders; vaccination requirements for child care,
school, and college attendance; vaccination programs in schools or child care centers; reducing
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patient out-of-pocket costs; healthcare provider reminders, assessment, and feedback; and patient
reminder and recall systems. Health care provider recommendations have been shown to have a
strong impact on improving vaccine uptake [359-368].
An example of a direct intervention includes strong recommendations from a health care
provider can overcome VH more than soft recommendations [364, 369]. The type of
conversations healthcare providers have with their patients can have a significant impact on the
response of parents. In one study, parents of infants who were 19 months or younger had
encounters with their physicians that either used conversational language (“What are you
planning to do about the vaccines?”) or presumptive language (“We have to do some shots.”)
[370]. Parents who heard presumptive language from their physician were 17.5 times more
likely to accept vaccines than parents hearing conversational language [370]. Unfortunately,
parents of adolescents report hearing presumptive language less than 15% of the time [371]
while parents of infants report more than 70% of physician interactions involve presumptive
language [370].
In this next example, direct methods competed against indirect methods. In one study,
parents were randomly assigned to 1 of 4 web based interventions that ranged from direct
information explaining the lack of evidence that MMR causes autism, to indirect textual
information about the dangers of diseases prevented by MMR, to images of children who have
the disease, and finally to a dramatic narrative about an infant that almost died from measles
[347]. The material for each intervention was created by the Centers for Disease Control (CDC)
and Prevention. However, none of these interventions increased parental intent to vaccinate. As
suggested, directly confronting the MMR-autism link by citing an absence of data reduced the
misperceptions of the myth yet decreased the parental intent to vaccinate. Counterintuitively,
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images of sick children increased the belief of the vaccine-autism link while the narrative about
the sick infant increased belief that vaccines have serious side effects [347]. However, another
study refuted these findings using similar materials from the CDC. This study found that while
direct confrontation of vaccines myths (such as vaccines cause autism) did not improve parental
vaccine attitudes, focusing parental attention on the consequences of not vaccinating their
children improved vaccination [354]. Thus, interventions seeking to inform parents of the
dangers of VPDs have had mixed results. In these examples, direct interventions (confronting
the false vaccine-autism link) rarely improves vaccine rates, and indirect interventions (education
about VPDs) had opposing effects. The differences between these two studies may have been
the timing or application of the materials used.
As parents seem to remain VH even after introduction to information designed to reduce
vaccine misperception, children and adolescents may be important agents of change [347, 372].
As seen for other conditions such as asthma, hypertension, smoking, and weight/physical
activity, children can be important behavior change agents relaying information learned at school
to create child-led positive health changes in their homes [373-376]. Furthermore, teenagers and
children will eventually become future influencers and parents and make decisions for their own
families [377]. One way to educate children and parents is to involve teachers and doctors.
Teachers and doctors are generally considered credible and respected sources of information and
when they communicate directly with children and adolescents, they can enact highly effective
change [378-380]. In one study, VH parents reported that doctors who took time to establish a
trusting relationship and provide appropriate educational materials were the most effective at
changing the parents’ minds [381]. Thus, future VH interventions should consider including
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children and teenagers as important vectors of change in their homes, especially in conjunction
with healthcare providers and teachers who have creditability.
In conclusion, vaccines are the most effective public health intervention available for
VPDs and yet VH threatens the efficacy of vaccine success. While VH interventions can be
effective, they must be tailored to unique populations and beliefs. Reviews addressing the
effectiveness of interventions concur that few interventions were directly targeted to vaccine
hesitant individuals [382]. Furthermore, there is no strong evidence to recommend any specific
interventions [382, 383]. There are hints that multicomponent and dialogue-based interventions
were most effective, but that was compounded by the complexity of vaccine hesitancy and
limited evidence about intervention effectiveness currently available [382, 383]. It is important
to prioritize research to understand VH groups and to identify effective interventions that avoid
confirmation bias or solidification of false concepts regarding vaccine risk and effectiveness.
1.4 Summary of research chapters
Chapter 2 is a recently submitted manuscript where we explore the effects of TCRpMHCII affinity on T cell activation with and without CD4 signaling. We show that increased
TCR affinity is correlated with increased production of IL-2. IL-2 production is dependent on
the presence of CD4. While low affinity constructs are reliant on CD4-Lck signaling, high
affinity construct signaling is abrogated by CD4 expression. This mechanism relies on the
availability of Lck sequestered by the cytoplasmic tail of CD4. When CD4 is present for high
affinity TCRs, CD4 is not efficiently recruited to the immunological synapse and thus
sequestered Lck cannot begin the activation phosphorylation cascade. However, CD4 itself is
inhibitory for high affinity constructs. If the CD4 cytoplasmic domain is truncated and Lck is
free, there is still an inhibition signal from CD4 binding to MHCII. This pattern is shown for
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both flTCRs and TCR-SCS CAR constructs. However, the affinity threshold for this effect is
construct dependent: flTCRs demonstrate CD4 independent inhibition at intermediate affinity,
while TCR-SCS CARs show CD4-independent inhibition at high affinity. Thus, CD4-Lck,
TCR-pMHCII affinity, and construct design play crucial roles in helper TCR signaling and are
important considerations when designing immunotherapies.
Chapter 3 is a recently submitted manuscript detailing the interaction of systemic lupus
erythematosus (SLE) or multiple sclerosis (MS), viral infections and cancer. SLE and MS
patients have dysregulated immune function that results in abnormal cancer risk and viral
susceptibility. This is compounded by the fact that SLE and MS patients are generally treated
with immune suppression drugs. It is unclear whether the dysregulated immune conditions
found in SLE and MS patients independently lead to increased viral incidences and abnormal
cancer risk, or if the increased viral incidence leads to increased cancer risk. Using electronic
medical records from Vanderbilt University we used logistic regression to show that overall
cancer risk for SLE patients is similar to control populations, but somewhat raised for MS
patients, indicating that autoimmune disorders overall have unique underlying effects on cancer
surveillance. SLE and MS patients both had increased risk for virus infections overall. This
heightened risk extended to Epstein Barr virus (EBV) which is implicated in hematological
cancers. As expected, hematological cancer risk was raised for SLE and MS patients in the
presence of EBV, therefore hematological cancer increase is not solely due to the autoimmune
disorders. SLE patients had decreased risk for hormone-based cancers, including breast and
prostate cancers, which confirms previous findings. Overall, our results demonstrated that rather
than autoimmune disorders independently increasing the risk of cancer and viral incidence,
autoimmune disorders increased the risk of viral incidence and therefore viral-based cancer risk.
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Chapter 4 is a published research paper describing an interview- and education-based
intervention for vaccine hesitant college students. In 2019, the World Health Organization listed
vaccine hesitancy as one of the top ten threats to global health. Urban centers with large clusters
of vaccine-hesitant individuals are especially vulnerable to vaccine preventable disease (VPD)
outbreaks. In 2016-2017, Utah County ranked sixth nationally for the total number of
kindergartners that were under-vaccinated. To help combat this trend, we created an interviewbased intervention deployed in three classes on BYU campus including Bio 100 (non-science
students, vaccine discussion), MMBio 240 (science students, no vaccine discussion) and MMBio
261 (science students, vaccine discussion). Students were surveyed for their initial vaccine
attitude score (VAS), asked to interview a member of the community that had had either a VPD
or an autoimmune disorder, and surveyed again for their final VAS. We found that vaccine
hesitant students who completed VPD interviews had significantly increased VAS. However,
education had a greater effect when the course focused on diseases and immune function
(MMBio 261), and a negative-neutral effect when the course focused on vaccine safety (Bio
100). Thus, educating the public about the risks of VPDs, the function of the immune system,
and encouraging discussions with VPD-victims may promote vaccine uptake in the community.
Chapter 5 is the final chapter and summarizes the main findings for TCR-pMHCII
affinity and T cell activation, autoimmune disorders-virus link for cancer, and vaccine hesitancy
intervention. Future research plans to further investigate the mechanism for CD4-dependent
inhibition is discussed.
1.5 Summary of appendices
Appendix I includes two abstracts published in Journal of Immunology. The first abstract
covers work on high affinity T cells (chapter 2). The first abstract was created for a poster
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presentation at the annual conference of The American Association of Immunologists presented
by me in San Diego, CA in April 2019. The second abstract discusses work accomplished with
Dr. Claudia M. Tellez Freitas on CD5 co-receptor in T cell metabolism and cognitive behavior.
While I designed further behavioral, IgA, and metabolomics experiments for this project, another
graduate student will complete the work. The abstract was created for an oral and poster
presentation at the annual conference of The American Association of Immunologists presented
by Claudia in Austin, TX in May 2018.
Appendix II is a list of presentations presented during my PhD.
Lastly, Appendix III contains a compilation of the work I published during my PhD/
dissertation as both a first author and co-author.
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CHAPTER 2: CD4 Inhibits Helper T cell Activation at Lower Affinity Threshold for FullLength T Cell Receptors Than Single Chain Signaling Constructs
The content of this chapter was submitted May 2020. It is currently under-review.
Authors: Deborah K. Johnson, Wyatt Magoffin, Sheldon J. Myers, Jordan G. Finnell, John C.
Hancock, Taylor S. Orton, Stephen P. Persaud, Kenneth A. Christensen and K. Scott Weber. It
has been reformatted for this dissertation, but is otherwise unchanged.
Abstract
CD4+ T cells are crucial for effective repression and elimination of cancer cells. Despite
a paucity of CD4+ T cell receptor (TCR) clinical studies, CD4+ T cells are primed to become
important therapeutics as they help circumvent tumor antigen escape and guide multifactorial
immune responses. However, because CD8+ T cells directly kill tumor cells, most research has
focused on the attributes of CD8+ TCRs. Less is known about how TCR affinity and CD4
expression affect CD4+ T cell activation in full length TCR (flTCR) and TCR single chain
signaling (TCR-SCS) formats. Here we generated an affinity panel of TCRs from CD4+ T cells
and expressed them in flTCR and three TCR-SCS formats modeled after chimeric antigen
receptors (CARs) to understand the contributions of TCR-pMHCII affinity, TCR format, and
coreceptor CD4 interactions on CD4+ T cell activation. Strikingly, the coreceptor CD4 inhibited
intermediate and high affinity TCR-construct activation by Lck-dependent and -independent
mechanisms. These inhibition mechanisms had unique affinity thresholds dependent on the TCR
format. Intracellular construct formats affected the tetramer staining for each TCR as well as IL2 production. IL-2 production was promoted by increased TCR-pMHCII affinity and the flTCR
format. Thus, CD4+ T cell therapy development should consider TCR affinity, CD4 expression,
and construct format.
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2.1 Introduction
CD4+ T cells are critical for tumor elimination through both indirect and direct
mechanisms. Indirectly, CD4+ T cells target tumor cells by activating tumor-killing cells such as
CD8+ T cells, macrophages, B cells and natural killer cells [143-145, 384]. CD4+ T cells have
direct cytotoxic effects against tumor cells that express major histocompatibility complex II
(MHCII) [143-145, 384] and direct CD4+ T cell responses are less toxic to the patient than a
CD8+ T cell response, especially when responding to overexpressed tumor associated antigens
(TAA) [146]. The presence of tumor-specific CD4+ T cells is correlated with improved patient
survival following vaccination with cancer-associated peptides whether or not they are directly
involved in tumor suppression [385-387]. Furthermore, CD4+ T cells can sustain an immune
response when CD8+-specific antigens are lost which otherwise might result in tumor escape
[388]. Despite these clear benefits, only one published clinical study [142] focuses on the
immunotherapeutic benefits of CD4+ T cell receptors (TCRs) [142, 389].
CD4+ T cells are activated by interactions between the TCR and its cognate peptide
presented on MHCII (pMHCII) [390]. TCRs can detect a single amino acid change and
distinguish between self-proteins and mutated neoantigens [389], uniquely suiting TCR-based
therapies for specific tumor targeting. Furthermore, unlike antibody-based chimeric antigen
receptors (CARs), which are limited to extracellular targets, TCRs can target intracellular
antigens presented by MHC molecules [389]. To rationally design optimal targeting strategies, it
is essential to understand how the TCR:pMHC interaction impacts T cell responses. The
relationship between TCR affinity and T cell activation is complex, but in general, T cell
functional activity correlates with TCR binding affinity for pMHC [85, 99, 391-395]. However,
there are important nuances to this general theme. For example, tumor-associated antigens may
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be skewed towards lower-affinity clones due to thymic negative selection [83, 396], even the
lowest-affinity TCRs can induce T cell proliferation, cytokine production and memory formation
[84, 85]. On the other end of the spectrum, high affinity TCRs have been shown to enhance
immune responses in some cases [104] and attenuate responses in others [111, 138, 397-400],
with some reports showing evidence of an affinity threshold beyond which increased affinity
does not impact the magnitude of the response [394, 395]. An additional consideration is that
even when high-affinity TCRs are capable of heightened cytotoxicity and tumor control, these
TCRs may be predisposed to autoimmunity [401]. Thus, the optimal affinities for TCRs
engineered against tumor-specific peptides may lie within a low or intermediate affinity [91, 99,
397-399, 401-406]. As most affinity studies to date have focused on CD8+ TCRs, CD4+ T cell
affinity thresholds are less well characterized.
The role of the CD4 coreceptor is an important consideration when associating TCRpMHCII affinity to CD4+ T cell activation. CD4 binds to MHCII as part of the TCR complex and
contributes to proximal TCR signaling, proving especially critical for T cell function when
cognate pMHC ligands are limiting (<30 complexes) [407]. TCR signaling dependence on CD4
is affected by the quality of TCR:pMHCII interaction and thus unnecessary upon stimulation
with optimal ligands [408]. Thus, CD4 may be restricted to improving the TCR dwell time on
pMHCII for lower affinity interactions [409]. As CD4+ T cells can function without CD4 [147],
CD4 may not have as great of an effect on T cell activation as CD8, particularly with high
affinity TCRs.
To determine how TCR-pMHCII affinity and CD4 coreceptor interactions affect CD4+ T
cell activation, we examined activation of the CD4 transgenic murine T cells LLO118 and
LLO56 that are stimulated by the same Listeria monocytogenes epitope. These TCRs differ by
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15 amino acids and recognize the LLO190-205 peptide presented by the MHCII molecule I-Ab with
similar affinity [148, 410]. LLO118 has a more robust primary response and LLO56 has a more
robust secondary response, indicating that TCR affinity is not the only parameter affecting
activation in these cells. To examine the role of affinity in the activation responses of LLO56 and
LLO118, we engineered an affinity panel of CD4+ TCRs (ranging from 4 µM to 200 nM). After
characterizing their affinity and avidity, the activation characteristics of two low affinity clones,
two intermediate affinity clones, and one high affinity clone were examined in the full length
TCR (flTCR) format or in three TCR-SCS CAR formats (CD28- and 4-1BB-based second
generation CARs, and CD28/4-1BB third generation CAR). T cell receptor single-chain
signaling chimeric antigen receptors (TCR-SCS CARs) are an exciting potential therapeutic
option and as CD4+ T cells are potent responders to cancer, we sought to understand how CD4+
TCRs respond to a variety of affinities. TCR-SCSs constructs avoid mispairing with endogenous
TCR chains, which is an inherent risk for engineered flTCRs [411]. CARs also produce more
cytokines and are activated by higher antigen densities than flTCRs and may be more likely to
ignore healthy cells with low amounts of TAAs, which may improve clinical outcomes [114,
412, 413].
We found that increased TCR affinity promotes production of IL-2 regardless of flTCR
or TCR-SCS format. The flTCRs are more responsive to lower amounts of peptide stimulation,
and contrary to CD8+ TCR findings [62], produce more cytokine than TCR-SCSs. While there
are some observable trends dependent on second and third generation TCR-SCS CAR format,
IL-2 production varies depending on whether the TCRs were engineered from the LLO56 or
LLO118 TCRs. CD4 promotes the activation of low affinity flTCRs and scTCRs, but CD4 is
inhibitory in intermediate affinity flTCR and high affinity TCR-SCS CARs. The flTCR reaches
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CD4 inhibition at a lower affinity than TCR-SCSs, suggesting that flTCRs perceive a stronger
initial activation signal. These findings suggest that therapeutic CD4 TCR development should
consider construct features, TCR affinity, and coreceptor activation contributions when choosing
or engineering therapeutic TCRs and cell lines.
2.2 Materials and methods
2.2.1 Library construction
The scTCR constructs for LLO56 (residues 1-116) and LLO118 (residues 1-120)
(Invitrogen) consist of the mature Vβ domain, a 13-aa linker (DAKKDAAKKDDAS) [414],
followed by the mature Vα domain (LLO118 residues 1-112 or LLO56 residues 1-113), and an
N-terminal HA tag (PYDVPDYA). To display scTCRs on yeast, the constructs were placed in
pCT302 (NheI and BglII) (Addgene plasmid # 41845 ; http://n2t.net/addgene:41845 ;
RRID:Addgene_41845) [415]. Stability clones were selected from scTCR transcripts replicated
by error-prone PCR (Standard Taq, New England BioLabs, B9014S) [416]. Affinity libraries
were generated using site directed mutagenesis of 5 amino acids in the CDR3β region and
splicing by overlap extension (SOE) PCR [416, 417] using LLO118 and LLO56 specific primers
(Q5 High Fidelity DNA Polymerase, New England BioLabs M0491) (Supplemental Materials).
To generate yeast libraries, 150 mL cultures of growth phase EBY100 yeast were
collected and washed twice with 50 mL ice-cold water and once with ice-cold electroporation
buffer (1 M Sorbitol/1 mM CaCl2) then resuspended in 0.1 M LiAc/10 mM DTT and incubated
at 30°C and 225 rpm for 30 mins [418]. Cells were washed with 50 mL electroporation buffer,
resuspended in 200 µL electroporation buffer and aliquoted with digested pCT302 backbone
(NheI and BglII, 1,250 ng) and inserted (6,250 ng) into 0.2 mm gap cuvettes then electroporated
(2.5 kV and 25 µF). Cells were allowed to recover for 1 hr in 4 mL 1 M sorbitol:YPD media
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(1:1) and were resuspended in SD-CAA media and incubated for 2-3 days at 30°C before
quantification. Stability and affinity library sizes ranged from 1.1 x 107 to 1.9 x 109.
2.2.2 Stability clone selection
Libraries calculated to have at least 10 copies of each clone were placed in 5 mL SGCAA media for 36-48 hrs to induce scTCR expression [419]. To select stability clones, yeast
libraries were incubated with either 2 µg/mL anti-mouse TCR Vα2 or anti-mouse TCR Vβ2
phycoerythrin-conjugated antibodies (BioLegend, clone B20.1 and B20.6, respectively) in 5 mL
PBS 1% BSA for 2 hrs at 4°C, washed with 15 mL PBS 1% BSA and stained with 50 µL anti-PE
MicroBeads in 2 mL PBS 1% BSA (Millitenyi 130-048-801) for 20 min at 4°C. Labeled clones
expressing properly folded Vα or Vβ were positively selected in magnetic LS columns
(Millitenyi 130-042-401). Selected cells were grown in 3 mL SD-CAA media (48 hrs) before
induction in SG-CAA (36-48 hrs). Each library was subjected to three rounds of growth and
sorting, and the most stable clone identified via flow cytometry (BD Accuri C6). Stability clones
were used as templates for subsequent stability or affinity libraries.
2.2.3 Affinity clone selection
To select affinity clones, induced yeast libraries were incubated with tetramer (LLO190b
201/I-A )

(I-A(b)CC (NEKYAQAYPNVS), NIH 22201), and sorted like stability clones. To

isolate high affinity clones, libraries were exposed to an increasingly strict temperature and
incubation regimen. Initially, libraries were subjected to high concentrations of tetramer (13.0
µg/mL), high temperatures (37°C), and long incubation times (3 hrs), and in later rounds,
combinations of lower tetramer concentrations (3.25 µg/mL), lower temperatures (RT or 4°C),
and shorter incubation times (1 hr) were used to isolate the clones with highest affinity. Each
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library was column sorted three times. Isolated clones with increased tetramer binding were
identified via flow cytometry (BD Accuri C6).
2.2.4 Tetramer dissociation
Each affinity and stability clone KD was determined through tetramer dissociation [420].
Aliquots of 1x106 induced cells were stained with 100 µL of various concentrations of LLO190b
201/I-A

tetramer (0.152 nM to 12.16 nM) for 1.5 hrs at room temperature and quantified via flow

cytometry. Tetramer binding was assessed as MFI of positive population and normalized to the
highest recorded MFI using FlowJo. KD was defined as 50% maximum binding concentration
[420].
2.2.5 Tetramer decay
Half-life (t1/2) was determined by staining 3x106 cells of each affinity clone with 6.5
µg/mL of tetramer for 1.5 hrs at room temperature [103]. Samples were washed three times in
PBS 1% BSA to remove excess tetramer. Following an initial timepoint measurement, 90 µL of
0.1 µg/mL or 1 µg/mL anti-mouse MHC class II (I-A/I-E) (clone: M5/114.15.2, eBioscience)
was added and the decrease of tetramer binding was quantified at various time points (2, 5, 10,
15, 20, 30, 45, and 60 mins) by placing 10 µL of cells into 90 µL of buffer and running
immediately on the flow cytometer.
2.2.6 scTCR expression, refolding and purification
The following protocol was modified from Garcia et al. Briefly, scTCR constructs were
cloned into pET28a (Novagen) using NcoI and SacI restriction sites. Constructs were expressed
in BL21 T7 Express E. coli (New England Biolabs) and protein expression was induced for 4 hrs
(0.4 mM isopropyl β-D-thiogalactoside). Cells were lysed with 1 mg/mL lysozyme
(ThermoFisher Scientific), 5 mM MgCl2, 1 µL/mL DNase I (Promega), 1% Triton-X 100, and
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10 mM dithiothreitol followed by two rounds of sonification (Branson Digital Sonifer) for 1 min
at 0.5 sec alternations at 40% power. 50-200 mg of inclusion body slurry was dissolved in 1 mL
of 7M GnHCl and 10 mM beta-mercaptoethanol. 400 mL of 2 M GnHCl, 50 mM Tris-HCl,
2mM GSH, 0.2 mM GSSG and 0.1% NaAz were dripped into dissolved inclusion bodies for 2-4
hrs at 4°C. Then 2-2.5 L of 200 mM NaCl, 50 mM Tris-HCl, and 0.1% NaAz were dripped for
24 hrs (1.5 mL/min speed) at 4°C. Following an additional 24 hr spinning at 4°C, the refolded
TCR solution was vacuum filtered with 0.22 µm PES membranes (Olympus Plastics), and then
concentrated in an Amicon 8400 unit (Ultracel 10 kdal Ultrafiltration Discs) under 55psi N2.
Once the volume was reduced to 50-100 mL of refolded scTCRs, the samples were again filtered
with 0.45 µm CA-membrane and GF prefilter syringe filter and purified by FPLC (AKTAstart)
on a HisTrap column (GE Life Sciences). Purified scTCRs were concentrated using Amicon
centrifugal filters (Ultra 4 10k) and quantified by Pierce BCA Protein Assay kit (Thermo
Scientific).
2.2.7 Bio-layer interferometry (BLI)
BLI experiments were performed with an Octet RED96. Streptavidin (SA) biosensors
(FortéBio) were hydrated and equilibrated in 1x HEPES buffered saline (HBS, 50 mM HEPES,
150 mM NalCl, pH 7.2), 2mM CaCl2, 1 mM MgCl2, 1 mg/ml milk, 0.1% Tween, and 0.02%
NaN3. SA sensors were loaded with 2.0 µg/mL biotinylated LLO190-201/I-Ab monomer or
DQB187-101/I-Ab monomer to 1.0-2.0 nm. Loaded biosensors were equilibrated in assay buffer
until baseline was achieved. scTCR association was probed in wells with assay buffer (stability
clones 2 µM, 1 µM, 0.5 µM, 0.25 µM, 0.125 µM, 0.061 µM; affinity clones 800 nM, 400 nM,
200 nM, 100 nM, 50 nM, and 25 nM, or 20 nM, 10 nM, 5 nM, 2.5 nM, 1.25 nM, and 0.625 nM )
with a blank reference-subtraction well for 400-600 sec. Ideal concentration range spanned one
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log above and below the KD where possible; however, this range had to be optimized depending
on the sensitivity of the assay, and on the amount of protein available. Matching of sample and
baseline imidazole and milk concentrations (through serial dilution of sample buffer into baseline
wells) was critical for detection of scTCR binding. Blocking with bovine serum albumin
increased non-specific binding while milk efficiently blocked NSB. Dissociation was observed
in baseline assay buffer (600-1200 sec). Assays were run at 30°C with a plate shake speed of
1000 rpm.
Data was collected at 5 Hz, using 20-point signal averaging and analyzed using custom
kinetic analysis. Due to non-specific binding at the later stages of the association and
dissociation steps, KD was calculated by extracting and selecting the data points from the initial
association to determine kobs (2-100 sec depending on the affinity of the constructs), plotting
concentration vs rate, and then plotting those slopes against scTCR concentration and estimating
kassoc from the slope. kdissoc is the slope of concentration vs rate of the dissociation step data (2100 sec depending on the affinity of the constructs). KD was determined by dividing kdiss/kassoc
and t1/2=ln2/kD.
2.2.8 Cell culturing
All 58-/- T cell hybridoma cell lines were cultured in RPMI 1640, 10% FBS, 2g/L
NaHCO3 (23.8 mM), HEPES (4.2mM), L-glutamine (3.24 mM), 1% Penn-strep and split 1:5 or
1:10 every 2-3 days. Platinum Ecotrophic cells (Plat E) were cultured in DMEM, 10% FBS, 1%
pen-strep, 1 µg/mL puromycin and 10 µg/mL blasticidin and split 1:4 every other day.
2.2.9 Retroviral transduction of T cell hybridomas
Affinity mutations were cloned into four possible constructs: full length TCRs (flTCRs),
and three TCR-single chain signaling formats based on chimeric antigen receptor (CAR) formats
52

(second generation 4-1BB and CD28 CARs, and third generation 4-1BB/CD28 CAR). Inserts
were cloned into pMSCV-IRES-GFP II (pMIGII) (Addgene plasmid # 52107 ;
http://n2t.net/addgene:52107 ; RRID:Addgene_52107) using MfeI and XhoI (GenScript) [421].
All constructs were led by a Kozak sequence and either Vα2 signal peptide
(MDKILTASFLLLGLHLAGVSGQ) and an additional Vβ2 signal peptide
(MWQFCILCLCVLMASVATD) for flTCRs or high affinity M33 3rd gen CAR signal peptide
(MLLALLPVLGIHFVLRDAQA) for all scTCR CAR constructs [422]. flTCR constructs have a
P2A cleavage domain (GSGATNFSLLKQAGDVEENPG) [423] between Cα2 and Vβ2
domains.
Vectors were transfected into Plat E packaging cells grown overnight in 6-well plates
with TransIT-VirusGEN (Mirus, MIR 6703). 48 h later, 1 mL of viral supernatant was mixed
with 1 mL of 1x106 58-/- CD4- or 58-/- CD4+ cells in a 6-well plate and spinfected for 2 h at 30°C
at 1000 G (acceleration 6, brake 2). After 48h recovery, clones Vβ2, Vα2, and GFP+ expression
was checked by flow cytometry. Clones with under 85-90% GFP expression were sorted 1-3
times with magnetic LS columns (Miltenyi Biotec, 130-042-401) using 10 µL Vβ2-PE antibodies
and 10 µL anti-PE MicroBeads (Miltenyi Biotec, 130-048-801) per manufacturer specifications.
Clones were checked for TCR expression after each sort round. CD4T+ and CD4T+ Δbind [424]
were cloned into pMIGII (MfeI/XhoI) and retrovirally transfected into existing 58-/- CD4- flTCR
and TCR-SCS clones and sorted for >95% CD4 expression (CD4 PE-Cy7, GK1.5, Biolegend) by
flow sorting (BD FACSAria II). 25,000 cells were stained with respective antibodies or tetramer
for all affinity and stability measurements and measured with flow cytometry (BD Accuri).
2.2.10 T cell hybridoma peptide-specific activation and IL-2 measurement
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2.8 x 104 T cell hybridoma clones were incubated with 2.8 x 105 splenocytes (1:10)
isolated from BL6.C57 mice with varying amounts (10-8 M to 10-3 M) of peptide (LLO190-205,
GenScript) in 75 µL 58-/- media in 96 well plate for 24 hrs. IL-2 production was measured using
an IL-2 ELISA kit (KIT) and measured on a microplate reader. This study was approved and
carried out in accordance with principles of the Basel Declaration and recommendations of
Brigham Young University’s Institutional Animal Care and Use Committee (IACUC protocol
#18-0708).
2.2.11 Statistical analysis
Statistical analysis was performed via one-way ANOVA with Tukey’s multiple
comparison test (p < 0.05 was significant, no alpha adjustments required). Half-life (t1/2) was
determined by linear regression between time point 0 and the time point where no tetramer
binding was detected [103]. To determine the KD, we fit the data with a non-linear curve, based
on one site-specific binding kinetics [420]. EC50 was determined with Sigmoidal, 4PL, X is
log(concentration) least squares fit. Standard deviation is reported for each value. All analyses
were conducted in GraphPad Prism.
2.3 Results
2.3.1 Yeast displayed TCR panel has varied affinities
Murine transgenic helper T cells LLO56 and LLO118 bear TCRs, which recognize the
same naturally occurring Listeria monocytogenes peptide (LLO190-205) presented on MHCII (IAb). The LLO56 and LLO118 TCR bind cognate pMHC with similar affinity (27.4 µM and 28.3
µM, respectively), yet have unique primary and secondary responses to TCR stimulus
(summarized in Table 2) [148, 410]. To further elucidate the effects of TCR-pMHCII affinity on
CD4+ T cell activation, the variable regions of LLO56 and LLO118 (Figure 10A) were used as
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templates for generating a panel of single-chain TCRs (scTCRs) with low (wild type),
intermediate, and high affinities. scTCR libraries generated by random mutagenesis and
expressed via yeast surface display were selected for protein folding stability through magnetic
column sorting (Figure 10B). Vβ2 stability mutations were conserved between constructs while
Vα2 stability mutations clustered in known stability hotspots (Figure 11). To generate affinity
mutants, five amino acids in the stability mutants LLO56low and LLO118low complementarity
determining region 3 of the β chain (CDR3β) were mutated by site directed mutagenesis and
selected for improved binding affinity for LLO190-201/I-Ab tetramers by magnetic column sorting.
Increases in scTCR affinity cannot be explained by increases in scTCR expression, as HA and
TCRα and TCRβ antibody binding remained the same across each experiment (Figure 10B).
Additionally, none of the isolated stability or affinity mutants bound significantly to a non-target
peptide tetramer (DQB187-101/I-Ab), indicating that the increase in tetramer binding is due to
peptide-specific binding and not increased affinity for I-Ab alone (Figure 10C). Affinity mutant
LLO56int with four CDR3β mutations (Figure 1D) bound LLO190-201/I-Ab 1.5 log better than
stability mutant LLO56low (Figure 10B). Affinity mutant LLO118high bound to the LLO190-201/IAb tetramer 1.0-log better than affinity mutant LLO118int and 2.5-log better than stability mutant
LLO118low (Figure 10B). LLO118int had three CDR3β mutations and LLO118Ahigh had five
additional CDR3β mutations (Figure 10D). While LLO56int and LLO118high mutants were used
as templates for mutant libraries of the complementary determining region 3 of the α chain
(CDR3α), no further clones with increased-affinity for LLO190-201/I-Ab tetramer were isolated,
suggesting that CDR3β is primarily responsible for LLO190-201 peptide interactions for these
specific TCRs. It is important to note that the stability clones initially isolated from yeast
libraries relied on a frameshift mutation at the stop codon that added 19-amino acids from the
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yeast expression vector to the carboxy end of Vα2 (RSDNNSVDVTKSTLFPPYF). While
LLO56low and LLO56int successfully retained stability and affinity gains without the 19 amino
acids, several attempts to create new LLO118 stability and affinity clones without the additional
amino acids were unsuccessful. Therefore, the stabilizing 19 amino acids were maintained for
LLO118 clones. Other studies have utilized TCR formats that express constant domains in order
to maintain scTCR folding while adding additional affinity mutations to the TCRs, therefore this
observation was not unexpected [425-427].
Table 2. Summary of T cell responses of LLO56 and LLO118 to antigen adapted from Persaud
et al
Parameter
Primary response in vivo
Secondary response in vivo
Proliferation in response to peptide LLO190-205 in vitro
Proliferation in response to Listeria monocytogenes in vitro
Rate of apoptosis in vivo
IL-2 production in vitro
KD (uM) LLO190-205 (surface plasmon resonance)

LLO56
+
+++
+
+
+++
++

LLO118
+++
+
+
+
+
+

+

+

LLO118 and LLO56 differentially respond to activation by peptide LLO190-205. LLO118 and LLO56 have
similar proliferation responses to LLO190-205 in vitro, but in vivo LLO118 has a more robust primary
response while LLO56 has a more robust secondary response. LLO56 produces more IL-2 in vitro and
undergoes higher rates of apoptosis during the primary response than LLO118. Surface plasma resonance
measurements of LLO56 and LLO118 dissociation constants are 27.4 µM and 28.3 µM, respectively
[148, 410].
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Figure 10. LLO118 and LLO56 stability and affinity maturation by yeast display
(A) Schematic of single-chain TCR (scTCR) which includes TCR α and β variable domains (Vα and Vβ)
spliced from TCR constant domains and connected with a 13 amino acid linker. Aga-2 is the yeast
mating protein that displays the scTCR on yeast cell membrane. Each construct contains an HA tag for
antibody detection. (B) Wild type LLO118 and LLO56 were engineered for improved stability and
higher affinity by yeast surface display. Clones with stability mutations were selected for using
monoclonal anti-Vα or anti-Vβ antibodies. The surface displayed constructs were then selected for
improved affinity using the peptide MHC tetramer LLO190-201/I-Ab. Staining of wild type clones
LLO56WT and LLO118WT (first and fourth columns), stability clones LLO56low and LLO118low (second
and fifth columns), intermediate affinity clones LLO56int and LLO118int (third and sixth columns) and
high affinity clone LLO118high (seventh column) is shown. Stains include antibodies against the HA
epitope (first row), Vα2 (second row), and Vβ2 (third row), or LLO190-201/I-Ab pMHCII tetramer (fourth
row). Gray-filled histogram represents cells-only control. Histograms are representative of n > 3
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experiments. (C) Affinity clones were incubated with saturating amounts of non-target tetramer
(DQB187-101/I-Ab). Histograms compare cells only (black clear) with affinity clones (colored, shaded).
(D) Vβ2 CDR3 mutations that confer increases in affinity. CDR3β regions are hypervariable; therefore,
gaps mark the length of other known Vβ2 CDR3β regions. First round of affinity selection (light gray)
for all affinity clones while second round of affinity selection (dark gray) applies only to LLO118high.

Figure 11. LLO118 and LLO56 single-chain TCRs stabilizing mutations
Wild type templates (LLO118WT and LLO56WT) compared to stabilized single-chain TCR (scTCR)
templates (LLO118low and LLO56low). The original LLO56WT scTCR template included mutations of the
amino acid K42βG, H36αY and S74αT (highlighted gray) known to enhance surface display levels in
related TCRs [428]. Stability mutations selected by random mutagenesis and directed evolution are
marked in red. Boxed amino acids show joint LLO118low and LLO56low selection (K42βG and T93βA),
and mutations in another known stability hotspot (L45αI and I49αM) are unmarked. LLO118low
independently selected I115αK, and LLO56low selected T93βA and S9αT.
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The multivalent binding avidity of each clone was determined by LLO190-201/I-Ab
tetramer titration (150 pM-15.00 nM) (Figure 12A). Avidities ranged from the highest clone
LLO118high (7.30 nM), to intermediate avidity clones LLO56int (39.20 nM) and LLO118int (44.80
nM) (Figures 12A and 2B and Table 3). Stability clones LLO56low and LLO118low were
excluded from these analyses because binding was undetectable even at the highest
concentrations of LLO190-201/I-Ab tetramer (Figure 12B). Tetramer decay analysis determined
that the multivalent half-life for LLO118high (t½= 165 min, r2= 0.76) was 165-times longer than
LLO118int and LLO56int (t½= ~1 min each, r2= 0.97 each) suggesting that the increased avidity of
LLO118high is predominantly due to a lengthened off-rate (Figure 12C). A second round of
tetramer decay with lower levels of MHC inhibiting-antibody better resolved the half-lives of
LLO118int (t½=6.7 mins, r2= 0.97) and LLO56int (t½= 3.5 mins, r2= 0.98) (Figure 12D), indicating
that LLO118int has a longer dissociation rate than LLO56int. The resulting panel of TCRs
provides a range of tetramer avidities ranging from high to low (Figure 12E).
While tetramer avidity measurements may be more physiologically relevant as multiple
TCR-pMHCs interact simultaneously during T cell activation, TCR-pMHC affinity
measurements provide a standard measurement to compare between TCR systems. Therefore,
TCR:pMHC affinity was measured by bio-layer interferometry. Due to non-specific binding at
the later stages of the association and dissociation steps, the KD was calculated manually by
extracting the data from the early measurements; kobs slopes (Figure 12F) were plotted against
scTCR concentration (Figure 12G) and kassoc estimated from the slope. kdiss is the slope of
dissociation graphs (Figure 12H). KD was determined by dividing kdiss/kassoc. LLO118high (20.0 ±
13.9 nM) KD was 215-fold higher than LLO118low (4.3 ± 0.7 µM) (Table 3). Intriguingly, while
LLO118int and LLO56int avidity measurements were similar, their affinity measurements were
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markedly different (20-fold). LLO118int (1.3 ± 0.3 µM) was only 3-fold higher affinity than
LLO118low and LLO56int (66.2 ± 39.8 nM) was 43-fold higher than LLO56low (3.8 ± 1.3 µM)
(Table 3).

Figure 12. Avidity and affinity measurements of scTCRs
(A) To estimate avidity KD, affinity clones presented by yeast were incubated with various concentrations
of LLO190-201/I-Ab tetramer (1.52 nM-50 nM) and 50,000 events were collected via flow cytometry. Grey
dotted lines represent non-linear, one site-specific binding analysis of tetramer binding measurements
used to estimate KD for LLO56int (red), LLO118int (blue), and LLO118high (dark grey) (n=3 experiments).
(B) Percent of cells bound by tetramer for each affinity clone. LLO56low had significantly lower binding

60

than LLO56int (0.75 ± 0.3% to 12.6 ± 3.4%, p = 0.0193) while LLO118low (1.1 ± 0.5%) was significantly
lower than LLO118int (24.5 ± 2.9%) and LLO118high (43.3 ± 8.9%) (p < 0.0001 and p < 0.0001,
respectively) and LLO118int was significantly lower than LLO118high (p = 0.0004). To determine t1/2,
yeast displayed affinity clones were incubated with (C) 1 M and (D) 0.1 M LLO190-201/I-Ab tetramer.
Following an initial measurement, 1.0 µg/mL anti-mouse MHC class II (I-A, I-E) monoclonal antibody
was added and tetramer binding measured at each time point by flow cytometry. t1/2 was estimated as the
time it took to reach 50% MFI modeled by non-linear dissociation one phase exponential decay (dotted
light grey lines) (n=3 experiments). (E) A graphical depiction of range of affinity clones. To estimate
TCR affinity, scTCRs were secreted by E. coli, chemically refolded, and incubated with streptavidin
sensors loaded with biotinylated LLO190-201/I-Ab monomer using BLI. No binding was observed between
scTCRs and streptavidin biosensors in the absence of LLO190-201/I-Ab loading (n = 3-6 independent
measurements). (F) kobs is the linear slope of nm vs time. (G) kassoc is the linear slope of kobs vs scTCR
concentration. (H) kdiss is the exponential slope of dissociation nm vs time.

Table 3. Summary of Figure 12

LLO56 low

Tetramer (Avidity)
r2
KD
kassoc (M-1s-1)
18300 ± 7000

LLO56 int

1 0.97 39.2 ± 46.7 nM 0.82 27600 ± 3000

2

t1/2 (m) r

Bio-layer Interferometry (Affinity)
kdissoc (s-1)
0.053 ± 0.020

t1/2 (s)
14.5 ± 5.7

0.018 ± 0.0007 422.0 ± 163.1

KD
2.9 ± 0.7 µM
66.2 ± 39.8 nM

LLO118 low

10200 ± 1500

0.043 ± 0.004

16.1 ± 1.3

4.3 ± 0.7 µM

LLO118 int

1 0.97 44.8 ± 52.3 nM 0.96 20000 ± 1400

0.025 ± 0.007

28.8 ± 7.4

1.3 ± 0.3 µM

LLO118 high

165 0.76 7.33 ± 1.37 nM 0.87 73000 ± 8600

0.002 ± 0.0007 460.0 ± 176.8

20.0 +/- 13.9 nM

IL-2 production data interpretation broken down into base TCR (LLO56 or LLO118), construct, and
TCR-pMHCII affinity. “-“ indicates that the condition inhibits or does not promote IL-2 production,
“NA” indicates that effects on IL-2 production were “not appreciable”, and “+” indicates that the
condition promotes or least does not inhibit IL-2 production. Bolded interior boxes highlight the
phenotype shared by intermediate affinity flTCR and high affinity TCR-SCS clones.

2.3.2 Construct format impacts surface expression and pMHCII-affinity independently
To quantitatively assess the effects of TCR-pMHC affinity, CD4, and construct format on
helper T cell activation, TCR constructs were retrovirally transduced into murine T cell
hybridomas, 58-/- CD4- (CD4-) and 58-/- CD4+ (CD4+), which do not express endogenous TCRs.
LLO56low and LLO56int were placed in the three TCR-SCSs formats, and LLO56WT and
LLO56int were placed in flTCR constructs without stability mutations (Figures 13A and 13B).
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Because of the necessity of the additional 19 amino acids, LO118low, LLO118int, and LLO118high
affinity changes were not transferred to flTCR constructs. LLO118low, LLO118int, and
LLO118high were placed in three TCR-SCSs formats based on commonly used second and third
generation chimeric antigen receptor (CAR) formats (Figures 13A and 13B). The transduced
cell lines were sorted with anti-Vβ2 antibodies via magnetic column selection for >85% GFP+
and TCR expression (Figure 13C).
TCR stable surface expression varied by individual constructs. As assessed by Vβ2
expression, flTCR constructs were less stably expressed than all TCR-SCS constructs perhaps
due to CD3 subunit availability, while TCR-SCS CD28 constructs were the most stably
expressed format for both LLO56 and LLO118 constructs (Figure 13D). While most construct
expression was equitable between CD4- and CD4+ cell lines, TCR-SCS 4-1BB constructs had the
most expression variability between constructs as CD4 expression destabilized LLO118low and
LLO118int TCR-SCS 4-1BB expression (p = 0.0018 and p = 0.0429, respectively) (Figure 13D).
CD4- LLO118high 4-1BB constructs were less stable than CD4- LLO118low 4-1BB and LLO118int
4-1BB (p = 0.0030 and p = 0.0002, respectively) (Figure 13D). CD4+ LLO118high 4-1BB was
also less stable than either LLO118low or LLO118int (p = 0.0285 and p = 0.0493) (Figure 13D).
Overall CD4 expression did not significantly destabilize 3rd gen constructs except LLO118low (p
= 0.0401) and LLO56int where CD4 stabilized VB2 expression (p = 0.0109) (Figure 13D).
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Figure 13. TCR-SCS and flTCRs are stably expressed in CD4- and CD4+ T cell hybridomas
(A) Diagrams depicting the flTCR formats and three TCR-SCS formats in the cell membrane. All TCRSCS constructs have signaling coreceptor CD3 in addition to the signaling domains of coreceptors CD28
and/or 4-1BB. (B) TCR constructs are produced from a bicistronic IRES-GFP vector. In addition to the
P2A cleavage domain, TCR-SCS formats rely on TCR M33 signal peptide [429], whereas the flTCR has
dedicated signal peptides for α2 and β2 to increase localization of both chains to the surface. The CD8
hinge acts as an intermembrane domain. (C) An example of TCR-SCS expression in CD4- (top) and
CD4+ (bottom) T cell hybridoma lines after magnetic column sorting with anti-Vβ2 monoclonal
antibodies (LLO118high TCR-SCS CD28). Initial retroviral transfections ranged from 11% to 85%
efficiency. Grey peaks in GFP histograms represent a GFP- cells-only control. GFP+ cells were gated for
CD4 expression and Vα2 and Vβ2 expression. Representative of n=3 measurements of 20,000 cells via
flow cytometry. (D) Mean fluorescent intensity (MFI) of Vβ2 was used as a proxy for stable expression
of constructs. Constructs were expressed in CD4- (solid bars) and CD4+ (hatched bars) T cell
hybridomas. Representative of n=3 measurements of 20,000 cells via flow cytometry.

Tetramer titrations were used to approximate the avidity of each flTCR or TCR-SCS
construct. Intriguingly, the intracellular format strongly influenced the avidity of each
intermediate and high affinity TCR construct (Figure 14A). There is no clear link across all
clones between stable Vβ2 expression and construct avidity, although the most stable
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constructs—TCR-SCS CD28—did have the highest apparent avidity (LLO56int and LLO118high)
(Figure 14A). Overall, CD4 expression (dotted lines) did not affect the avidity of the constructs,
excepting LLO118int and LLO118high 3rd gen constructs where CD4 lessened and heightened
avidity, respectively (Figure 14A). The MFI measured for each clone at 10-8 M (a non-saturated
concentration) were used to compare avidity differences between affinity clones. LLO56 4-1BB,
3rd gen and flTCR constructs had no significant differences between LLO56low and LLO56int
(Figure 14B). This may be due to the small affinity differences between LLO56low and LLO56int
as measured in tetramer and bio-layer interferometry assays. However, LLO118 3rd gen
constructs also did not show affinity-dependent avidity changes, thus intracellular signaling
domains may also affect the avidity of extracellular scTCRs. There were significant avidity
differences for LLO118 4-1BB clones; CD4- LLO118high 4-1BB had significantly better avidity
than its cognate CD4+ pairing (p = 0.0004), and was also significantly higher than CD4LLO118low and LLO118int 4-1BB (p = 0.0003 and p = 0.0092, respectively) (Figure 14B).
Additionally, TCR-SCS CD28 constructs for both LLO56 and LLO118, which are the most
stably expressed constructs (Figure 13D), showed increased MFI by increasing TCR affinity
(Figure 4B). LLO56int CD28 had significantly greater avidity than LLO56low CD28 (CD4- p =
0.0122 and CD4+ p= 0.0086), as did LLO118high CD28 compared to LLO118low (CD4- p =
0.0129 and CD4+ p= 0.0113) (Figure 14B). Taken together, while there is no systematic
correlation, this data suggests that construct stability may influence avidity measurements, as
CD28 clones had the highest stability and avidity, and confirms that generally, CD4 does not
affect perceived avidity.

64

Figure 14. TCR-pMHCII avidity is affected by construct format
(A) flTCR or TCR-SCS expressing cell lines were incubated with varying amounts of LLO190-201/IAb tetramer (10-7 M to 10-12 M) at room temperature for 2 hrs. Each TCR-format pair expressed in CD4cell lines (solid lines) and CD4+ cell lines (dotted lines) have similar affinities, whereas each unique
construct format alters avidity of a single TCR. Representative of 3 independent measurements of 20,000
cells via flow cytometry. (B) Tetramer MFI measurements of 10-8 M separated by TCR and format where
CD4- cell lines (solid bars) and CD4+ cell lines (hashed bars) are paired.
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2.3.3 CD4 inhibits high affinity TCR IL-2 production
To assess the effects of TCR-pMHCII affinity, CD4 expression, and format on T cell
activation we measured IL-2 expression in response to increasing agonist peptide concentrations.
As anticipated, LLO56low flTCR IL-2 production improved with CD4 expression, but CD4
expression unexpectedly reduced IL-2 production for LLO56int flTCR (Figure 15A). Despite the
inconsistent role of CD4, flTCRs produced significantly more IL-2 at all affinity levels (Figure
15A) and were at least 1-log fold more sensitive to peptide than all TCR-SCSs (Figures 15B-D).
IL-2 production for CD4- clones rose with increased TCR affinity for most constructs except 3rd
gen constructs; LLO56int 3rd gen failed to produce more cytokines than LLO56low 3rd gen (Figure
15B) and LLO118high 3rd gen that produced less IL-2 than LLO118int 3rd gen (Figure 15C). This
pattern of uneven gains across affinity and base TCR was also observed for 4-1BB constructs
(Figures 15D and 15E); while LLO56 4-1BB did see gains across affinity (Figure 15D), LLO118
4-1BB constructs had limited affinity gains across the affinity gradient (Figure 15E). CD4LLO56int CD28 and CD4- LL0118high CD28 produced more IL-2 than other TCR-SCS constructs
which suggested that their heightened stable expression may promote IL-2 production (Figure
15F and 15G).

66

Figure 15. CD4 inhibits IL-2 production of intermediate and high affinity TCRs
CD4- (solid lines) and CD4+ (dotted lines) T cell hybridoma cell lines were incubated with various
concentrations of LLO190-201 peptide (10-8 M to 10-3 M) presented by BL6/C57 splenocytes for 24 hrs. IL2 production was measured by ELISA. Each sample was normalized by subtracting baseline IL-2
production from T cell hybridoma/splenocytes controls incubated without peptide. (A) LLO56 flTCRs,
(B) LLO56 3rd gen SCS-TCRs, (C) LLO118 3rd gen SCS TCRs, (D) LLO56 4-1BB SCS-TCRs, (E)
LLO118 4-1BB SCS-TCRs, (F) LLO56 CD28 SCS-TCRs, and (G) LLO118 CD28 SCS-TCRs. ELISAs
run n=3 times.

While CD4 promoted the activation of all low affinity clones, it unexpectedly suppressed
IL-2 production for all intermediate and high affinity constructs (Figure 15). The magnitude of
IL-2 suppression is greatly dependent on whether the construct was a flTCR or TCR-SCS
construct. For example, while LLO56low flTCR IL-2 production was assisted by CD4
expression, LLO56int flTCR IL-2 production was reduced 2.2-fold (p = 0.0707) at 10-3 M peptide
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stimulation (Figure 16). In contrast, only one TCR-SCS had such a mild IL-2 reduction. CD4+
LL056int 4-1BB IL-2 production was reduced by 2.5-fold (p = 0.1551) (Figure 16). The IL-2
production for the other intermediate and high affinity TCR-SCS constructs was intermediately
reduced for LLO56int CD28 (6.4-fold, p = 0.0104), and severely reduced for LLO118int 3rd gen
(28.1-fold, p = 0.0004), LLO118int CD28 (21.2-fold, p = 0.0400), LLO118high 3rd gen (16.5-fold,
p = 0.0051) and LLO118high CD28 (25.9-fold, p < 0.0001) (Figure 16). Peptide sensitivity,
defined as the lowest concentration where IL-2 response exceeds baseline IL-2 production, was
equitable between CD4- and CD4+ for constructs LLO56int flTCR and LLO56int 4-1BB (Figure
15A and 15D), but delayed 1-log fold for LL056int CD28 and 2-log fold for all LLO118int and
LLO118high constructs (Figure 15C and 15E-G). This suggests that CD4 reduced peptide
sensitivity for most TCR-SCS constructs, possibly in a TCR-dependent manner.
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Figure 16. Comparison of IL-2 production at 10-3 M peptide stimulation
Analysis of levels of IL-2 production from Fig. 5 at 10-3 M peptide stimulation. IL-2 production between
58-/-CD4- affinity clones was significantly different for LLO56low and LLO56int 4-1BB (p = 0.0211),
LLO56low and LLO56int CD28 (p = 0.0039) and LLO56low and LLO56int flTCR (p = 0.0033),
LLO118low and LLO118int 3rd gen (p = 0.0006), LLO118low and LLO118high 3rd gen (p = 0.0070),
LLO118low and LLO118int 4-1BB (p = 0.0441), LLO118low and LLO118high 4-1BB (p = 0.0115),
LLO118low and LLO118int CD28 (p = 0.0489), LLO118low and LLO118high CD28 (p < 0.0001), and
LLO118int and LLO118high CD28 (p < 0.0001).

2.3.4 Lck sequestration by CD4 inhibits some TCR IL-2 production
Lck is an early proximal signaling kinase that colocalizes to the cytoplasmic domain of
CD4 [51, 52]. If Lck is poorly recruited to the TCR-pMHCII synapse, then T cell activation may
be diminished [62]. We hypothesized that our high affinity clones may poorly recruit CD4-Lck
to the immunological synapse, decreasing activation, and therefore reducing IL-2 production as
observed in CD4+ intermediate and high affinity clones. To parse out the potential contributions
of CD4-Lck sequestration, CD4-MHCII interactions, and any CD4-dependent inhibition, we
expressed a selection of our flTCR and TCR-SCS clones in four 58-/- T cell hybridoma lines [62,
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424]. LLO56 TCR-SCS 3rd gen and LLO118 TCR SCS 4-1BB clones were dropped due to their
poor performance in the first IL-2 tests. The 58-/- CD4- T cell hybridoma cell line (CD4-) lack
CD4, which allows Lck to interact freely with the TCR-pMHCII complex and nullifies CD4MHCII interactions (Figure 17A). The 58-/- CD4+ T cell hybridoma cell line (CD4+) has wild
type CD4 which sequesters Lck to its cytoplasmic tail and binds to MHCII (Figure 17B). 58-/CD4T+ T cell hybridoma line (CD4T+) is truncated C-terminally (maintains amino acids 1-421)
which allow Lck to colocalize but not bind to CD4 while CD4 still binds to MHCII (Figure 17C)
[424, 430]. Finally, 58-/- CD4T+ Δbind (CD4T+ Δbind) frees Lck and is mutated to prevent CD4
binding to MHCII by altering residues 68–73 from KGVLIR to DGDSDS (Figure 17D) [424].
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Figure 17. IL-2 production of intermediate and high affinity clones is influenced by Lck
sequestration, CD4-MHCII interaction and CD4 presence
(A) CD4- has no CD4 and Lck is spread ubiquitously along the inner membrane. (B) CD4+: wild type
CD4 interacts with MHCII and the majority of Lck is sequestered to the cytoplasmic tail of CD4. (C)
CD4T+: mutant CD4T interacts with MHCII but does not sequester Lck which is spread ubiquitously
along the inner membrane. (D) CD4T+ Δ bind: mutant CD4T Δ bind does not bind to MHCII nor Lck
(Lck is not sequestered to the cytoplasmic tail of CD4). LLO56 low (E) or intermediate (F) flTCRs
expressed in various T cell hybridoma clones [CD4- (dark blue), CD4+ (dark blue hatched), CD4T+ (light
blue), CD4T+ Δ bind (light blue hatched)] were incubated with 10-3 M LLO190-205 presented on Bl6.C57
splenocytes for 24 hrs. IL-2 production was measured by ELISA. LLO56 low (G), LLO56 intermediate
(H), LLO118 intermediate (I), and LLO118 high (J) TCR-SCS (41BB, CD28, or 3rd gen) were expressed
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in various T cell hybridoma clones (CD4-, CD4+, CD4T+, CD4T+ Δ bind) that were incubated with 10-3 M
LLO190-205 presented on Bl6.C57 splenocytes for 24 hrs. IL-2 production was measured by ELISA (n=3).
TCR-SCS format is defined by the color [TCR-SCS 4-1BB (light green, dark green), TCR-SCS CD28
(purple, pink), and TCR-SCS 3rd gen (red, orange)]. The combination of color shade and presence or
absence of hatched lines identifies the specific hybridoma. p-values were determined by multiple
comparison one-way ANOVA for each graph are from left to right LLO56int 4-1BB CD4- to CD4T+ (p =
0.0176), CD4+ to CD4T+ (p = 0.0036), and CD4T+ to CD4T+ Δ bind (p = 0.0138); LLO56int CD28 CD4to CD4+ (p = 0.0054), CD4- to CD4T+ (p = 0.0232), CD4+ to CD4T+ (p = 0.0002), CD4+ to CD4T+ Δ bind
(p = 0.0245), and CD4T+ to CD4T+ Δ bind (p = 0.0153); LLO118int 3rd gen CD4- to CD4T+ (p = 0.0027),
and CD4T+ to CD4T+ Δ bind (p = 0.0077); LLO118int CD28 CD4- to CD4T+ (p = 0.0018), and CD4T+ to
CD4T+ Δ bind (p = 0.0010); LLO118high 3rd gen CD4+ to CD4T+ Δ bind (p = 0.0366); and LLO118high
CD28 CD4- to CD4+ (p = 0.0010), CD4- to CD4T+ (p = 0.0221), CD4T- to CD4T+ Δ bind (p = 0.0021),
and CD4+ to CD4T+ (p = 0.0117).

CD4T+ and CD4T+ Δbind constructs were retrovirally transduced into existing CD4- T
cell hybridomas containing TCR-SCS or flTCR constructs and the clones were sorted for GFP,
TCR, and CD4 expression by flow sorting. CD4- hybridomas did not express CD4, and there
was consistent CD4 expression between the various CD4+ clones (Figure 18A). TCR surface
expression was consistent across cell lines for most TCR constructs, except LLO56low and
LLO56int CD28 clones which were most stably expressed in CD4+ cells (p < 0.0001 and p <
0.0001, respectively) (Figure 18B). Similarly, avidity measured by tetramer was mainly
consistent between clones except for LLO56low 4-1BB where CD4- had higher avidity than all
CD4+ clones (p = 0.0014), and LLO118int CD28 where CD4+ clone had the highest avidity (p =
0.0063) (Figure 18C).
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Figure 18. CD4 variant-expression does not affect construct stable expression or avidity
(A) Representative histogram of post-sort CD4 expression between T cell hybridoma cell lines for a
single TCR construct. 58-/- CD4- hybridoma (red peak) is shifted above the cells only control (grey peak)
due to background fluorescence from the antibody master mix, and the 58-/- CD4+ clones (blue peaks) are
expressed similarly. (B) Stable expression of Vβ2 by construct in order of 58-/- CD4-, 58-/- CD4+, 58-/CD4T+, 58-/- CD4T+ Δbind T cell hybridomas. LLO56low (pink colors), LLO56int (red colors), LLO118int
(light blue colors), LLO118high (dark blue colors). Hatched lines indicate CD4-MHC interactions.
LLO56low CD28 (p < 0.0001) and LLO56int CD28 (p < 0.0001) (C) To ascertain whether avidity was
maintained within each TCR-construct despite CD4 variations, each cell line was tested at sub-saturating
tetramer concentrations: LLO56low (10-8 M), LLO56int (5 x 10-10 M), LL0118int (10-9 M), and LL0118high
(5 x 10-10 M). Colors and order as found in (B). LLO118int CD28 (p = 0.033). Groups analyzed for
differences with one way ANOVA.

As expected, LLO56low flTCR IL-2 production was promoted by the presence of CD4MHCII interactions (CD4+ p = 0.0105 and CD4T+ p = 0.0014) and the absence of CD4-MHCII
interaction in the CD4- and CD4T+ Δbind abrogated LLO56low flTCR IL-2 production (Figure
17E). CD4 Lck-sequestration did not affect LLO56low flTCR IL-2 production since the CD4+
and CD4T+ clones responded the similarly to antigen (Figure 17E). In contrast, intermediate
affinity LLO56int flTCR IL-2 production is inhibited by CD4 Lck-sequestration, as CD4+
produced significantly less IL-2 than CD4T+ (p = 0.0162). However, the more striking
phenotype is LLO56int flTCR CD4-dependent inhibition, as IL-2 production is significantly
reduced by the presence of CD4 in any form. CD4- LLO56int flTCR cells produced significantly
more IL-2 than any clone expressing CD4 (CD4+ p < 0.0001, CD4T+ p = 0.0019, and CD4T+
Δbind p = 0.0002) (Figure 17F). Furthermore, CD4-MHCII interaction was not a significant
contributor to intermediate affinity flTCR IL-2 production as there was no significant change in
IL-2 production between the CD4T+ and CD4T+ Δbind clones (Figure 17F).
Low affinity TCR-SCS clones LLO56low 4-1BB and LLO56low CD28 were low IL-2
producers and the role of CD4 was conflicting as all CD4 iterations inhibited IL-2 production for
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4-1BB but promoted IL-2 production for CD28 whether or not CD4 binds to MHCII (Figure
17G). It was also difficult to draw conclusions about Lck-sequestration for low affinity TCRSCS constructs due to low levels of IL2 production. Intermediate TCR-SCS clones LLO56int 41BB, LLO56int CD28, LLO118int 3rd gen and LLO118int CD28 had a unique ubiquitous
phenotype comparable to the phenotype described for intermediate affinity flTCR clones. IL-2
production was most reduced when CD4 sequestered Lck in the CD4+ clones (Figure 17H and
17I). However, intermediate TCR-SCS CD4T+ constructs produced the most IL-2, indicating
unrestricted Lck promotes the greatest T cell activation (Figure 17H and 17I). CD4T+ Δbind
compared to CD4T+ significantly reduced intermediate TCR-SCS construct IL-2 production to
CD4- levels suggesting that CD4-MHCII binding supports IL-2 production for intermediate
TCR-SCS affinity (Figure 17H and 17I). Noticeably, high affinity LLO118 TCR-SCSs followed
the same inhibition patterns seen for LLO56int flTCR where inhibition by Lck sequestration and
CD4 presence was not significantly affected by MHCII-CD4 binding (Figure 17J). Taken
together, these data indicate that flTCRs and TCR-SCS have independent affinity thresholds for
the inhibitory effects of Lck-sequestration and CD4-dependent inhibition, and the activation
promoting effects of CD4-MHCII interactions (summarized in Table 4). Thus, IL-2 inhibition is
affected by CD4-Lck sequestration, CD4-pMHCII interaction, and by a CD4-dependent
mechanism in an affinity- and format-dependent manner.
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Table 4. Summary of Figure 17
TCR

LLO56

low

Affinity
int

flTCR

CD4
Lck free
CD4-MHCII

NA CD4
NA Lck free
+ CD4-MHCII

+
NA

4-1BB

CD4
Lck free
CD4-MHCII

- CD4
+ Lck free
NA CD4-MHCII

NA
+
+

CD28

CD4
Lck free
CD4-MHCII

+ CD4
NA Lck free
NA CD4-MHCII

NA
+
+

Construct

high

CD28

CD4
Lck free
CD4-MHCII

NA CD4
+ Lck free
+ CD4-MHCII

+
NA

3rd gen

CD4
Lck free
CD4-MHCII

NA CD4
+ Lck free
+ CD4-MHCII

NA
+
NA

LLO118

IL-2 production data interpretation broken down into base TCR (LLO56 or LLO118), construct, and
TCR-pMHCII affinity. “-“ indicates that the condition inhibits or does not promote IL-2 production,
“NA” indicates that effects on IL-2 production were “not appreciable”, and “+” indicates that the
condition promotes or least does not inhibit IL-2 production. Bolded interior boxes highlight the
phenotype shared by intermediate affinity flTCR and high affinity TCR-SCS clones.

2.4 Discussion
Here we generated a panel of MHCII-specific TCRs with increasing affinity in order to
interrogate the relationships between TCR format, TCR-pMHCII affinity, and the coreceptor
CD4 on CD4+ T cell activation. The contributions of these factors were assessed using IL-2
production; flTCRs produced more IL-2 than all TCR-SCS constructs at each affinity level and
IL-2 production generally increased with rising TCR affinity for all constructs. In low affinity
TCRs, CD4 enhanced IL-2 production for both flTCR and TCR-SCS formats. For intermediate
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or high affinity TCR clones, IL-2 production was abrogated by CD4-Lck sequestration and an
unknown CD4-dependent mechanism. These effects, activation promotion by increased affinity
and CD4-MHCII, or activation suppression by Lck-sequestration and CD4 itself, had unique
affinity thresholds that are dependent on construct type (flTCR or TCR-SCS). Lck sequestration
affected activation for all intermediate and high affinity constructs, while CD4-MHCII ceased to
promote activation and CD4-dependent inhibition repressed IL-2 production at unique affinity
thresholds for flTCR constructs (intermediate affinity) and TCR-SCS constructs (high affinity).
Following colocalization to the TCR, CD4 signals via Lck bound to its cytoplasmic tail
[51, 52]. Lck phosphorylates immune-receptor tyrosine-based activating motifs (ITAMs) of the
CD3 subunits of the TCR complex, which then initiates other early signaling machinery of the T
cell [51, 53, 431]. CD4-bound Lck activation may be reliant on a mechanism distinct from CD4free Lck activation, which is likely mediated by tyrosine-protein kinase Fyn, thus may obscure
mechanism comparison [407, 432, 433]. However, despite this complication, CD4-Lckdependent inhibition could occur in two fashions. First, optimal TCR affinity-mediated signaling
is dependent on fine-tuning the intensity and duration of the Lck phosphorylation cascade and
high affinity TCRs may have early intense Lck phosphorylation resulting in acute transient
activation [434]. Conversely, if CD4 is not recruited to the TCR, it could sequester Lck away
from the activation complex, which prevents the activation phosphorylation cascade thereby
attenuating T cell activation [62]. The first option suggests that all high-affinity TCR signaling
would be attenuated regardless of whether Lck was interacting with CD4; however, IL-2 output
reduction in the presence of CD4-Lck sequestration is clearly demonstrated by our intermediate
and high affinity CD4+ T cell hybridoma clones. It is also possible that with an increase in
affinity and the subsequent decrease in off-rate or increase in half-life, CD4-Lck fails to cycle
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through the TCR-pMHC synapse, thereby decreasing CD3 phosphorylation and thus downstream
activation. Signaling activation is affected by both TCR-pMHCII dwell time and CD4-Lck
interactions [430, 435, 436]. CD4 increases TCR signaling on low-affinity pMHCII by
increasing TCR-CD3 dwell time [409]. CD4 dwell time on pMHCII is proportional, yet faster,
to TCR dwell time, suggesting that TCR:pMHCII interaction kinetics would directly affect the
duration that CD4 molecules cycle through the immunological synapse in a processive-like
manner [435]. TCR-pMHCII interactions are highly ordered and uniform, increasing the
likelihood that the spatial relationship between Lck and the ITAMs of the TCR-SCS or flTCRs
are consistent. Thus, kinetic factors, such as TCR-pMHCII affinity would greatly influence the
stability of the macrocomplex and consequently the duration of Lck interactions with the ITAMs
[409, 437]. These kinetics alone could explain the drop in activation observed for our highaffinity, slow off-rate TCR clones. To support this idea, CD8 also acts as a dominant negative
inhibitor for ligands that do not recruit fresh CD8 to the TCR-CD3 complex [62].
Previous research suggests that CD4 can send an inhibitory signal independent of Lck via
post activation antibody-mediated ligation, which attenuates IL-2 production and ongoing
activated T cell response [64]. This response was also observed in a clonal variant expressing a
form of CD4 unable to associate with Lck, suggesting that CD4 has independent inhibitory or
regulatory function [64]. Furthermore, CD4-mediated inhibition has also been observed during
CD4-MHCII interactions leading to a decrease in IL-2 mRNA [64]. While we did not seek the
source for our Lck-independent CD4 inhibition nor acquire IL-2 mRNA levels, we noted that
there was an affinity threshold for this behavior that was independent of MHC interaction, and
therefore may be a unique mechanism to that reported in Chervin et al. 2009. The affinity
threshold for this Lck-independent CD4 inhibition was lower for flTCR (intermediate affinity)
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than TCR-SCS (high affinity). This may be due to the signaling power of each construct: flTCRCD3 complexes have 10 ITAMs with 20 tyrosine residues available for phosphorylation,
whereas TCR-SCS domains have only 3 ITAMs and 6 tyrosine residues [413, 438, 439]. The
increased availability of ITAMs per activated Lck may also explain why LLO56int flTCR
experienced less IL-2 production inhibition in the presence of CD4—more signal per Lck
molecule despite CD4-Lck movement restriction. It is also curious that the CD4-MHCII
interaction supports activation in intermediate affinity TCR-SCS clones, suggesting that while
CD4 may not contribute to the overall affinity of TCR-SCS constructs, it may stabilize the
interaction between TCR-pMHCII or provide an additional Lck-independent activation signal.
The increased interaction stability is more likely as high affinity TCR-SCS IL-2 production is not
significantly improved when CD4 interacts with MHCII, suggesting high affinity constructs
likely have stable interactions independent of CD4 contributions. Taken together this data
suggests an affinity threshold where, up to a point, increased time for CD4-MHCII interactions
improves TCR-dependent signaling when it is not Lck-limited, but after a certain affinity point,
increased dwell time slows TCR-dependent signaling and positive benefits of CD4-MHCII
interactions become redundant.
In addition to the stability challenges presented by scTCR format, the TCR-SCS
intracellular format also affected the stability of each TCR. TCR-SCS CD28 format was more
stably expressed than other TCR-SCS or flTCR formats, and as noted in other studies, the
enhanced surface expression of TCR-SCS CD28 formats via increased stability may explain their
improved avidity and T cell activation [440-442]. However, it is difficult to ascertain whether
the increased IL-2 production of TCR-SCS CD28 is due to enhanced stable surface expression or
the innate characteristics of CD28-intracellular signaling domains. As observed in numerous
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antibody-based CAR studies comparing CD28 domains to 4-1BB domains, intracellular
signaling domains differentially impact multifactorial T cell response characteristics, including
cytokine production [443]. For example, CD28-CAR constructs are well known for their
increased IL-2 production and subsequent T cell exhaustion compared to 4-1BB CARs [444,
445]. Thus, the observed increase in IL-2 production for TCR-SCS CD28 constructs may be
attributable to the innate characteristics of CD28-intracellular signaling domains rather than
increased stable surface expression. As CD28-CARs phosphorylate CD3 more quickly yet do
not exceed the levels of CD3 phosphorylation exhibited by 4-1BB CARs, this may be due to
signaling intensity [445]. Additionally, because CD28 recruits Lck to lipid rafts where it
associates with CD4, CD28 may be better able to recruit Lck [446, 447]. While TCR-SCS 3rd
generation constructs had mixed activation success and overall reduced cytokine production
compared to TCR-SCS CD28 constructs, this may be attributable to 3rd generation CAR T cells
improved expansion and persistence and may mimic some characteristics of 4-1BB CAR T cells,
like reduced cytokine production [448, 449].
CD4+ T cells are promising newcomers to immunotherapy. CD4+ TCRs convey exquisite
target specificity and direct robust immune responses through indirect mechanisms that avoid
tumor antigen escape. While much development and thought has been devoted to the activation
benefits and off-target effects of increased TCR-pMHC affinity, especially for CD8+ TCRs,
further TCR-therapeutic development should give consideration to the unique affinity thresholds
of TCR-SCS and flTCR formats and the potential inhibitory effects of CD4.
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CHAPTER 3: Contributions of Viral Infections to Risk for Cancer in Systemic Lupus
Erythematosus and Multiple Sclerosis
The content of this chapter was submitted in April 2020. It is currently under review. Authors:
Deborah K. Johnson, Kaylia M. Reynolds, Matthew D. Montierth, Vera M. Todd, Joshua C.
Denny, April Barnado, Brian D. Poole, and Mary F. Davis. It has been reformatted for this
dissertation, but is otherwise unchanged.
Abstract
Patients with systemic lupus erythematosus (SLE) have a heightened risk for
hematological, lung, liver, vulvar/vaginal, cervical, and thyroid malignancies and decreased risk
for breast, ovarian, and prostate malignancies. We examined the effects of viral infections in
SLE patients on this pattern of susceptibility to cancer, focusing especially on hematological
cancers. A multiple sclerosis (MS) cohort control was included to assess the contribution of a
systemic autoimmune disease that also predominantly affects women of childbearing ages and
lupus-specific factors on virus susceptibility and cancer risk.
Materials and methods
Electronic medical records were extracted from Vanderbilt University. ICD-9/10 codes
and laboratory values were collected for carcinogenic viruses including Epstein Barr virus
(EBV), Herpesviruses (HPV), and Hepatitis A/B/C (Hep), and SLE-associated cancers including
hematological, lung, anal-vaginal, thyroid, hepatobiliary, bladder cancers, prostate, and breast
cancers. The case matched SLE cohort (SLE-cases n=2,313, and SLE-controls n=5,702) and MS
cohort (MS-case n=7,277, MS-control n=7,277) were examined by multilinear logistic
regression.
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Results
Viral infection was strongly associated with increased risk for cancer, especially
hematological cancers. SLE and MS patients were more susceptible to all viral infections,
including EBV. Confirming previous findings, patients with SLE were more susceptible to
hematological cancers when viruses were present and less susceptible to breast and prostate
cancers. Patients with SLE did not demonstrate altered risk for overall incidences of malignancy
compared to the control population. In comparison, MS patients were slightly more prone to
overall malignancies than control patients and had increased risk for hematological cancers when
viral infection was also present.
Conclusions
The increased prevalence of viral infection in SLE patients heightens their risk for
hematological cancers. The increased risk for virus-associated cancer is strong enough that it
counterbalances the lower risk for other types of cancer observed in SLE patients when
considering overall cancer risk. Both SLE and MS patients had increase viral infection and
subsequent hematological cancer risk. MS patients, however, had increased risk for cancers in
general, and did not show the decreased risk for hormonally-affected cancers seen in SLE.
Preventing viral infections by vaccination may be especially helpful in controlling risk for cancer
in SLE and MS patients.
3.1 Introduction
Systemic lupus erythematosus (SLE) is a common, debilitating, and complex systemic
autoimmune disease primarily affecting women of childbearing age. Its diverse symptoms
include arthritis, fatigue, rash, sensitivity to sunlight, and in severe cases, kidney damage, blood
disorders, neurological damage, and death. While SLE survival has improved, disease- and
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treatment-related morbidity remain substantial. SLE patients have an increased risk for certain
cancers [302] despite having a lower risk for hormonally-based cancers such as breast, ovarian
and prostate cancers [450, 451]. Several studies suggest that SLE patients are also more
susceptible to viral infections, including viruses associated with cancer such as Epstein-Barr
virus or Human Papilloma virus [253, 256].
It is unclear how the overall cancer risk of SLE patients is affected by the relative
contributions of SLE itself, its treatments, and other environmental factors such as increased
viral infection [283, 284]. Compared to the general population, SLE patients experience
increased incidence of hematological, hepatobiliary, vulvar, vaginal, and cervical cancers, all of
which have conspicuous links to viruses [274, 452]. SLE patients may lack viral control due to
immune dysfunction. For example, SLE T cells are dysregulated in response to Epstein-Barr
virus (EBV) [287, 288] and dysregulated immune response to EBV can lead to increased
Burkitt’s lymphoma [289]. EBV infection is also associated with non-Hodgkin’s lymphoma and
diffuse large B cell lymphoma [290, 291]. The increased EBV viral loads in SLE patients [453]
may help explain the increased incidence of hematological cancers.
EBV is also implicated in the development of multiple sclerosis (MS) [304], a chronic
autoimmune inflammatory disease affecting the central nervous system that, like SLE, primarily
affects women of childbearing ages [305]. Furthermore, similar to SLE, immunosuppressive
treatment in MS may alter the risk of cancer development compared to the general public [308,
309]. While MS patients have a decreased risk for ovarian and prostate cancers, hematological
cancers are consistently increased, again suggesting that poor viral control may lead to cancer
development [310]. Thus, MS patients are a good autoimmune disease control to identify the
relative contributions of SLE and viruses to cancer risk development.
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This study seeks to understand the contributions of SLE and viruses to cancer
development in SLE patients. The risk of viral infections and cancers were compared using
electronic health records by logistic regression examining ICD-9 and -10 billing codes and
laboratory values from Vanderbilt University Medical Center’s electronic health record database.
Our data demonstrates that viral status within an autoimmune disorder more fully predicts cancer
risk than autoimmune-induced immune dysfunction alone.
3.2 Materials and methods
3.2.1 Study population
Patient demographic information, virus laboratory results, and ICD-9/10 billing codes
were extracted from Vanderbilt University Medical Center Synthetic Derivative (VUMC SD)
database, which contains de-identified electronic health records for over 3 million patients seen
at Vanderbilt University Medical Center. We used a previously identified systemic lupus
erythematosus (SLE) cohort with matched controls by age, race and gender (Figure 19) [454].
These SLE cases were identified using previously validated and published algorithms with
positive predictive values (PPVs) ≥ 90% [455]. Controls were subjects who had ≥ 3 outpatient

visits in the past 5 years at VUMC. Multiple sclerosis (MS) cases were identified with a

computer algorithm as previously described [456]. Briefly, selected MS control patients did not
have any ICD codes for other autoimmune diseases and were matched by age in 2018, race, and
gender (Table 5). Patients missing values for their sex, who were older than 95 years in 2018, or
who had both SLE and MS were excluded. Furthermore, MS case and control patients were
removed if they overlapped with the SLE controls. The final MS study cohort consisted of 7,277
cases and 7,277 controls, and the SLE final study groups was composed of 2,313 cases and 5,702
controls (Figure 19).
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Figure 19. Filtering procedure for MS and SLE cohorts
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Cancer Status

Viral Status

Demographic Information

Table 5. Demographic information, viral incidence and cancer incidence for SLE and MS cohorts
by case and control
SLE
MS
SLE Case
MS Case
Control
Control
Total (n)
2313
5702
7277
7277
2058
5132
5603
5167
Female
(89%)
(90%)
(77%)
(71%)
Age
55
52.3
56.7
54.4
Asian
36 (2%)
123 (2%)
20 (0%)
88 (1%)
535
1419
African American
659 (9%) 606 (8%)
(23%)
(25%)
Hispanic
57 (2%)
166 (3%)
66 (1%)
111 (2%)
Native American
2 (0%)
5 (0%)
6 (0%)
2 (0%)
1552
3729
5461
4503
Caucasian
(67%)
(65%)
(75%)
(62%)
Other
6 (0%)
16 (0%)
7 (0%)
43 (1%)
2+ Ethnicities
5 (0%)
7 (0%)
8 (0%)
6 (0%)
1050
1918
Unknown
120 (5%) 237 (4%)
(14%)
(26%)
2016
5194
7116
7221
None
(87%)
(91%)
(98%)
(99%)
297
Any
508 (9%) 161 (2%) 56 (0.8%)
(13%)
Hep A/B/C +
198 (9%) 326 (6%) 20 (0.3%) 9 (0.1%)
EBV+
163 (7%) 196 (3%) 115 (2%) 33 (0.5%)
HPV+
30 (1%)
62 (1%)
28 (0.4%) 15 (0.2%)
232
All
571 (10%) 297 (4%) 236 (3%)
(10%)
Breast
39 (2%)
175 (3%)
89 (1%)
68 (0.9%)
Prostate
8 (0.3%) 48 (0.8%) 32 (0.4%) 37 (0.5%)
Hematological
163 (7%) 203 (4%) 124 (2%) 65 (0.9%)
Lung
17 (0.7%)
63 (1%)
44 (0.6%) 36 (0.5%)
Thyroid
12 (0.5%) 52 (0.9%) 24 (0.3%) 12 (0.2%)
Anal/Vagina/Cervical 10 (0.4%) 46 (0.8%) 11 (0.2%) 13 (0.2%)
Hepatobiliary
4 (0.2%) 31 (0.5%) 3 (0.04%) 9 (0.1%)
Bladder
3 (0.1%) 24 (0.4%) 7 (0.1%)
8 (0.1%)
3.2.2 Identifying malignancies and viral infections
Patients were classified as having a malignancy (hematological, lung, vaginal, anal,
hepatobiliary, bladder, thyroid, breast, or prostate) if their records contained at least two ICD87

9/10 billing codes for a specific cancer (Table 5). Anal and vaginal cancers are both associated
with HPV infection, and thus were grouped to achieve sufficient patient numbers for analysis.
To confirm viral infection history, patients were assigned positive viral status if they had a
minimum of two instances of a positive laboratory value and/or ICD-9/10 billing code in their
records (Table 6). More viral infections were detected in the SLE cohort than the MS cohort
(Table 5). Hepatitis (hep) includes both hepatitis B and hepatitis C infections.
Table 6. ICD-9 /10 and lab codes used to identify patient cancer and viral incidence
Cancer Codes
Hematological

ICD-10
C81, C82, C83, C84, C85, C86,
C87, C88, C89, C90, C91, C92,
C93, C94, C95, C96, D46, D47,
Z85.79
C34, Z85.11

ICD-9
200-207 by 0.01, 273, 287.30,
287.3

C22, C23, Z85.05
C67, Z85.51
C73, Z85.85
C50, Z85.3
C61, D07.5, Z85.46

162-163 by 0.01
180-181 by 0.01, 184.0, 184.4,
154.2, 154.3, 154.8
155-157 by 0.01
188-189 by 0.01
193-194 by 0.01
174-176 by 0.01
185-186 by 0.01

Hep

ICD-10
B27
B97.7, B85.81, B85.82, R87.81,
R87.82, R85.81, R85.82
B15, B16, B17, B18, B19

ICD-9
75-76 by 0.01
079.4, 78.11, 795.05, 795.15,
796.75, 795.79, 795.099, 795.19
70-71 by 0.01

Lab Viral Names
EBV
HPV
Hep

EBV
HPV
HCV, HBV

Lung
Anal/Vaginal/Cervica
l
Hepatobiliary
Bladder
Thyroid
Breast
Prostate
Viral Codes
EBV
HPV

C51, C52, C53, C21
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3.2.3 Statistical analysis
Multilinear logistic regression models were used to predict overall viral incidence and
cancer risk, and calculate risk for individual viruses and cancers (Table 7). To account for
multiple testing, p-values were adjusted via a Bonferroni correction by multiplying the p-value
by the number of regressions run for each autoimmunity group (SLE = 8, MS = 4). All filtering
and statistical tests were completed in R 3.6.2.
Table 7. Covariate and cohort specifications for each regression performed

Viral Status

Disease
Status
SLE/MS

Malignancy Status

SLE/MS

M/F

Hematological
Status

SLE/MS

M/F

Age EBV

(SLE/MS)*EBV

Lung Status

SLE

M/F

Age

Anal/Vaginal Status

SLE

F

Breast Status

SLE

F

Prostate Status

SLE

M

EBV, HPV,
HEP
Age HPV
EBV, HPV,
Age
HEP
EBV, HPV,
Age
HEP

SLE*Viral
Status
SLE*HPV
SLE*Viral
Status
SLE*Viral
Status

Response Variable

Viral
Infections
Age None
EBV, HPV,
Age
HEP

Gender Age
M/F

Interaction
None
(SLE/MS)*Viral
Status

3.3 Results
3.3.1 Overall viral incidence and cancer incidence
To uncover the link between autoimmune disorders, viral incidence and cancer incidence,
we determined whether patients with systemic lupus erythematosus (SLE) and multiple sclerosis
(MS) had higher incidence of positive viral status for Epstein Barr virus (EBV), Human
Papilloma virus (HPV), and Hepatitis B or C (Hep) compared to control patients. Only
infections that led to a physician visit or laboratory test would be entered into the medical
records; most viral infections do not meet these criteria. Positive viral status is therefore a better
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proxy for serious infections than for all infections. SLE patients had an increased overall viral
incidence (odds ratio (OR) 1.60, 95% CI 1.37, 1.87, p = 1.58 x 10-6) than controls. Males
(considering both the SLE patients and controls) were more likely to have higher viral incidence
(OR 1.58, 95% CI 1.27, 1.95, p = 2.16 x 10-4) (Fig. 20a). MS patients had an even larger
increased viral incidence compared to controls (OR 3.31, 95% CI 2.44, 4.56, p = 2.15 x 10-13),
however, there was no increased risk for men compared to the MS cohort as a whole (OR 1.10,
95% CI 0.80, 1.49, p = 1.00) (Fig. 20b). This may be due to a larger number of men included in
the MS cohort (n=1674) compared to the male SLE cohort (n=255), or because men diagnosed
with SLE tend to have severe disease and may be prone to heightened viral incidence. For all
logistic regressions, while age was statistically significant, its meaningful significance is unclear
as the OR was close to 1.00 for both SLE and MS cohorts.
SLE and MS patients have increased viral incidence as well as an autoimmune disorder.
Therefore, we examined whether the autoimmune disorder or viral incidence better predicted
overall cancer risk by looking at overall cancer risk in both SLE patients and MS patients. SLE
patients have increased risk for some cancers and decreased risk for others; therefore it was
unsurprising that SLE alone did not significantly predict overall cancer incidence (OR 0.81, 95%
CI 0.67, 0.96, p = 0.17) (Fig. 20c). Furthermore, the interaction between SLE and overall viral
incidence did not predict overall cancer incidence (OR 1.75, 95% CI 1.12, 2.72, p = 0.11) (Fig.
20c). However, SLE patients with a positive viral test (OR 1.76, 95% CI 1.33, 2.31, p = 4.12 x
10-4) and male SLE patients (OR 1.65, 95% CI 1.33, 2.03, p = 2.72 x 10-5) had increased cancer
risk (Fig. 20c). The interaction between MS and viral status did not predict overall cancer
incidence (OR 1.41, 95% CI 0.56, 4.11, p = 1.00) (Fig. 2d). While not significant, MS alone
showed a trend for increased in risk of overall cancer incidence (OR 1.25, 95% CI 1.05, 1.50, p =
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0.059) (Fig. 20d). Additionally, gender was not a meaningfully significant contributor for cancer
risk in the MS cohort (OR 1.20, 95% CI 0.98, 1.45, p = 0.27) (Fig. 2d). As in the SLE patients,
viral status significantly predicted overall cancer risk for the MS cohort (OR 4.64, 95% CI 1.74,
10.4, p = 0.0025) (Fig. 20d). This suggests that viral status is a more important predictor for
cancer development than either autoimmune disorder. Since autoimmune patients have an
increased risk for viral incidence, this may explain the heightened risk in SLE patients for virusassociated cancers documented in other studies [274, 283, 452].
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Figure 20. Autoimmune disorders increase viral incidence and viral incidence increases overall
cancer risk
Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts. For all graphs, the dotted line
represents an OR of 1.0. An OR to the right of the dotted line represents an increase in risk. An OR to
the left of the solid line represents a reduction in risk. (a) Overall viral incidence for SLE cohort is
significantly predicted by SLE (OR 1.60, 95% CI 1.37, 1.87, p = 1.58x10-6) and male (OR 1.58, 95% CI
1.27, 1.95, p = 2.16x10-4). (b) Overall viral incidence for MS cohort is significantly predicted by MS (OR
3.31, 95% CI 2.44, 4.56, p = 2.15x10-13). (c) Overall cancer incidence for SLE cohort is significantly
predicted by the viral status (OR 1.76, 95% CI 1.33, 2.31, p = 4.12x10-4) and male (OR 1.65, 95% CI
1.33, 2.03, p = 2.72x10-5). (d) Overall cancer incidence for MS cohort is significantly predicted by viral
status (OR 4.65, 95% CI 1.74, 10.41, p = 0.0025).

3.3.2 Hematological cancers
To more specifically examine this heightened risk for viral-influenced cancers, we next
investigated if viral incidence and SLE or MS increased the risk for hematological cancers. SLE
and MS patients were more likely to have tested positive for EBV infection (OR 2.27, 95% CI
1.83, 2.81, p = 6.99 x 10-13; and OR 3.99, 95% CI 2.72, 6.00, p = 2.49 x 10-11) (Fig. 21a and b).
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Male participants in both the SLE and MS cohorts may have a slight, though not significant,
increase in EBV incidence (OR 1.50, 95% CI 1.09, 2.02, p = 0.079; and OR 1.47, 95% CI 1.03,
2.08, p = 0.13) (Fig. 21a and b).
The best predictor for hematological cancer risk was the interaction of SLE or MS with
EBV (OR 1.92, 95% CI 1.53, 2.41, p = 1.38 x 10-7; and OR 1.83, 95% CI 1.33, 2.52, p = 7.85 x
10-4) (Fig. 21c and d). Men were also significantly more likely to develop hematological cancer
in both cohorts (OR 3.69, 95% CI 2.22, 5.84, p = 7.56 x 10-7; and OR 17.12, 95% CI 4.90, 46.20,
p = 1.43 x 10-6) (Fig. 21c and d). Taken together, these data suggest that patients with SLE or
MS are more likely to have clinically relevant EBV infections and therefore more likely to
develop hematological cancer compared to healthy controls.
We sought to confirm this finding with other SLE-increased cancers including
hepatobiliary, anal/vaginal, bladder and thyroid cancers. The MS cohort had surprisingly few
tests for these viruses overall (Hep C (n=29, 0.2%), HPV (n=43, 0.3%)) compared to the SLE
cohort (Hep C (n=524, 6.5%), HPV (n=92, 1.1%)) (Methods: Table 5). To compound this
problem, the number of patients in both the SLE and MS cohort with cancer and positive viral
ICD-9/ICD-10 and lab codes were too low for statistical power to see correlations for these
cancers (Methods: Table 5). Therefore, we could not run logistical regression on these cancer
and viral combinations.
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Figure 21. Autoimmune disorders increases risk of EBV infection and autoimmune disorder with
EBV increases risk for hematological cancers
Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts. For all graphs, the dotted line
represents an OR of 1.0. An OR to the right of the dotted line represents an increase in risk. An OR to
the left of the solid line represents a reduction in risk. (a) EBV viral incidence for SLE cohort is
significantly predicted by SLE (OR 2.27, 95% CI 1.83, 2.81, p = 6.99 x 10-13). (b) EBV incidence for MS
cohort is significantly predicted by MS (OR 3.99, 95% CI 2.72, 6.00, p = 2.49x10-11). (c) Hematological
cancer incidence for SLE cohort is significantly predicted by the interaction of SLE with EBV (OR 1.92,
95% CI 1.53, 2.41, p = 1.28x10-7) and male (OR 3.69, 95% CI 2.23, 5.84, p = 7.56x10-7). (d)
Hematological cancer incidence for MS cohort is predicted by interaction of MS with EBV (OR 1.83,
95% CI 1.34, 2.52, p = 7.85x10-4) and male (OR 17.12, 95% CI 4.90, 46.20, p = 1.43x10-6).

3.3.3 Cancers for which SLE and MS patients are at decreased risk
SLE patients have decreased risk for hormonally-influenced cancers, including breast and
prostate cancers. To confirm that our SLE cohort was properly curated and that viruses are not
involved in these cancers we examined how SLE and viral status (HPV, EBV, Hep) affected
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breast and prostate cancer incidence for women and men, respectively. Breast cancer risk was
halved for patients with SLE (OR 0.517, 95% CI 0.35, 0.74, p = 0.0036) (Fig. 22a). Neither viral
infection alone (OR 1.35, 95% CI 0.77, 2.23, p = 1.00) nor SLE and virus interaction (OR 0.60,
95% CI 0.13, 1.96, p = 1.00) predicted breast cancer incidence. Prostate cancer risk was also
greatly reduced for SLE patients (OR 0.22, 95% CI 0.089, 0.50, p = 0.0053) (Fig. 22b). Again,
neither viruses alone (OR 0.31, 95% CI 0.050, 1.10, p = 0.99) nor SLE and viruses together (OR
5.63, 95% CI 0.23, 74.69, p = 1.00) predicted prostate cancer incidence for the SLE cohort (Fig.
22b). In contrast, MS patients had similar breast (n = 89, 1%) and prostate cancer (n = 32, 0.4%)
risk compared to control populations (n = 68, 0.9% and n = 37, 0.5% respectively). Logistic
regression was not run for MS samples as there was a lack of viral medical records for these
patients. This evidence demonstrates that not all cancers are increased in SLE patients and that
not all cancer risk is heightened by viral infections.
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Figure 22. SLE decreases risk for hormonal cancers
Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts. For all graphs, the dotted line
represents an OR of 1.0. An OR to the right of the dotted line represents an increase in risk. An OR to
the left of the solid line represents a reduction in risk. (a) Breast cancer incidence in female SLE cohort is
significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). (b) Prostate cancer
incidence in male SLE cohort is significantly decreased by SLE status (OR 0.23, 95% CI 0.089, 0.50, p =
0.0053).
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3.4 Conclusions and Discussion
Systemic lupus erythematosus (SLE) patients experience increased incidences of some
types of cancers including hematological, lung, vulvar, vaginal, and cervical malignancies. It is
difficult to differentiate whether the disease, medication side effects, or the effects of
autoimmune disease on virus infections are the underlying cause of elevated cancer risk in SLE
patients. For example, increased SLE disease activity often leads to intensified drug treatments,
making it difficult to tease out the relative contributions of immunosuppressive drugs and SLE
itself on cancer risk [277, 283]. Cancer diagnosis tends to occur early after SLE diagnosis, often
within the first year, suggesting SLE itself influences cancer risk more strongly than drug
exposure given the limited time for drug exposure [276].
In this study, we found that viral infection status is a powerful risk factor for
malignancies in general and hematological malignancies in two autoimmune diseases. SLE and
multiple sclerosis (MS) patients have a heightened risk of positive viral infection status as noted
by laboratory results and ICD-9/10 codes, indicative of increased viral infection incidence or
heightened intensity of viral infections compared to controls. SLE patients are at a higher risk
than controls for cancers associated with viral infection, but lower or equal risk for other types of
malignancies. SLE patients overall cancer risk was not significantly different from controls. MS
patients showed a different pattern; MS status itself conferred a slightly higher, though not
significant, risk for malignancy overall, as well as a higher risk for viral infections. Viral
infections continued to have the strongest influence on risk for cancer in the MS patients. Thus,
we can conclude that increased susceptibility to more severe viral infection substantially
contributes to overall cancer risk in both SLE patients and MS patients.
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The contributions of autoimmune disease and viral infections to cancer development are
particular to the type of cancer. SLE and MS patients are greatly more susceptible to clinically
relevant EBV infection, and hematological cancers are also associated with SLE or MS and EBV
infection status. Thus, the risk for hematological cancers is likely largely due to EBV infection,
which is associated with Non-Hodgkin’s lymphoma, Burkitt’s lymphoma, and other B cell
malignancies [290, 291, 457]. Control of EBV infection is known to be dysregulated in both SLE
and MS, and there is weaker immunity to this virus in these diseases [264, 291, 458-463].
Therefore, it is likely that this dysregulation leads to increased risk for hematological cancers.
We confirmed previous findings that suggest that SLE itself confers a lower risk for
breast and prostate cancer [282, 464, 465]. It is likely that SLE affects hormones or hormone
regulation important for the development or proliferation of these cancers [466]. As expected by
general population studies, viral infection did not affect the rate of these types of malignancies in
the SLE population.
The use of an EHR system allowed access to thousands of records, and made this project
possible. However, it also has limitations. Determining what is a “positive viral status” is
challenging, and we certainly missed many viral infections. Only infections that led to a
physician visit or laboratory test were entered into the medical records; most viral infections do
not meet these criteria. Positive viral status is therefore a better proxy for serious infections than
for all infections. Some viral infections, such as EBV, may not be commonly noted in the
medical records. For example, although nearly all SLE patients are infected with EBV, increased
viral replication or viral load, which is common in SLE patients [274, 452], would not
necessarily be tested for unless it lead to mononucleosis or other symptoms, and would therefore
not contribute to a positive viral status for this work. This may have resulted in an
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underestimation of EBV cases in both SLE and healthy patients and may have affected the
results regarding hematological cancers and HPV-associated cancers. Furthermore, SLE and MS
patients are commonly screened for hepatitis B/C before beginning immunosuppressive
medications, therefore these viruses may have been oversampled compared to the control
population. As we relied on clinical notes from the HER, we do not have SLE disease activity
measures recorded, so we cannot assess the impact of lupus activity on risk for viral infection or
malignancy.
Finally, due to the success of early screening programs in the United States, cervical
cancer is relatively rare, as are the other HPV-associated cancers. Instead of cervical cancer,
therefore, we used cervical changes as an indicator for cervical malignancy. This likely altered
the final HPV incidences since this cancer indicator would have been used to denote positive
viral status, and HPV infections that do not lead to abnormalities are less likely to be noted.
Our findings indicate that increased viral infection in SLE and MS patients better
explains the elevated risk of certain cancers than SLE and MS disease alone. However, patients
with MS had a slight increased risk of malignancies separate from viral risk factors, highlighting
that different autoimmune diseases may uniquely affect cancer risks. Both SLE and MS patients
had increased risk for hematologic cancers, which were also affected by risk for viral infection.
The increased rate of viral infection seems to overcome a general decrease in risk for cancers in
SLE patients, leading to an equivalent overall malignancy risk compared to controls. Therefore,
special care should be taken with viral infections in SLE patients. Although EBV infection
interventions are currently limited to monitoring patients with active infections, there are
vaccines for hepatitis B and HPV and treatment for hepatitis C. It is likely that these vaccines
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and treatments would especially benefit SLE patients by reducing the associated risk for
malignancy.
3.5 Acknowledgments
Much thanks to the Vanderbilt University Synthetic Derivative Database team and to Dr.
Scott Weber for critical review.

99

CHAPTER 4: Combating Vaccine Hesitancy with Vaccine-Preventable Disease Familiarization:
An Interview and Curriculum Intervention for College Students
The content in this chapter was previously published in Vaccines. Johnson, D. K. et al.
“Combating Vaccine Hesitancy with Vaccine-Preventable Disease Familiarization: An Interview
and Curriculum Intervention for College Students.” Vaccines, 2019 May; 12:7(2). doi:
10.3390/vaccines7020039. I hereby confirm that the use of this article is compliant with all
publishing agreements. The content is unchanged but has been formatted for this dissertation.
Abstract
In 2019, the World Health Organization (WHO) listed vaccine hesitancy in its top ten
threats to global health. Vaccine hesitancy is a “delay in acceptance or refusal to vaccinate
despite availability of vaccination services”. Urban areas with large amounts of vaccine
hesitancy are at risk for the resurgence of vaccine-preventable diseases (VPDs). Many vaccinehesitant (VH) parents may be unfamiliar with the consequences of VPDs, and thus might be
swayed when confronted with the symptoms and dangers of VPDs. As such, we sought to
educate college students (future parents) in an urban vaccine-hesitant hotspot by assigning them
to interview family or community members who had experienced a VPD. Student vaccine
attitudes were assessed by surveys before and after the interviews. Vaccine-hesitant students who
conducted a VPD interview but received no additional vaccine educational materials were
significantly more likely (interaction term p < 0.001) to become pro-vaccine (PV) (68%) than
students who conducted an autoimmune interview and received no additional educational
materials. Additionally, students whose interviewees experienced intense physical suffering or
physical limitations or students who were enrolled in a course with intensive VPD and vaccine
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curriculum had significantly increased vaccine attitudes. This suggests that introducing students
to VPDs can decrease vaccine hesitancy.
4.1 Introduction
Vaccines are victims of their own success. Due to the effectiveness of vaccination
programs, many people have limited or no experience with vaccine-preventable diseases (VPDs)
[333]. Parents increasingly assume that the risks associated with VPDs are minimal compared to
potential health and safety risks of vaccinations themselves [335-338]. This has led to a rise in
vaccine hesitancy by parents that results in a “delay in acceptance or refusal to vaccinate despite
availability of vaccination services” [326]. Urban centers with large clusters of vaccine-hesitant
individuals are particularly vulnerable to VPD outbreaks among exposed, unimmunized children.
In the 2016–2017 school year, Utah County (Provo) in Utah, USA ranked sixth nationally for the
total number of entering kindergartners that were under-vaccinated as measured by non-medical
exemption (NME) waivers (n = 662 NME) [467]. As many of these parents may have never
experienced VPDs, we hypothesized that designing an intervention for college students (future
parents) in Provo, Utah might help improve vaccine attitudes and future vaccine uptake for
themselves and their families.
Influencing students before they become parents will likely encourage pro-vaccination
behaviors for their future and current families, as children and adolescents who participate in
health education activities in school can positively influence family health management [373375]. However, there is evidence that correcting erroneous assumptions about potential health

and safety risks may be ineffective, causing a “backfire effect” and further entrenching vaccinehesitant individuals’ beliefs [346, 347]. Vaccine hesitancy often arises from deep-rooted
ideological beliefs and conspiracist ideational tendencies. As this kind of thinking has been
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shown to become further entrenched when those holding it are presented with contradictory
information, correcting misinformation is often counterproductive [344, 345, 468]. Further, it is
difficult to provide convincing data for the absence of risk; consequently, vaccine-hesitant
parents may be recalcitrant to messages aimed at alleviating concerns about vaccine safety and
side effects [354, 469]. Rather, pro-vaccine interventions may be more effective if they warn of
health dangers to individuals from VPDs [354]. Additionally, the vaccine-hesitant movement
uses emotionally charged stories with dire long-term consequences to effectively convey antivaccine ideology. Combating this rhetoric with a similarly emotional appeal may be an effective
preventative strategy [470]. Therefore, we predicted that hearing about the effects of VPDs from
family and community members who suffered from VPDs would improve the students’ attitudes
towards vaccination. We further predicted that classroom education could improve attitudes
towards vaccines.
In this study, we analyzed three courses with different vaccine instructional approaches
varying from none to intensive. Enrolled students were also assigned to interview a family or
community member about their personal experience with either an autoimmune disease (control)
or a VPD. Students exposed to either intensive VPD-focused vaccine instruction or who
interviewed individuals who had had a VPD had statistically significant and meaningful gains in
vaccine attitude.
4.2 Materials and methods
4.2.1 Study population
Students at a large private institution in the Western United States were enrolled in a
quasi-experimental survey-based intervention study. Students were eligible if they attended one
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of three courses in the Winter 2018 semester: general education non-science major BIO 100
(Principles of Biology-one section), and microbiology and molecular biology major-specific
courses MMBio 240 (Molecular Biology-two sections), and MMBio 261 (Infection and
Immunity-one section). Vaccination principles were taught in BIO 100 and MMBio 261, but not
in MMBio 240. All students enrolled in the courses were encouraged to participate and offered
extra credit for their time and efforts. Our study sample consisted of 425 students who
completed the study requirements (574 began the study). The study was conducted in
accordance with the Declaration of Helsinki, and study procedures were approved by the
Institutional Review Board at the institution (study # E17263). All participants received and
signed a consent form that included a description of the study and were assigned a random
number to protect their identities. Students were informed that their instructors would never see
their names associated with any of the survey results, and steps were taken to avoid such
instructor access.
4.2.2 Assigning vaccine attitude groups and randomization process
To determine initial vaccine attitudes, students took a pre-interview survey (see Table 8)
and were asked to rate each question from 1–5 where 1 is “strongly disagree” and 5 is “strongly
agree”. Each question concerning vaccine attitude was chosen to cover a specific aspect of
vaccine hesitancy. Pre-intervention vaccine attitude scores (VASs) were tallied from questions 1,
4, 9, 11, and 13 (Table 8). Question 1 is a test of general attitude towards vaccines. Question 4
addresses side effects, relevant since many vaccine-hesitant individuals are afraid of these side
effects. Question 9 is about the common belief that vaccines cause autism, a major concern for
many vaccine-hesitant people. Question 11 gives an opportunity for the participants to opine on
the positive aspects of vaccination in terms of how well they work. Question 13 is a question
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about how the vaccine attitude would affect action and give it a more real-world, rather than
theoretical, effect. To avoid answer bias, students were not informed that the study was about
vaccination opinions and additional questions about autoimmune diseases and depression were
included in the survey. Scores from questions 4 and 9 were reverse coded to account for the
negative nature of the question. These questions were written in a negative way to avoid biasing
the study by presenting vaccines in only a positive light in the questions. Students with VASs
between 20 and 25 points were categorized as “Pro-Vaccine” (PV) and students that had a VAS
less than 20 points were categorized as “Vaccine-Hesitant” (VH). A cutoff value of 20 was
chosen because it meant, on average, that the student at least “agreed” (score or converted score
of 4) with all of the vaccine attitude questions. A score of less than 20 would mean that the
student on average either did not at least “agree” with the pro-vaccine statements, or that they
had a serious disagreement with at least one statement about vaccines. Students were assigned to
interview groups by alternating autoimmune (negative control for survey and interview effects)
and vaccine-preventable disease (VPD) interview assignments alphabetically within PV and VH
categories so that equal numbers of students were assigned to each interview intervention.
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Table 8. Pre-Interview Survey (VPD)
Pre-Interview Survey:

Table 8

Rate each question from 1 to 5 where 1 is “strongly disagree” and 5 is “strongly agree”
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

Vaccines are more helpful than harmful
Treatment for autoimmune diseases is more helpful than harmful
Medications for depression are more helpful than harmful
Vaccines often have severe side effects
People with autoimmune diseases suffer considerably
Medication for depression is effective at treating depression
There are effective treatments for autoimmune diseases
Depression can be overcome using willpower
Vaccines cause autism
Exercise is the best treatment for autoimmune diseases
Vaccines are effective at preventing disease
Medications for depression have severe side effects
I am likely to fully vaccinate my children/I have fully vaccinated my children

Students were emailed their survey assignments and related paperwork, and based on
their group assignment, were asked to interview members of the community who had
experienced either a VPD or an autoimmune disease before the end of the semester using the
interview questions shown in Table 9. To encourage study completion, students received full
points for extra credit with completed survey submission (Bio 100 10 points, 1% of grade;
MMBio 240 20 points, 2.3% of grade; MMBio 261 20 points, 2.3% of grade). At the end of the
semester, students were administered a post-interview survey (see Table 10) that reiterated the
pre-interview survey questions and included follow-up questions about the survey itself. These
questions (14–18 in the post-interview survey) were written to identify the aspects of the
interview that had the most significant impact on vaccine attitudes. They provided both an
opportunity to rank several factors and the ability to explain in their own words how the various
aspects of the interview affected them. We then assigned students a post-intervention VAS and
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assessed for changes in overall vaccine scores between the pre-and post-intervention surveys.
Included in this analysis was determining whether students moved from the vaccine-hesitant to
pro-vaccine group, or vice-versa.
Table 9. Interview Questions (VPD)
Interview Questions
1.
2.
3.
4.
5.
6.
7.
8.
9.

Table 9

What is your relationship to the person who had the disease?
When did they develop the disease?
Which disease was involved?
What type of physical suffering did the disease cause? How bad was it?
How did the disease limit the person’s ability to do normal activities?
How did the disease affect the person’s interaction with other people?
How did the disease affect the person’s friends, family, or loved ones?
How did the disease affect the person financially?
Were there any other effects of the disease?
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Table 10. Post-Interview Survey (VPD)
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Post-Interview Survey:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

Table 10

Vaccines are more helpful than harmful
Treatment for autoimmune diseases is more helpful than harmful
Medications for depression are more helpful than harmful
Vaccines often have severe side effects
People with autoimmune diseases suffer considerably
Medication for depression is effective at treating depression
There are effective treatments for autoimmune diseases
Depression can be overcome using willpower
Vaccines cause autism
Exercise is the best treatment for autoimmune diseases
Vaccines are effective at preventing disease
Medications for depression have severe side effects
I am likely to fully vaccinate my children/I have fully vaccinated my children

Complete next section only if you interviewed a VPD-subject
Circle an answer: much more opposed, slightly more opposed, no effect, slightly more in favor, much more in
favor
14. How did hearing about the subject’s physical suffering affect your opinion of vaccines?
15. How did hearing about how the disease limited normal activity affect your opinion of vaccines?
16. How did hearing about how the disease affected the subjects’ interactions with other people affect
your opinion of vaccines?
17. How did hearing about how the disease affected the subject’s family, friends or loved ones affect your
opinion of vaccines?
18. How did hearing about the disease’s financial impact on the subject affect your opinion of vaccines?
Rank the following:
___ Physical suffering
___ Limitation of activities
___ Interactions with other people
___ Effect on family, friends or loved ones
___ Financial impact
19. Please explain briefly, what effect, if any, the project had on your attitude towards vaccination and
why it has that effect.
20. If this interview did NOT affect your attitude towards vaccination, why not?

4.2.3 Analyses
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Changes between groups’ pre- and post-intervention VASs were assessed with factorial
ANOVAs. Individual group changes over time were assessed by paired sample t-tests, and
differences between two groups at specific time points were assessed by independent sample ttests. Bonferroni corrections were applied to any multiple comparisons to account for alpha
inflation. Standard deviations were reported for statistics less than 5 points. All other statistics
reported 95% confidence intervals (CI). All analyses were performed using SPSS Statistics 25
(IBM). Figures were generated in Prism 8 (GraphPad) and tables were generated in Excel 2016
(Microsoft).
4.3 Results
4.3.1 Overview and pre-interview intervention vaccine attitudes
A total of 574 students volunteered to take the pre-interview survey during the Winter
2018 semester. Based on their pre-intervention vaccination attitude scores (VASs), students were
designated either pro-vaccine (PV) (87%) or vaccine-hesitant (VH) (13%) and assigned to the
control group (autoimmune survey, n = 286) or the intervention group (vaccine-preventable
disease (VPD) survey, n = 288). Of the students, 74% (n = 425) completed all requisite parts of
the study (pre-interview survey, community/family interview, post-interview survey) and were
included in the final analysis (Figure 23). The VH group was defined as VAS < 20 and the PV
group was defined as VAS ≥ 20 based on the pre-interview survey responses. There were no
statistically significant differences in the sociodemographic characteristics among the classes nor
did the course they were enrolled in significantly affect the assignment to VH and PV groups
(Table 11). Course year explains the age difference between the courses: Bio 100 is a general
education course for first year students, MMBio 240 is a second-year major-specific course, and
MMBio 261 is a second to third year major-specific course. Furthermore, sex, race, and age were
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not significantly correlated with pre-intervention vaccine attitudes (Table 12). Student
willingness to vaccinate current/future children was significantly different between VH and PV
groups (scale of 1–5 from strongly disagree to strongly agree) with means of 3.84 and 4.92,
respectively (independent t-test CI 95% 0.814–1.355; p < 0.001).

Figure 23. Participant flow through the randomized treatment

Table 11. Baseline characteristics of the participating classes (n=425)
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Class Demographics
Total

Total % (n) BIO 100 % (n) MMBio 240 % (n)
100% (425)
13% (56)
70% (298)

Gender
Male
Female
Age
Pre-Vaccine Attitude
Score
Vaccine Hesitant
Pro Vaccine

MMBio 261 % (n)
17% (71)

62% (263)
38% (162)
21.2 ± 0.21

70% (39)
30% (17)
19.7 ± 0.50

61% (182)
39% (116)
21.3 ± 0.24

59% (42)
41% (29)
22.1 ± 0.40

13% (56)
87% (369)

18% (10)
82% (46)

14% (41)
86% (257)

7% (5)
93% (66)

There are no statistically significant differences among the classes for gender distribution, age, or ProVaccine or Vaccine-Hesitant group assignment.

Table 12. Baseline characteristics of Vaccine Hesitant and Pro-Vaccine groups (n=425)
Socio-Demographic
Characteristic
Total

Total % (n)
100% (425)

Vaccine Hesitant %
(n)
13% (56)

Pro-Vaccine % (n)
87% (369)

Gender
Male
Female
Age

62% (263)
38% (162)
21.2 ± 0.21

14% (36)
12% (20)
21.0 ± 0.74

86% (227)
88% (142)
21.3 ± 0.21

Race/Ethnicity
African American
Asian
Caucasian
Hispanic
Native American
Other

1% (3)
3% (11)
87% (370)
3% (12)
0.2% (1)
6% (26)

27% (3)
13% (48)
17% (2)
100% (1)
8% (2)

100% (3)
73% (8)
87% (322)
83% (10)
92% (24)

There were no statistically significant differences in ethnicity, gender, or age between vaccine opinion
groups.

4.3.2 Interview intervention improves student vaccine attitude scores
Vaccine attitudes improved when the participants gained a personal understanding of
how vaccine-preventable diseases affect individuals and communities. Vaccine-hesitant students
enrolled in MMBio 240 (no vaccine curriculum) who were part of the intervention group (n =
19) showed a significant increase in VAS; average VAS shifted from 17.58 ± 0.84 to 20.53 ±
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0.94 (paired t-test CI difference (diff) 95% 4.077–0.817; p < 0.001), an average increase of 2.95
± 2.34 points (Figure 24). Of these students, 68% (n = 13) had sufficient increases in their VASs
to move from the vaccine-hesitant group to the pro-vaccine group. Conversely, vaccine-hesitant
students who were part of the control group (n = 22) had no significant increase in VAS (paired
t-test CI diff 95% 1.856–0.038; p = 0.059) which shifted only 17.27 ± 0.87 to 18.18 ± 1.31, an
average increase of 1 ± 2.05 point (p = 0.059). Only 27% (n = 6) of students in the control group
increased their scores sufficiently to move from the vaccine-hesitant group to the pro-vaccine
group. Post-intervention VASs are significantly different between control and intervention VH
groups (independent t-test CI diff 95% 4.066–0.623; p = 0.009), whereas post-intervention VASs
are still significantly different between VH and PV students in the intervention group
(independent t-test CI diff 95% 3.702–1.733; p < 0.001). α = 0.0125.

Vaccine Attitude Score
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MMBio 240-PV VPD interview
20

MMBio 240-PV autoimmune interview

*

MMBio 240-VH VPD interview
15

10

MMBio 240-VH autoimmune interview
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Figure 24. Vaccine-preventable disease interview significantly improves attitudes towards vaccines
A significant difference (interaction term p < 0.001) for vaccine-hesitant (VH) students in MMBio 240.

4.3.3 Interview intervention improves student vaccine attitude scores
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Intensive vaccine education may be even more effective at improving vaccine attitudes
than interviewing individuals who have had a VPD. All vaccine-hesitant students (n = 5)
enrolled in MMBio 261 (intensive immune, VPD, and vaccine education) significantly increased
their VASs by 7.00 ± 1.41 points on average regardless of survey intervention (p < 0.001), (precontrol group MMBio 261 VH mean 16.50, CI 95% 14.41–18.59; post-control group VH mean
23.500, CI 95% 12.616–25.384; pre-intervention group VH mean 14.000, CI 95% 12.29–15.71;
post-intervention group VH mean 21.00, CI 95% 19.46–22.54) (Figure 25a). For all VH
students, including intervention and control groups, the pre-intervention VAS mean was 15.00 ±
2.06 and the post-intervention VAS mean was 22.00 ± 2.23, decidedly in the pro-vaccine range.
Four out of five VH students increased their VASs sufficiently to move from the vaccine-hesitant
category to the pro-vaccine category with an average increase of 7.50 ± 1.00 points. The final
student, who participated in the intervention group, increased their VAS from 13 to 18 points, an
increase of 5 points. There is a significant difference between pre- and post-intervention group
MMBio 261 VH students (p = 0.026, n = 3 paired t-test CI diff 95% 11.97–2.03). Statistics
cannot be run across time between pre- and post-control group VH students since there
are a low number of respondents (n = 2). Although these results are promising, large in
magnitude, and statistically significant, they are based on a small number of vaccine-hesitant
students in the class (n = 5). Furthermore, students in MMBio 261 are majoring in a life sciences
degree and may be more prone towards persuasion by scientific reasoning than the non-major
students in the general education Bio 100 course.
To highlight the need for tailored and intensive vaccine education, vaccine-hesitant
students in Bio 100 had a non-significant yet distinct upward trend over time regardless of
survey intervention (Figure 25b). Overall, VASs do significantly change across time (p = 0.036)
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and vaccine attitude/survey groups (p < 0.001). All students in Bio 100 received brief instruction
on how vaccines work, the rarity of vaccine side effects, the benefits of herd immunity to
society, and no specific conversation about VPDs. The average VH student increased 1.9 ± 2.37
points between pre- and post-intervention VASs. There is no significant difference after the
survey intervention between post-control group and post-intervention group VH students
(independent t-test CI diff 95% 3.47–7.47; p = 0.42), or between post-control group PV and postcontrol group VH students (independent t-test CI diff 95% 8.32–1.57; p = 0.136). There is a
significant difference after survey treatment between post-intervention group PV and postintervention group VH students (independent t-test CI diff 95% 8.24–3.38; p < 0.001).
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Figure 25. Education can significantly increase vaccine attitude
(a) Vaccine attitude scores (VASs) of MMBio 261 vaccine-hesitant students significantly increased
regardless of survey intervention (p < 0.001), Difference between pre-control group VH and preintervention group MMBio 261 VH students is not significant (CI diff 95% 4.72–9.71; p = 0.35). (b)
While there is an upward VAS trend for all Bio 100 VH students, it is not significant, suggesting that
education has more influence than intervention.

4.3.4 Vaccine-hesitant students’ VAS change dependent on pre-intervention VASs and
class
This intervention focuses on the vaccine attitudes and responses of vaccine-hesitant
students to an interview intervention. To better understand what aspects of the interview
intervention positively influenced VH students, we focused on analyzing the scores of VH
students by comparing pre- and post-intervention VASs. Overall, most VH students (75%) have
increased VASs, while 50% of all VH students advance to PV scores by the end of the study
(Table 13). This gain, however, depends on class or interview group as previously described. For
example, interview group determines the fate of MMBio 240 VH students but not Bio 100 VH
students (Table 13). Class enrollment predicts pre- to post-intervention VAS changes (Figure
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26a). MMBio 261 students have the greatest increase (7.50 ± 1.00), while students in Bio 100
and MMBio 240 had similar gains (3.40 ± 1.50 and 3.50 ± 2.00 points, respectively).
Yet, once students are broken into groups based on pre-intervention VASs, it becomes
clear that not all VH students are alike (Figure 26b, Table 14). Students with the lowest preintervention VASs (11–15 points) are unlikely to become PV (n = 2.18%) and only gain an
average of 2.91 ± 2.74 points (p < 0.001). This average is clearly defined by survey groups:
intervention group students gain an average of 4.67 ± 2.65 points, whereas control group
students gain an average of 0.8 ± 1.92 points. Students in this low score category who gained 5+
points (n = 4) were all part of the intervention group. This suggests that the most vaccine-hesitant
students are swayed by VPD interviews. Students with middle VH pre-intervention VASs (16 or
17 points) gain an average of 4.00 ± 3.07 (p = 0.0095) and are more likely to become PV (n = 9,
60%). Overwhelmingly, students in this middle category who gained 5+ points were either in
MMBio 261 (n = 3) or had conducted a VPD survey in Bio 100 or MMBio 240 (n = 4). Two
students in this category were not in MMBio 261 and conducted autoimmune surveys, thus their
reasons for change are not predictable. The final group of VH students with the highest preintervention VAS (18 or 19 points) gained the least, an average of 1.27 ± 2.02 points (p =
0.0018, n = 17.57%). As these students are near the highest range already, it is not surprising that
no students gained more than 5 points as a 6 point gain places them at the top of the VAS range.
Table 13. Survey intervention and education significantly improves vaccine hesitant student VAS
Change posttreatment
Total
VAS Increased
VAS No Change

Overall VH %
(n)
56
75% (42)
11% (6)

BIO 100 %
(n)
10
80% (8)
0% (0)
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MMBio 240 %
(n)
41
71% (29)
17% (7)

MMBio 261 %
(n)
5
100% (5)
0% (0)

VAS Decreased
Pro Vaccine VAS
(20+ pts)

14% (8)

20% (2)

12% (5)

0% (0)

50% (28)

50% (5)

46% (19)

80% (4)

Breakdown of all vaccine hesitant (VH) post-intervention VAS regardless of survey-treatment. All
students who reached a VAS of 20+ were reassigned pro vaccine (PV). “VAS Increased” includes
students who became PV.
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Figure 26. Vaccine-hesitant students make varying gains based on starting score and class attended
(a) VAS changes for VH students with PV post-intervention VASs. VH to PV students in MMBio 261
had an average VAS increase of 7.5 ± 1.0 points, whereas students in Bio 100 and MMBio 240 gained an
average of 3.4 ± 1.5 and 3.5 ± 2.0 points, respectively. (b) VH students’ gains are determined by preintervention VASs. Plotting pre-intervention VASs against post-intervention VASs for VH students
shows student responsiveness is dependent on pre-intervention VASs. The line indicates no change
between pre-and post-intervention scores, so the farther away from the line the larger the change.
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Table 14. Numerical breakdown of all VH students by pre-intervention VAS (figure 26b)
Pre-intervention
VAS

11 to 15 pts

16-17 pts

18-19 pts

total

11

15

30

Post-intervention
VAS
VH
VP
Change (avg)
VAS Decreased

82% (9)
18% (2)
2.91 ± 2.74
1

40% (6)
60% (9)
4.00 ± 3.07
1

43% (13)
57%(17)
1.27 ± 2.02
6

Age (avg)

20.9 ± 0.9

21.0 ± 0.2

21.1 ± 1.3

4.3.5 Vaccine-hesitant student post-intervention VAS increase correlated with perceived
physical suffering and physical limitations
In the post-survey interview, students in the intervention group were asked to assess how
much each of the following characteristics affected their opinion of vaccines: physical suffering,
limited normal activity, limited interaction with others, impact on family and friends, and
financial costs (Methods, Box 3). These attributes were assessed from “strongly more opposed to
vaccination” to “strongly more in favor of vaccination” and assigned the values of 1–5 points.
VH students’ post-intervention VASs are significantly and moderately correlated with physical
suffering (4.08 ± 0.845, r2 = 0.405, p = 0.04) (Figure 27a) and limitation on normal activities
(3.88 ± 0.653, r2 = 0.518, p = 0.007) (Figure 27b). VH students with a positive pre- to postintervention VAS change agree or strongly agree that physical suffering is of major importance;
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although the amount change in VAS compared to strength of agreement is not significant, there
is a visible upward trend (one-way ANOVA, p = 0.3089) (Figure 27c). Even more strikingly, VH
students with the greatest VAS change (6–9 points, n = 5) strongly agree that normal activity
limitations affect their vaccine opinions (one-way ANOVA, p = 0.0206) (Figure 27d). This
suggests that VH students are more influenced by stories from VPD victims that include physical
suffering and activity limitation.
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Figure 27. Post-intervention VAS and positive pre- to post-intervention VAS changes are influenced
by (a,c) physical suffering and (b,d) physical activity limitations
(a) Post-intervention VAS is predicted by physical suffering (r2 = 0.405, p = 0.04) and (b) physical
limitations (r2 = 0.518, p = 0.007). (c) While the student’s perception of physical suffering did not predict
the amount of VAS change (p = 0.3089), (d) the student’s perception of normal activity limitations is
significantly predicted (p = 0.0206). * p < 0.05.

4.3.5.1 Interview examples correspond to student perceptions of physical suffering and
physical limitations
Examples of interview responses for physical suffering and physical limitations from

students with the greatest VAS change (6–9 points) suggest that extreme cases enhance student
response. One student interviewed a member of their church congregation who had shingles:
“The pain was so bad that she ended up at a pain management clinic where they did steroid shots
into her spine. The pain meds didn’t even touch [reduce] her pain, even the heavy ones. For
months she couldn’t leave the house.” This interview led the student to explain (Methods, Table
10, question 25) that “The project showed how the lack of vaccination is essentially accepting
the pain and suffering that comes with disease.” Another student interviewed his or her
grandmother about tuberculosis: “Before getting diagnosed and during the time that she was
treated, she could work her eight-hour temple shift and then she would go straight to bed after
getting home. After a couple of hours nap, she would get up for a short time to get small tasks
done before retiring to bed for the night.” This student summarized the interview experience as
“I dislike the idea of physical suffering so hearing about someone getting a disease made the idea
of getting a disease if I don’t get vaccinated seem more real.” These students both became PV
with VAS increases of 7 and 6 points, respectively.
In keeping with this idea, many VH students with smaller VAS gains generally reported
less serious physical suffering and physical limitations from the people they interviewed. A
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student who gained 4 points and interviewed a shingles patient wrote: “She considered her case
very minor and she did not suffer physically much. She had some difficulty sleeping for a couple
of weeks. She was a stay-at-home wife at that time, so she wasn’t missing work [or] school.”
Similarly, a student who gained 3 points and interviewed a German measles case remarked,
“Mother developed typical rash for about 3 days with high fever and remained bed bound. She is
a school teacher and didn’t work for a few days.” While some VH students who gained low to
middle VAS points had extreme examples, overall the tone was more moderate than the students
who gained the greatest VAS points.
4.4 Discussion
In this study, we succeeded in improving student vaccine attitudes through either (1)
having students interview individuals who had experienced a VPD or (2) providing intensive
vaccine- and VPD-related course material. Combining intervention styles allowed us to assess
the strength of each intervention. VPD interviews (intervention group) were most successful at
swaying student vaccine attitudes when the coursework did not discuss vaccines or if the
interviews had strong themes of physical suffering and limitations. The majority of students in
the intervention group who became pro-vaccine and the resulting increase in vaccine attitude
scores mirrored those achieved through intensive education (MMBio 261). Thus, encouraging
students to conduct VPD interviews may be an easy and effective intervention when the course
has little to do with VPDs or lacks vaccine-related content.
In courses that do address vaccines, it may be advantageous to first rigorously introduce
students to VPD consequences before addressing, lightly, vaccine safety and societal
implications. While Bio 100 introduces vaccines through a homework assignment that seeks to
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correct misconceptions about vaccine safety and societal implications, MMBio 261 begins with
rigorous weeks-long sections on immunity and VPDs but only briefly discusses vaccine safety
and herd immunity. This may explain why Bio 100 VH students did not have significantly
increased post-intervention VASs, only a suggestive upward trend, whereas MMBio 261 VH
students had significantly improved post-intervention VASs. The comparison between Bio 100
and MMBio 261 students mirrors earlier research that discussing VPD ramifications has a
greater impact on combating vaccine hesitancy than correcting flawed assumptions or asserting
an absence of risk about vaccines [344-347, 468].
This study does have limitations. We did not examine whether an interview-based
intervention would be successful in a non-science course. Any biological instruction discussing
vaccines might provide some boost to vaccine attitudes. Additionally, for logistical reasons, we
did not assess whether the increase in VAS is meaningful by following whether students
vaccinate their current and future children. Furthermore, this study focuses on college students
and may not be expandable to the general population. Nonetheless, despite these limitations,
interview-based interventions and intensive VPD-dependent vaccine education does significantly
increase vaccine attitudes, in a population susceptible to anti-vaccine attitudes. Vaccine
hesitancy is a complex, situation-dependent problem, and requires unique and tailored
interventions. Interview-based interventions are easy to implement and can supplement courses
or even community outreach programs seeking to address vaccine hesitancy. Predisposing
students to think more favorably about vaccinations by openly discussing the consequences of
vaccine-preventable diseases may improve their prospective individual and familial vaccine
uptake. Future research should tease apart the contributions of science education and personal
familiarity with VPDs towards improving vaccine attitudes in diverse populations.
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4.5 Conclusions
There are two major conclusions of this work. First, an interview-based intervention,
where students discuss vaccine-preventable diseases with people who have actually experienced
these diseases, can significantly improve attitudes towards vaccination. Second, the subject
matter used while teaching about vaccine-preventable diseases matters. In the class with
extensive discussion of the diseases themselves, there was a strong increase in vaccine attitudes
among vaccine-hesitant students, while this effect was not seen in the class that discussed mostly
vaccine safety. Taken together, these findings indicate that increasing familiarity with vaccinepreventable diseases leads to improved attitudes towards vaccination. This should help to create
solutions to the worldwide problem of vaccine hesitancy or denial, by indicating aspects of
education that are important for affecting those attitudes.
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CHAPTER 5: Conclusions and Future Directions
The work presented in this dissertation summarizes research focused on understanding 1) T cell
activation 2) the contribution of autoimmune disorders to viral incidence and cancer, and 3)
opinions about vaccine hesitancy. Individual sections for these projects address concluding
remarks and future directions for each of these three areas of research.
5.1 Helper T cell receptor affinity influencing T cell activation
Clinical research studies have focused mainly on T cell receptors (TCRs) expressed in
killer T cells to directly eliminate cancer cells [142, 389]. Helper T cells can promote both
indirect and direct immune responses to cancer, playing a key role in preventing tumor antigen
escape [388] and may be less toxic against overexpressed tumor associated antigens [146].
Helper T cell activation is influenced by a confluence of factors including TCR-peptide:major
histocompatibility complex II (TCR-pMHCII) affinity, coreceptor expression, and
immunological conditions such as the proximal cytokine milieu [11, 36, 49, 50]. Here we
described work testing the hypothesis that increased helper TCR-pMHCII affinity promotes T
cell activation and that CD4 expression would modulate IL-2 expression in both full length TCR
(flTCR) and TCR-single chain signaling chimeric antigen receptors (TCR-SCS CARs). We
determined that while increased TCR-pMHCII affinity does promote increased T cell activation,
CD4 expression moderated or abrogated IL-2 production for intermediate and high affinity
constructs. While the main inhibitory mechanism was Lck sequestration by CD4, CD4 was
independently inhibitory at intermediate affinity for full length TCRs and at high affinity for
TCR-SCS CARs. This work revealed several important T cell activation phenotypes and more
work is needed to understand the mechanisms involved. Below are a series of questions that
could be addressed in the future:
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1. How does increased TCR affinity in helper T cells alter novel downstream phosphorylation
cascades? Much is known about how increased TCR affinity affects killer T cell activation,
yet increased TCR affinity in helper T cells may alter novel downstream phosphorylation
cascades, affect helper T cell persistence and apoptosis rates, alter T cell subset fate and the
production of other cytokines such as IFN-γ, IL-4, and IL-10. These traits could be measured
in murine T cells (CD4+ and CD4-) transduced with high affinity TCRs through: A)
measuring in vitro common signaling phosphorylation amounts on CD3ζ and ERK (a
measure of T cell activation readiness) by phospho-flow or western blot; B) using flow
cytometry to measure in vivo rates of T cell proliferation and apoptosis; and C) stimulating T
cells with various LLO peptide concentrations and measuring cytokine output with a BD
bead cytometric array to determine the Th subtype.
2. How does our high affinity TCRs affect T cell efficiency clearing Listeria monocytogenes
infection in established in vivo mouse models? This could be measured by injecting CD4+ or
CD4- murine T cells transduced with high affinity TCRs into mice, followed by L.
monocytogenes injection, and then plating dilutions of the infected spleens at Day 3 postinfection to count bacterial colonies. For controls, mice injected with our transgenic WT
LLO56, LLO118, or no T cells would be assessed for their bacterial clearance. Mice would
be closely monitored for physical signs of adverse reaction. During a pre-experiment check,
all TCR-transduced T cells would screened for reactivity to self-peptide by incubating them
with splenocytes from C57/Bl.6 mice and measuring IL-2 production and T cell proliferation
by CFSE flow cytometry. Alternatively, T cells transduced high affinity TCRs in vivo
effectiveness could be measured in reaction to tumor cells engineered to express LLO
peptide.
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3. What is the mechanistic root of the Lck-independent and CD4-dependent IL-2 production
inhibition? Does CD4 have an activation regulatory role? A CD4-specific inhibition
phenotype has been noted in literature [64], but the mechanism itself has not been described.
Furthermore, constructs expressed in the Lck-free T cell hybridoma line, 58-/- CD4-, had
massive amounts of non-peptide-specific constitutive IL-2 production, indicating that a
regulatory mechanism was disabled by the absence of CD4. It is possible that CD4 is more
of a negative regulator in peptide-specific activation than previously understood. An easy
experiment would be to sort our T cell hybridoma clones for high and low expression of
TCR-SCS to see if constitutive activation is TCR-SCS concentration dependent. We could
also sort T cells with stringent TCR expression into CD4low and CD4high populations for each
of our CD4+ clones to see if CD4 expression dictated constitutive IL-2 production and the
observed activation phenotypes.
4. How does CD4T binding pMHCII enhance activation when it cannot interact with Lck
directly? Can we replicate these findings with MHCII (I-Ab) that have mutated CD4 binding
domains? We noted CD4T, an intracellular truncated form of CD4, enhanced the activation
of low affinity flTCRs and intermediate affinity TCR-SCS. This is surprising, because
CD4T cannot interact directly with Lck to phosphorylate CD3 ITAMs. It is therefore likely
that CD4T provides a structural help by perhaps prolonging the contact between MHCII and
the TCR. Additionally, it is possible that the CD4T truncated form adversely affected CD4
function. Thus repeating the experiments with splenocytes that have I-Ab molecules that do
not bind CD4 would clarify whether CD4T provides structural support to improve activation
and whether CD4 truncation altered our initial observations about CD4 extracellular domain
inhibition.
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5. Would expressing high affinity MHCII-specific TCRs in CD4- cell lines improve immune
responses? As CD4 expression in helper T cells abrogates IL-2 production for intermediate
flTCR and high affinity TCR-SCS CARs, expressing the constructs in alternative cells lines
such as CD8+ killer T cells or natural killer cells (NK) may produce novel immunological
responses. CD8 does not bind Lck as well as CD4 [471], thus more free-Lck may be
available to promote TCR-MHCII activation where CD8 would be excluded. CD8 may also
act as a dominant-negative inhibitor when it is not recruited to the TCR-MHC complex [62].
Additionally, helper TCRs transduced into CD8 T cells may promote more cytotoxic activity
against MHCII+ tumors [389]. CAR T cells can have substantial toxic effects to patients.
CAR-NK cells have been shown to have reduced cytokine release syndrome, neurotoxicity,
graft-versus host disease, and maintain baseline levels of inflammatory cytokines such as IL6 [472-474]. Natural killer cells express both CD4 and Lck [475, 476], thus it is unknown
whether NK cells transduced with helper TCRs would maintain the gains seen in CAR NK
cells or would have abrogated or altered immunological responses.
5.2 Future directions SLE-virus promoting cancer risk
Systemic lupus erythematosus (SLE) and viruses have a reciprocal relationship. Not only
do viruses promote and exacerbate SLE onset [251], viral infection can also promote the
development of certain cancers such as hematological malignancies [289-291], cervical cancer
and liver cancer [273, 274]. In our study we demonstrated that SLE patients have an increased
risk for viral infections and these infections interacted with SLE to promote hematological and
overall cancer development. We also demonstrated that SLE and Multiple sclerosis (MS)
uniquely affect cancer development. While SLE by itself did not promote cancer development,
MS may increase overall cancer risk. There were some limitations to this study, including that
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our cohort was too small to detect enough HPV and hepatitis ICD-9/10 codes and lab codes to
assess the contribution of those viruses to cervical cancer and liver cancer, respectively. We also
did not have enough viral tests in our MS cohort to detect viral patterns for this autoimmune
disorder. Therefore, follow up studies could include the following:
1. Can we improve the robustness of our results with a larger cohort? Because we had so few
viruses reported in the MS cohort, and too few incidences of rare cancers, repeating the study
with a larger cohort of SLE and MS patients could improve the power of these rare
incidences and expand our predictive capabilities.
2. Do multiple risk factors for hematological cancers contribute to cancer risk independently or
concomitantly? The improved cohort could also be used to investigate whether there are
interactions between three SLE patient hematological cancer development risk factors:
cyclophosphamide, glucocorticoid use, or EBV activity [274]. It is possible that the
immunosuppressive drugs increase EBV activity thereby increasing cancer risk or that they
are separate risk factors for hematological malignancy development. This kind of work
could inform clinicians about which patients are at risk for adverse cancer events, and might
uncover ways to create preventative screening tools to identify at-risk patients prior to
prescribing cyclophosphamides and glucocorticoids.
3. Do vaccination recommendations improve patient cancer rates and survival? At the end of
our paper, we recommended preventative vaccines such as the HPV vaccine (Gardasil) for
SLE patients to prevent oncological viral infections. Again, a longitudinal electronic medical
records study may be an excellent way to follow up on whether this recommendation
decreases cervical cancer incidence in SLE patients.
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4. Could a mouse model help uncover the links between SLE, EBV and hematological cancer
incidence? This is a whole grant in and of itself. Developing this model requires choosing
the correct lupus murine model and murine virus as mice cannot be infected with EBV.
However, this model could reveal important triggers for cancer development that could lead
to therapeutics or models of care for at-risk SLE patients.
5.3 Future directions vaccine hesitancy
Vaccine hesitancy is a complex and variable problem driven by factors that change over
time, place and vaccine [311]. There is no “one size fits all” solution. Confronting inaccurate
vaccine information directly often causes further entrenchment in erroneous beliefs [346, 347].
Children and adolescents may be more likely to influence their family’s current and future
behaviors [373-375]. In this paper, we sought to educate a specific young adult population with
shared cultural values (BYU undergraduates) about the importance of vaccines by teaching them
about vaccine preventable diseases (VPDs) through classroom instruction or interviews with
community members. We found that students who either interviewed a community member
about a VPD and received no education about vaccines, or students who received education
about VPDs and the immune system significantly improved their vaccine attitude scores (VAS).
Students that interviewed a community member about an autoimmune disorder or received
vaccine-safety education did not improve their before and after VAS. This work has led to the
following questions that would be important to address in the future.
1. Did the intervention have longevity? Will it improve vaccine rates for the students and their
families over time? To answer these questions, the study would need to be extended with
follow-ups over 5-10 years tracing students and their children from birth-kindergarten. We
could also observe the whether the students themselves choose adult vaccinations such as
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yearly influenza vaccines or the HPV vaccine. If there is no persistent effect, it is possible
that an intervention like this could be used in the short-term to encourage students to get
influenza vaccines or HPV vaccines.
2. Would an interview-based intervention work for a non-science course like a history or
English course? Are there course topics such as discussing the Black Plague in a European
history course or consumption (tuberculosis) in Gothic literature that would complement the
intervention and improve its efficacy? Designing a second study to investigate this would
include controls such as running the original study in science courses as positive controls, in
addition to deploying different interventions in non-sciences course sections taught by the
same instructor. These interventions would include the interviews compared to sections that
receive a few lectures discussing either vaccine safety or VPD/immunology in a way that
complements the usual course content. The interview sections could be designed to support
class goals as either a writing project for an English or journalism course or as a tool to teach
interviewing skills to history students.
3. Would stories based on VPD-interviews make an effective intervention in a doctor’s office
and increase vaccine uptake by patients? Previous research using stories from the CDC
about a child sick with measles had mixed results [347]. Could this be because the CDC
story is about a child told in the third person? Are stories told retroactively in the first person
more effective? Is it more effective to have video clips vs written stories or does the
interaction need to be live with someone the listener knows well? A study could be designed
with a set story told in multiple perspectives from third person to first person using active to
retroactive language. These stories could be deployed in doctors’ offices and administered
randomly to patients with children due for shots. As clinician use of presumptive language
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and conversational language has a decided effect on patient vaccine uptake [370], clinicians
would need to use a set script. The vaccine uptake could be tracked and compared across
treatments and between doctors’ offices.
4. What content creates stories that change VAS? In our study, we noted that severe physical
suffering and limitations to normal activity were effective at changing minds. We could
generate a panel of stories with increasing pain or limitations and measure the effect on VAS
for a variety of participants including students and parents. This could potentially be
deployed in clinics in a similar manner as discussed above.
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APPENDIX I: Journal of Immunology Abstracts
The following appendix contains two published abstracts from the Journal of
Immunology: Abstract 1: Johnson, D. J., Myers, S., Magoffin, W., Orton, T., Tellez-Frietas,
C.M., Christensen, K., and Weber, K. S. Effects of high affinity engineered class II-restricted full
length and single chain CAR-format T cell receptors specific for a naturally occurring Listeria
monocytogenes epitope on T cell activation and specificity. The Journal of Immunology 202,
196.16 (2019). The data for this abstract was presented at the American Association of
Immunologists (AAI) Annual Meeting in San Diego, CA, 2019.
Abstract 2: Freitas, C. T., Cox, T., Johnson, D. & Weber, K. S. CD5 expression
influences T cell metabolism and mice behavior. The Journal of Immunology 200, 108.116108.116 (2018). The data for this abstract was presented at the American Association of
Immunologist (AAI) Annual Meeting in Austin, TX, 2018.
Abstract 1: Effects of high affinity engineered class II-restricted full length and single
chain CAR-format T cell receptors specific for a naturally occurring Listeria monocytogenes
epitope on T cell activation and specificity
High affinity T cell receptors (TCRs) are absent from the native T cell repertoire. While
current hypotheses propose that high affinity TCRs are more sensitive to antigen and have a
competitive advantage in immune responses, emerging evidence suggests that higher affinity T
cells may reach a threshold where they experience decreased functionality, loss of binding
specificity, and become prone to anergy. High affinity TCRs are especially attractive to facilitate
immunotherapies as native TCR binding affinity may be too low to effectively initiate activation.
However, the effects of increased TCR affinity for CD4+ T cells specific for naturally occurring
epitopes is poorly understood. To address this question, we engineered via yeast display several
176

class II-restricted high affinity TCRs specific for a naturally occurring peptide from Listeria
monocytogenes protein listeriolysin O. Our high affinity clones have KD values as low as 8.7 nM
and half-lives as long as 174 minutes when measured by tetramer dissociation assays. This panel
of class II restricted high affinity TCRs specific for a naturally occurring Listeria
monocytogenes epitope provides a novel means of testing the role of affinity and CD4+ T cell
activation responses in the context of an infection.

Abstract 2: CD5 Expression Influences T cell Metabolism and Mice Behavior
T cells are key players in the adaptive immune response and undergo metabolic changes
upon activation. CD5 is a co-receptor found on T cells and plays a significant role in regulating T
cell thymic development, intracellular signaling and cytokine production. Previous studies have
177

found that naïve T cells with high CD5 expression (CD5hi) have increased TCR signal strength
and enhances immune response to foreign peptide in the periphery. Additionally, we have
reported that CD5hi naïve T cells have higher calcium mobilization and improved T cell
activation compared to CD5lo T cells. Calcium influx levels can modulate and influence
metabolic changes in T cells. Thus, we hypothesized that CD5hi, CD5lo and CD5 deficient T cells
have different bioenergetic demands that affect metabolic pathways and T cell activation. We
evaluated the effects of CD5 levels on metabolism using CD5 deficient mice vs wild type
controls and found CD5 deficient T cells had significant differences in metabolic function.
Recently published work has described a connection between increased T cell metabolism and
altered cognitive function in PD-1 deficient mice. We have also found significant differences
between CD5 deficient and wild type mice in marble burying rates, elevated plus and water maze
behavior and open field activity.
These behavioral test results suggest CD5 deficient mice have altered cognitive function and
higher levels of anxiety. Thus, CD5 deficiency alters T cell metabolic and cognitive function.
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Abstract: In 2019, the World Health Organization (WHO) listed vaccine hesitancy in its top ten
threats to global health. Vaccine hesitancy is a “delay in acceptance or refusal to vaccinate
despite availability of vaccination services”. Urban areas with large amounts of vaccine
hesitancy are at risk for the resurgence of vaccine-preventable diseases (VPDs). Many vaccinehesitant (VH) parents may be unfamiliar with the consequences of VPDs, and thus might be
swayed when confronted with the symptoms and dangers of VPDs. As such, we sought to
educate college students (future parents) in an urban vaccine-hesitant hotspot by assigning them
to interview family or community members who had experienced a VPD. Student vaccine
attitudes were assessed by surveys before and after the interviews. Vaccine-hesitant students
who conducted a VPD interview but received no additional vaccine educational materials were
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significantly more likely (interaction term p < 0.001) to become pro-vaccine (PV) (68%) than
students who conducted an autoimmune interview and received no additional educational
materials. Additionally, students whose interviewees experienced intense physical suffering or
physical limitations or students who were enrolled in a course with intensive VPD and vaccine
curriculum had significantly increased vaccine attitudes. This suggests that introducing students
to VPDs can decrease vaccine hesitancy.
Keywords: vaccine hesitancy; college student; vaccine; vaccine curriculum; interview
intervention for college students (future parents) in Provo, Utah might help improve vaccine
attitudes and future vaccine uptake for themselves and their families.
Introduction

Vaccines are victims of their own success. Due to the effectiveness of vaccination programs,
many people have limited or no experience with vaccine-preventable diseases (VPDs) [1].
Parents increasingly assume that the risks associated with VPDs are minimal compared to
potential health and safety risks of vaccinations themselves [2–5]. This has led to a rise in
vaccine hesitancy by parents that results in a “delay in acceptance or refusal to vaccinate despite
availability of vaccination services” [6]. Urban centers with large clusters of vaccine-hesitant
individuals are particularly vulnerable to VPD outbreaks among exposed, unimmunized
children. In the 2016–2017 school year, Utah County (Provo) in Utah, USA ranked sixth
nationally for the total number of entering kindergartners that were under-vaccinated as
measured by non-medical exemption (NME) waivers (n = 662 NME) [7]. As many of these
parents may have never experienced VPDs, we hypothesized that designing an intervention
Influencing students before they become parents will likely encourage pro-vaccination behaviors
for their future and current families, as children and adolescents who participate in health
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education activities in school can positively influence family health management [8–10].
However, there is evidence that correcting erroneous assumptions about potential health and
safety risks may be ineffective, causing a “backfire effect” and further entrenching vaccinehesitant individuals’ beliefs [11,12]. Vaccine hesitancy often arises from deep-rooted ideological
beliefs and conspiracist ideational tendencies. As this kind of thinking has been shown to
become further entrenched when those holding it are presented with contradictory information,
correcting misinformation is often counterproductive [13–15]. Further, it is difficult to provide
convincing data for the absence of risk; consequently, vaccine-hesitant parents may be
recalcitrant to messages aimed at alleviating concerns about vaccine safety and side effects
[16,17]. Rather, pro-vaccine interventions may be more effective if they warn of health dangers
to individuals from VPDs [17]. Additionally, the vaccine-hesitant movement uses emotionally
charged stories with dire long-term consequences to effectively convey anti-vaccine ideology.
Combating this rhetoric with a similarly emotional appeal may be an effective preventative
strategy [18]. Therefore, we predicted that hearing about the effects of VPDs from family and
community members who suffered from VPDs would improve the students’ attitudes towards
vaccination. We further predicted that classroom education could improve attitudes towards
vaccines.
In this study, we analyzed three courses with different vaccine instructional approaches varying
from none to intensive. Enrolled students were also assigned to interview a family or community
member about their personal experience with either an autoimmune disease (control) or a VPD.
Students exposed to either intensive VPD-focused vaccine instruction or who interviewed
individuals who had had a VPD had statistically significant and meaningful gains in vaccine
attitude.
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2. Methods
2.1. Study Population
Students at a large private institution in the Western United States were enrolled in a quasiexperimental survey-based intervention study. Students were eligible if they attended one of
three courses in the Winter 2018 semester: General education non-science major Bio 100
(Principles of Biology, one section), and microbiology and molecular biology (MMBio) majorspecific courses MMBio 240 (Molecular Biology, two sections) and MMBio 261 (Infection and
Immunity, one section). Vaccination principles were taught in Bio 100 and MMBio 261, but not
in MMBio 240. All students enrolled in the courses were encouraged to participate and offered
extra credit for their time and efforts. Our study sample consisted of 425 students who completed
the study requirements (574 began the study). The study was conducted in accordance with the
Declaration of Helsinki, and study procedures were approved by the Institutional Review Board
at the institution (study #E17263). All participants received and signed a consent form that
included a description of the study and were assigned a random number to protect their
identities. Students were informed that their instructors would never see their names associated
with any of the survey results, and steps were taken to avoid such instructor access.
2.2. Assigning Vaccine Attitude Groups and Randomization Process
To determine initial vaccine attitudes, students took a pre-interview survey (see Box 1) and were
asked to rate each question from 1–5 where 1 is “strongly disagree” and 5 is “strongly agree”.
Each question concerning vaccine attitude was chosen to cover a specific aspect of vaccine
hesitancy. Pre-intervention vaccine attitude scores (VASs) were tallied from questions 1, 4, 9,
11, and 13 (Box 1). Question 1 is a test of general attitude towards vaccines. Question 4
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addresses side effects, relevant since many vaccine-hesitant individuals are afraid of these side
effects. Question 9 is about the common belief that vaccines cause autism, a major concern for
many vaccine-hesitant people. Question 11 gives an opportunity for the participants to opine on
the positive aspects of vaccination in terms of how well they work. Question 13 is a question
about how the vaccine attitude would affect action and give it a more real-world, rather than
theoretical, effect. To avoid answer bias, students were not informed that the study was about
vaccination opinions and additional questions about autoimmune diseases and depression were
included in the survey. Scores from questions 4 and 9 were reverse coded to account for the
negative nature of the question. These questions were written in a negative way to avoid biasing
the study by presenting vaccines in only a positive light in the questions. Students with VASs
between 20 and 25 points were categorized as “Pro-Vaccine” (PV) and students that had a VAS
less than 20 points were categorized as “Vaccine-Hesitant” (VH). A cutoff value of 20 was
chosen because it meant, on average, that the student at least “agreed” (score or converted score
of 4) with all of the vaccine attitude questions. A score of less than 20 would mean that the
student on average either did not at least “agree” with the pro-vaccine statements, or that they
had a serious disagreement with at least one statement about vaccines. Students were assigned to
interview groups by alternating autoimmune (negative control for survey and interview effects)
and vaccine-preventable disease (VPD) interview assignments alphabetically within PV and VH
categories so that equal numbers of students were assigned to each interview intervention.
Box 1. Pre-interview survey.
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Rate each question from 1–5 where 1 is “strongly disagree” and 5 is “strongly agree”
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

Vaccines are more helpful than harmful
Treatment for autoimmune diseases is more helpful than harmful
Medications for depression are more helpful than harmful
Vaccines often have severe side effects
People with autoimmune diseases suffer considerably
Medication for depression is effective at treating depression
There are effective treatments for autoimmune diseases
Depression can be overcome using willpower
Vaccines cause autism
Exercise is the best treatment for autoimmune diseases
Vaccines are effective at preventing disease
Medications for depression have severe side effects
I am likely to fully vaccinate my children/I have fully vaccinated my children

Students were emailed their survey assignments and related paperwork, and based on their group
assignment, were asked to interview members of the community who had experienced either a
VPD or an autoimmune disease before the end of the semester using the interview questions
shown in Box 2. To encourage study completion, students received full points for extra credit
with completed survey submission (Bio 100 10 points, 1% of grade; MMBio 240 20 points,
2.3% of grade; MMBio 261 20 points, 2.3% of grade). At the end of the semester, students were
administered a post-interview survey (see Box 3) that reiterated the pre-interview survey
questions and included follow-up questions about the survey itself. These questions (14–18 in
the post-interview survey) were written to identify the aspects of the interview that had the most
significant impact on vaccine attitudes. They provided both an opportunity to rank several
factors and the ability to explain in their own words how the various aspects of the interview
affected them. We then assigned students a post-intervention VAS and assessed for changes in
overall vaccine scores between the pre-and post-intervention surveys. Included in this analysis
was determining whether students moved from the vaccine-hesitant to pro-vaccine group, or
vice-versa.
Box 2. Interview questions.
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1.

What is your relationship to the person who had the disease?

2.

When did they develop the disease?

3.

Which disease was involved?

4.

What type of physical suffering did the disease cause? How bad was it?

5.

How did the disease limit the person’s ability to do normal activities?

6.

How did the disease affect the person’s interaction with other people?

7.

How did the disease affect the person’s friends, family, or loved ones?

8.

How did the disease affect the person financially?

9.

Were there any other effects of the disease?
Box 3. Post-interview survey.

1.

Vaccines are more helpful than harmful

2.

Treatment for autoimmune diseases is more helpful than harmful

3.

Medications for depression are more helpful than harmful

4.

Vaccines often have severe side effects

5.

People with autoimmune diseases suffer considerably

6.

Medication for depression is effective at treating depression

7.

There are effective treatments for autoimmune diseases

8.

Depression can be overcome using willpower

9.

Vaccines cause autism

10.

Exercise is the best treatment for autoimmune diseases

11.

Vaccines are effective at preventing disease

12.

Medications for depression have severe side effects

13.

I am likely to fully vaccinate my children/I have fully vaccinated my children
Complete next section only if you interviewed a VPD-subject
Circle an answer: much more opposed, slightly more opposed, no effect, slightly more in favor, much more in
favor

14.

How did hearing about the subject’s physical suffering affect your opinion of vaccines?

15.

How did hearing about how the disease limited normal activity affect your opinion of vaccines?

16.

How did hearing about how the disease affected the subjects’ interactions with other people affect your opinion
of vaccines?

17.

How did hearing about how the disease affected the subject’s family, friends, or loved ones affect your opinion
of vaccines?

18.

How did hearing about the disease’s financial impact on the subject affect your opinion of vaccines?
Rank the following:
(a)
(b)
(c)
(d)
(e)

Physical suffering
Limitation of activities
Interactions with other people
Effect on family, friends, or loved ones
Financial impact
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19.

Please explain briefly, what effect, if any, the project had on your attitude towards vaccination and why it has
that effect.

20.

If this interview did NOT affect your attitude towards vaccination, why not?

2.3. Analyses
Changes between groups’ pre- and post-intervention VASs were assessed with factorial
ANOVAs. Individual group changes over time were assessed by paired sample t-tests, and
differences between two groups at specific time points were assessed by independent sample ttests. Bonferroni corrections were applied to any multiple comparisons to account for alpha
inflation. Standard deviations were reported for statistics less than 5 points. All other statistics
reported 95% confidence intervals (CI).
All analyses were performed using SPSS Statistics 25 (IBM). Figures were generated in Prism 8
(GraphPad) and tables were generated in Excel 2016 (Microsoft).
3. Results
3.1. Overview and Pre-Interview Intervention Vaccine Attitudes
A total of 574 students volunteered to take the pre-interview survey during the Winter 2018
semester. Based on their pre-intervention vaccination attitude scores (VASs), students were
designated either pro-vaccine (PV) (87%) or vaccine-hesitant (VH) (13%) and assigned to the
control group (autoimmune survey, n = 286) or the intervention group (vaccine-preventable
disease (VPD) survey, n = 288). Of the students, 74% (n = 425) completed all requisite parts of
the study (pre-interview survey, community/family interview, post-interview survey) and were
included in the final analysis (Figure 1). The VH group was defined as VAS < 20 and the PV
group was defined as VAS ≥ 20 based on the pre-interview survey responses. There were no
statistically significant differences in the sociodemographic characteristics among the classes nor
did the course they were enrolled in significantly affect the assignment to VH and PV groups
(Table 1). Course year explains the age difference between the courses: Bio 100 is a general
190

education course for first year students, MMBio 240 is a second-year major-specific course, and
MMBio 261 is a second to third year major-specific course. Furthermore, sex, race, and age
were not significantly correlated with pre-intervention vaccine attitudes (Table 2). Student
willingness to vaccinate current/future children was significantly different between VH and PV
groups (scale of 1–5 from strongly disagree to strongly agree) with means of 3.84 and 4.92,
respectively (independent t-test CI 95% 0.814–1.355; p < 0.001).

Figure 1. Participant flow through the randomized treatment.
Table 1. Baseline characteristics of the participating classes (n = 425).
Class Demographics
Total
Gender Male
Female

Total % (n)

Bio 100 % (n)

MMBio 240 % (n)

MMBio 261 % (n)

100% (425)

13% (56)

70% (298)

17% (71)

62% (263)

70% (39)

61% (182)

59% (42)

38% (162)

30% (17)

39% (116)

41% (29)
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±
21.2 0.21

±
19.7 0.50

±
21.3 0.24

±
22.1 0.40

Pre-Intervention
Vaccine Attitude Score
Vaccine-Hesitant

13% (56)

18% (10)

14% (41)

7% (5)

Pro-Vaccine

87% (369)

82% (46)

86% (257)

93% (66)

Age

There are no statistically significant differences among the classes for gender distribution, age, or Pro-Vaccine or Vaccine-Hesitant group
assignment.

Table 2. Baseline characteristics of vaccine-hesitant and pro-vaccine groups (n = 425).
Sociodemographic Characteristic
Total

Total % (n)

Vaccine-Hesitant % (n)

Pro-Vaccine % (n)

100% (425)

13% (56)

87% (369)

62% (263)

14% (36)

86% (227)

Female

38% (162)

12% (20)

88% (142)

Age

±

21.2 0.21

±

21.0 0.74

±
21.3 0.21

1% (3)

-

100% (3)

Gender Male

Race/Ethnicity African
American
Asian

3% (11)

27% (3)

73% (8)

Caucasian

87% (370)

13% (48)

87% (322)

Hispanic
Native American
Other

3% (12)

17% (2)

83% (10)

0.2% (1)

100% (1)

-

6% (26)

8% (2)

92% (24)

There were no statistically significant differences in ethnicity, gender, or age between vaccine opinion groups.

3.2. Interview Intervention Improves Student Vaccine Attitude Scores
Vaccine attitudes improved when the participants gained a personal understanding of how
vaccine-preventable diseases affect individuals and communities. Vaccine-hesitant students
enrolled in MMBio 240 (no vaccine curriculum) who were part of the intervention group (n =
19) showed a significant increase in VAS; average VAS shifted from 17.58 ± 0.84 to 20.53 ±
0.94 (paired t-test CI difference (diff) 95% 4.077–0.817; p < 0.001), an average increase of 2.95
± 2.34 points (Figure 2). Of these students, 68% (n = 13) had sufficient increases in their VASs to
move from the vaccine-hesitant group to the pro-vaccine group. Conversely, vaccine-hesitant
students who were part of the control group (n = 22) had no significant increase in VAS (paired
t-test CI diff 95% 1.856–0.038; p = 0.059) which shifted only 17.27 ± 0.87 to 18.18 ± 1.31, an
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average increase of 1 ± 2.05 point (p = 0.059). Only 27% (n = 6) of students in the control group
increased their scores sufficiently to move from
the vaccine-hesitant group to the pro-vaccine
group. Post-intervention VASs are significantly

different between control and intervention VH
groups (independent t-test CI diff 95% 4.066–0.623; p = 0.009),
whereas post-intervention VASs are still significantly different between VH and PV students in
the intervention group (independent t-test CI diff 95% 3.702–1.733; p < 0.001). α = 0.0125.
Figure 2. Vaccine-preventable disease interview significantly improves attitudes towards vaccines. Treatment makes
a significant difference (interaction term p < 0.001) for vaccine-hesitant (VH) students in MMBio 240.

3.3. Vaccine Education Likely Improves Student Vaccine Attitudes
Intensive vaccine education may be even more effective at improving vaccine attitudes than
interviewing individuals who have had a VPD. All vaccine-hesitant students (n = 5) enrolled in
MMBio 261 (intensive immune, VPD, and vaccine education) significantly increased their
VASs by
7.00 ± 1.41 points on average regardless of survey intervention (p < 0.001), (pre-control group
MMBio 261 VH mean 16.50, CI 95% 14.41–18.59; post-control group VH mean 23.500, CI
95% 12.616–25.384; pre-intervention group VH mean 14.000, CI 95% 12.29–15.71; postintervention group VH mean 21.00, CI 95% 19.46–22.54) (Figure 3a). For all VH students,
including intervention and control groups, the pre-intervention VAS mean was 15.00 ± 2.06 and
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the post-intervention VAS mean was 22.00 ± 2.23, decidedly in the pro-vaccine range. Four out
of five VH students increased their VASs sufficiently to move from the vaccine-hesitant
category to the pro-vaccine category with an average increase of
7.50 ± 1.00 points. The final student, who participated in the intervention group, increased their
VAS from 13 to 18 points, an increase of 5 points. There is a significant difference between preand post-intervention group MMBio 261 VH students (p = 0.026, n = 3 paired t-test CI diff 95%
11.97–2.03). Statistics cannot be run across time between pre- and post-control group VH
students since there are a low number of respondents (n = 2). Although these results are
promising, large in magnitude, and statistically significant, they are based on a small number of
vaccine-hesitant students in the class (n = 5). Furthermore, students in MMBio 261 are majoring
in a life sciences degree and may be more prone towards persuasion by scientific reasoning than
the non-major students in the general education Bio 100 course.
To highlight the need for tailored and intensive vaccine education, vaccine-hesitant students in
Bio 100 had a non-significant yet distinct upward trend over time regardless of survey
intervention (Figure 3b). Overall, VASs do significantly change across time (p = 0.036) and
vaccine attitude/survey groups (p < 0.001). All students in Bio 100 received brief instruction on
how vaccines work, the rarity of vaccine side effects, the benefits of herd immunity to society,
and no specific conversation about VPDs. The average VH student increased 1.9 ± 2.37 points
between pre- and post-intervention VASs. There is no significant difference after the survey
intervention between post-control group and post-intervention group VH students (independent
t-test CI diff 95% 3.47–7.47; p = 0.42), or between post-control group PV and post-control group
VH students (independent t-test CI diff 95% 8.32–1.57; p = 0.136). There is a significant
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difference after survey treatment between post-intervention group PV and post-intervention
group VH students (independent t-test CI diff 95% 8.24–3.38; p < 0.001).

(a)

(b)
Figure 3. Education can significantly increase vaccine attitude. (a) Vaccine attitude scores (VASs) of MMBio 261
vaccine-hesitant students significantly increased regardless of survey intervention (p < 0.001), Difference between
pre-control group VH and pre-intervention group MMBio 261 VH students is not significant (CI diff 95% 4.72–9.71;
p = 0.35). (b) While there is an upward VAS trend for all Bio 100 VH students, it is not significant, suggesting that
education has more influence than intervention.

3.4. Vaccine-Hesitant Students’ VAS Change Dependent on Pre-Intervention VASs and Class
This intervention focuses on the vaccine attitudes and responses of vaccine-hesitant students to
an interview intervention. To better understand what aspects of the interview intervention
positively influenced VH students, we focused on analyzing the scores of VH students by
comparing pre- and post-intervention VASs. Overall, most VH students (75%) have increased
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VASs, while 50% of all VH students advance to PV scores by the end of the study (Table 3).
This gain, however, depends on class or interview group as previously described. For example,
interview group determines the fate of MMBio 240 VH students but not Bio 100 VH students
(Table 3). Class enrollment predicts pre- to post-intervention VAS changes (Figure 4a). MMBio
261 students have the greatest increase (7.50 ± 1.00), while students in Bio 100 and MMBio 240
had similar gains (3.40 ± 1.50 and 3.50 ± 2.00 points, respectively).
Yet, once students are broken into groups based on pre-intervention VASs, it becomes clear that
not all VH students are alike (Figure 4b, Table 4). Students with the lowest pre-intervention
VASs (11–15 points) are unlikely to become PV (n = 2.18%) and only gain an average of 2.91 ±
2.74 points (p < 0.001). This average is clearly defined by survey groups: intervention group
students gain an average of 4.67 ± 2.65 points, whereas control group students gain an average
of 0.8 ± 1.92 points. Students in this low score category who gained 5+ points (n = 4) were all
part of the intervention group. This suggests that the most vaccine-hesitant students are swayed
by VPD interviews. Students with middle VH pre-intervention VASs (16 or 17 points) gain an
average of 4.00 ± 3.07 (p = 0.0095) and are more likely to become PV (n = 9, 60%).
Overwhelmingly, students in this middle category who gained 5+ points were either in MMBio
261 (n = 3) or had conducted a VPD survey in Bio 100 or MMBio 240 (n = 4). Two students in
this category were not in MMBio 261 and conducted autoimmune surveys, thus their reasons for
change are not predictable. The final group of VH students with the highest pre-intervention
VAS (18 or 19 points) gained the least, an average of 1.27 ± 2.02 points (p = 0.0018, n =
17.57%). As these students are near the highest range already, it is not surprising that no students
gained more than 5 points as a 6 point gain places them at the top of the VAS range.
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Table 3. Survey intervention and education significantly improves vaccine-hesitant student VASs.
Change
Post-Treatment

Overall VH % (n)

Total
VAS Increased
VAS No Change
VAS Decreased
Pro-Vaccine VAS (20+
points)

BIO 100 % (n)

MMBio 240 % (n)

MMBio 261 % (n)

56

10

41

5

75% (42)
11% (6)
14% (8)

80% (8)
0% (0)
20% (2)

71% (29)
17% (7)
12% (5)

100% (5)
0% (0)
0% (0)

50% (28)

50% (5)

46% (19)

80% (4)

Breakdown of all vaccine-hesitant (VH) post-intervention VASs regardless of survey treatment. All students who reached a VAS of 20+
were reassigned as pro-vaccine (PV). “VAS Increased” includes students who became PV.

(b)
Figure 4. Vaccine-hesitant students make varying gains based on starting score and class attended. (a) VAS changes for
VH students with PV post-intervention VASs. VH to PV students in MMBio 261 had an average VAS increase of 7.5 ±
1.0 points, whereas students in Bio 100 and MMBio 240 gained an average of 3.4 ± 1.5 and 3.5 ± 2.0 points,
respectively. (b) VH students’ gains are determined by pre-intervention VASs. Plotting pre-intervention VASs against
post-intervention VASs for VH students shows student responsiveness is dependent on pre-intervention VASs. The line
indicates no change between pre-and post-intervention scores, so the farther away from the line the larger the change.
Table 4. Numerical breakdown of all VH students by pre-intervention VAS.
Pre-Intervention VAS
Total

11–15 Points

16 or 17 Points

18 or 19 Points

11

15

30
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Post-intervention VAS
VH

82% (9)

40% (6)

43% (13)

18% (2)

60% (9)

57% (17)

Change (average)

±
2.91 2.74

±
4.00 3.07

±
1.27 2.02

VAS Decreased

9% (1)

7% (1)

20% (6)

Age (average)

±
20.9 0.9

±
21.0 0.2

±
21.1 1.3

VP

All VH students broken down by pre-intervention VAS. Age is not significantly different between the groups.

3.5. Vaccine-Hesitant Student Post-Intervention VAS Increase Correlated with Perceived
Physical Suffering and Physical Limitations
In the post-survey interview, students in the intervention group were asked to assess how much
each of the following characteristics affected their opinion of vaccines: physical suffering,
limited normal activity, limited interaction with others, impact on family and friends, and
financial costs (Methods, Box 3). These attributes were assessed from “strongly more opposed to
vaccination” to “strongly more in favor of vaccination” and assigned the values of 1–5 points.
VH students’ post-intervention VASs are significantly and moderately correlated with physical
suffering (4.08 ± 0.845, r2 = 0.405, p = 0.04) (Figure 5a) and limitation on normal activities (3.88
± 0.653, r2 = 0.518, p = 0.007) (Figure 5b). VH students with a positive pre- to post-intervention
VAS change agree or strongly agree that physical suffering is of major importance; although the
amount change in VAS compared to strength of agreement is not significant, there is a visible
upward trend (one-way ANOVA, p = 0.3089) (Figure 5c). Even more strikingly, VH students
with the greatest VAS change (6–9 points, n = 5) strongly agree that normal activity limitations
affect their vaccine opinions (one-way ANOVA, p = 0.0206) (Figure 5d). This suggests that VH
students are more influenced by stories from VPD victims that include physical suffering and
activity limitation.
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3.5.1. Interview Examples Correspond to Student Perceptions of Physical Suffering and Physical
Limitations
Examples of interview responses for physical suffering and physical limitations from students
with the greatest VAS change (6–9 points) suggest that extreme cases enhance student response.
One student interviewed a member of their church congregation who had shingles: “The pain
was so bad that she ended up at a pain management clinic where they did steroid shots into her
spine. The pain meds didn’t even touch [reduce] her pain, even the heavy ones. For months she
couldn’t leave the house.” This interview led the student to explain (Methods, Box 3, question
25) that “The project showed how the lack of vaccination is essentially accepting the pain and
suffering that comes with disease.” Another student interviewed his or her grandmother about
tuberculosis: “Before getting diagnosed and during the time that she was treated, she could work
her eight-hour temple shift and then she would go straight to bed after getting home. After a
couple of hours nap, she would get up for a short time to get small tasks done before retiring to
bed for the night.” This student summarized the interview experience as “I dislike the idea of
physical suffering so hearing about someone getting a disease made the idea of getting a disease
if I don’t get vaccinated seem more real.” These students both became PV
with VAS increases of 7 and 6 points, respectively.
In keeping with this idea, many VH students with smaller VAS gains generally reported less
serious physical suffering and physical limitations from the people they interviewed. A student
who gained 4 points and interviewed a shingles patient wrote: “She considered her case very
minor and she did not suffer physically much. She had some difficulty sleeping for a couple of
weeks. She was a stay-at-home wife at that time, so she wasn’t missing work [or] school.”
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Similarly, a student who gained 3 points and interviewed a German measles case remarked,
“Mother developed typical rash for about 3 days with high fever and remained bed bound. She is
a school teacher and didn’t work for a few days.” While some VH students who gained low to
middle VAS points had extreme examples, overall the tone was more moderate than the students
who gained the greatest VAS points.
3.5.2. Student Ranking of Influential Factors Does Not Match Actual Impact
We sought to confirm this finding by examining the ranking data (Methods, Box 3). We asked
students to rank which factor (physical suffering, limitation of activities, interactions with other
people, effects on family/friends, and financial impact) they perceived to have the greatest
impact on the interviewee. Interestingly, 62% of all students ranked physical suffering as having
the most impact, and 54% of students ranked financial costs as having the least impact.
However, neither of these factors was significant for the whole population. There were no clear
ranking distinctions for limitation of activities, and interactions with other people and
family/friends. These findings are replicated for VH students. Therefore, in many cases,
physical suffering of the interviewee is represented as the greatest symptom reported by the
interviewer, but does not surpass other factors in influencing post-intervention VASs in general,
at least as perceived by the student’s ranked understanding. This may be because what was most
important to the interviewee does not necessarily directly correlate with the interviewers “take
away”. For example, while students perceived that the interviewee might have emphasized
characteristics other than physical suffering in their interview, the students themselves perceived
pain as an important concept. This may be important to consider while designing interventions.
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(a)

(b)

(c)

(d)
Figure 5. Post-intervention VAS and positive pre- to post-intervention VAS changes are influenced by

(a,c) physical suffering and (b,d) physical activity limitations. (a) Post-intervention VAS is predicted by physical
suffering (r2 = 0.405, p = 0.04) and (b) physical limitations (r2 = 0.518, p = 0.007). (c) While the student’s perception
of physical suffering did not predict the amount of VAS change (p = 0.3089), (d) the student’s perception of normal
activity limitations is significantly predicted (p = 0.0206). * p < 0.05.

4. Discussion
In this study, we succeeded in improving student vaccine attitudes through either (1) having
students interview individuals who had experienced a VPD or (2) providing intensive vaccineand VPD-related course material. Combining intervention styles allowed us to assess the
strength of each intervention. VPD interviews (intervention group) were most successful at
swaying student vaccine attitudes when the coursework did not discuss vaccines or if the
interviews had strong themes of physical suffering and limitations. The majority of students in
the intervention group who became pro-vaccine and the resulting increase in vaccine attitude
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scores mirrored those achieved through intensive education (MMBio 261). Thus, encouraging
students to conduct VPD interviews may be an easy and effective intervention when the course
has little to do with VPDs or lacks vaccine-related content.
In courses that do address vaccines, it may be advantageous to first rigorously introduce students
to VPD consequences before addressing, lightly, vaccine safety and societal implications. While
Bio 100 introduces vaccines through a homework assignment that seeks to correct
misconceptions about vaccine safety and societal implications, MMBio 261 begins with rigorous
weeks-long sections on immunity and VPDs but only briefly discusses vaccine safety and herd
immunity. This may explain why Bio 100 VH students did not have significantly increased postintervention VASs, only a suggestive upward trend, whereas MMBio 261 VH students had
significantly improved post-intervention VASs. The comparison between Bio 100 and MMBio
261 students mirrors earlier research that discussing VPD ramifications has a greater impact on
combating vaccine hesitancy than correcting flawed assumptions or asserting an absence of risk
about vaccines [11–15].
This study does have limitations. We did not examine whether an interview-based intervention
would be successful in a non-science course. Any biological instruction discussing vaccines
might provide some boost to vaccine attitudes. Additionally, for logistical reasons, we did not
assess whether the increase in VAS is meaningful by following whether students vaccinate their
current and future children. Furthermore, this study focuses on college students and may not be
expandable to the general population. Nonetheless, despite these limitations, interview-based
interventions and intensive VPD-dependent vaccine education does significantly increase
vaccine attitudes, in a population susceptible to anti-vaccine attitudes. Vaccine hesitancy is a
complex, situation-dependent problem, and requires unique and tailored interventions.
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Interview-based interventions are easy to implement and can supplement courses or even
community outreach programs seeking to address vaccine hesitancy. Predisposing students to
think more favorably about vaccinations by openly discussing the consequences of vaccinepreventable diseases may improve their prospective individual and familial vaccine uptake.
Future research should tease apart the contributions of science education and personal familiarity
with VPDs towards improving vaccine attitudes in diverse populations.
5. Conclusions
There are two major conclusions of this work. First, an interview-based intervention, where
students discuss vaccine-preventable diseases with people who have actually experienced these
diseases, can significantly improve attitudes towards vaccination. Second, the subject matter
used while teaching about vaccine-preventable diseases matters. In the class with extensive
discussion of the diseases themselves, there was a strong increase in vaccine attitudes among
vaccine-hesitant students, while this effect was not seen in the class that discussed mostly
vaccine safety. Taken together, these findings indicate that increasing familiarity with vaccinepreventable diseases leads to improved attitudes towards vaccination. This should help to create
solutions to the worldwide problem of vaccine hesitancy or denial, by indicating aspects of
education that are important for affecting those attitudes.
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We previously identified a nuclear variant of bone morphogenetic protein 2 (BMP2),
named nBMP2, that is translated from an alternative start codon. Decreased nuclear
localization of nBMP2 in the nBmp2NLStm mouse model leads to muscular, neurological,
and immune phenotypes—all of which are consistent with aberrant intracellular calcium
(Ca2+) response. Ca2+ response in these mice, however, has yet to be measured directly.
Because a prior study suggested impairment of macrophage function in nBmp2NLStm
mutant mice, bone marrow derived (BMD) macrophages and splenic macrophages were
isolated from wild type and nBmp2NLStm mutant mice. Immunocytochemistry revealed
that nuclei of both BMD and splenic macrophages from wild type mice contain nBMP2,
while the protein is decreased in nuclei of nBmp2NLStm mutant macrophages. Live-cell
Ca2+ imaging and engulfment assays revealed that Ca2+ response and phagocytosis in
response to bacterial supernatant are similar in
BMD macrophages isolated from naïve (uninfected) nBmp2NLStm mutant mice and wild
type mice, but are deficient in splenic macrophages isolated from mutant mice after
secondary systemic infection with Staphylococcus aureus, suggesting progressive
impairment as macrophages respond to infection. This direct evidence of impaired Ca2+
handling in nBMP2 mutant macrophages supports the hypothesis that nBMP2 plays a role
in Ca2+ response.
Our group has reported the existence of a nuclear variant of the growth factor bone
morphogenetic protein 2 (BMP2), designated nBMP21. This variant protein is produced by
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translation from an alternative downstream start codon that eliminates the N-terminal
endoplasmic reticulum signal peptide, thus preventing the protein’s delivery to the secretory
pathway. Instead, nBMP2 is translated in the cytoplasm and translocated to the nucleus by means
of an embedded bipartite nuclear localization signal (NLS)1. Using immunohistochemistry, we
have detected nBMP2 in skeletal muscle nuclei and in the nuclei of CA1 neurons in the
hippocampus2,3.
To examine the function of nBMP2, we generated a mutant mouse strain (nBmp2NLStm) in
which a three-amino acid substitution in the NLS inhibits translocation of nBMP2 to the nucleus
while still allowing normal synthesis and secretion of the conventional BMP2 growth factor2.
The mice appear overtly normal and are fertile. They do, however, lack nBMP2 in myonuclei,
and electrophysiological studies revealed that skeletal muscle relaxation is significantly slowed
after stimulated twitch contraction, a process that is regulated by intracellular Ca2+ transport.
Consistent with impaired intracellular Ca2+ transport, sarco/endoplasmic reticulum Ca2+ ATPase
(SERCA) activity is decreased in skeletal muscle2. The mutant mice also lack nBMP2 in CA1
hippocampal neurons, and electrophysiological studies revealed reduced long-term potentiation
(LTP) in the hippocampus3. LTP is dependent on intracellular Ca2+ transport and is thought to be
the cellular equivalent of learning and memory4–6. Behavioral tests revealed that the nBMP2
mutant mice have impaired object recognition memory3.
Intracellular Ca2+ elevation also regulates the activation and differentiation of several different
types of immune cells including T cells, B cells, dendritic cells, and macrophages7–10. To see if
nBmp2NLStm mutants had compromised immune response, mice were challenged by systemic
infection with Staphylococcus aureus. While the mutants’ immune response to a primary
infection appeared normal, their immune response to a secondary infection challenge 30 days
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later resulted in higher levels of bacteremia, increased mortality, and failure of spleens to enlarge
normally11. Although we did not observed differences in the total number of macrophages in
spleen, thymus, or lymph node from wild type compared to mutant mice, we did observe that
after the secondary infection, spleen from nBmp2NLStm mutant mice showed fewer
hemosiderin-laden macrophages than spleen from wild type mice11. Macrophages in the spleen
accumulate hemosiderin by phagocytosing damaged red blood cells and hemoglobin, which
would be present in the blood stream of S. aureus-challenged mice due to the hemolysins that S.
aureus expresses12–14. The observation of fewer hemosiderin-laden macrophages in the spleens
of mutant mice after a secondary infection suggested to us that macrophage phagocytic activity
might be impaired in the absence of nBMP2, potentially providing us with an accessible cell type
in which to directly test our hypothesis that intracellular Ca2+ response is disrupted in the absence
of nBMP2.
To interrogate if nBMP2 might play a role in Ca2+ response, we isolated macrophages from
wild type and nBmp2NLStm mutant mice. These macrophages included bone marrow derived
(BMD) macrophages from uninfected mice, and splenic macrophages from mice that had
undergone primary and secondary infections with S. aureus15. Live-cell Ca2+ imaging as well as
bead engulfment assays were performed to measure intracellular Ca2+ response and phagocytic
activity. These analyses revealed deficient Ca2+ response and phagocytosis in splenic
macrophages isolated from mutant mice after secondary systemic infection with S. aureus, but
not in BMD macrophages from naïve mice, suggesting that as nBmp2NLStm mutant cells
respond to infection over time, Ca2+ response is progressively impaired.
Results
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The nuclear variant nBMP2 is expressed in BMD and splenic macrophages from wild type mice.

To

determine whether nBMP2 is expressed in macrophages, BMD macrophages and splenic
macrophages were isolated from naïve (uninfected) wild type and nBmp2NLStm mutant mice and
differentiated in vitro, and immunocytochemistry was performed using an anti-BMP2 antibody
that binds to both BMP2 and nBMP2. Consistent with our prior observation of impaired immune
response in nBmp2NLStm mutant mice11, nBMP2 was detected in the nuclei of wild type BMD
(Fig. 1a) and splenic (Fig. 1b) macrophages. As expected, nBMP2 was significantly decreased in
macrophage nuclei from nBmp2NLStm mutant mice (Fig. 1a,b, mutant). ImageJ software
quantification of immunofluorescence images showed that the density of nuclear BMP2 staining
was significantly more intense in wild type compared to mutant macrophages in both BMD
macrophages (p = 0.0005) and splenic macrophages (p < 0.0001) (Fig. 2). BMP2 staining was
visible throughout the cytoplasm of both wild type and mutant macrophages, as expected, given
that nBMP2 is synthesized in the cytosol before being translocated to the nucleus and that the
conventional BMP2 growth factor is synthesized in the rough ER and translocated through the
Golgi before being secreted from the cell.
BMD macrophages from uninfected nBmp2NLStm mutant mice and wild type mice have similar Ca2+
response. Naïve BMD macrophages

isolated from femurs and tibias of uninfected mice were

differentiated and activated in vitro then plated for live-cell Ca2+ imaging. Plated cells were
loaded with Fura-2AM, a UV-excitable ratiometric calcium indicator that changes its excitation
in response to Ca2+ binding; Fura-2AM emits at 380 nm when Ca2+ is not bound, and at 340 nm
when Ca2+ binds to the dye. The fluorescence ratio (F340/F380), increases as cytosolic Ca2+
levels increase16. At the 2 min time point, supernatant from Escherichia coli (ECS) cultures was
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added to stimulate Ca2+ flux (Fig. 3a)17–19. Following this stimulation, there were no observable
differences between naïve mutant and wild type BMD macrophages in peak Ca2+ response (Fig.
3b) or sustained Ca2+ levels (Fig. 3c).
Splenic macrophages isolated from nBmp2NLStm mutant mice after secondary infection show impaired Ca2+
response. In

our prior study, immune deficiencies in nBMP2NLStm mice were detectable only

after the mice received a secondary infection with S. aureus11. Because our current experiments
revealed no significant differences in Ca2+ response in naïve BMD macrophages from mutant
compared to wild type mice, we decided to replicate the in vivo conditions of our previous work
by examining splenic macrophage harvested from mice after a secondary infection with S.
aureus, and by using S. aureus supernatant as the stimulus to trigger Ca2+ flux11. Although S.
aureus is a gram positive bacteria that does not produce LPS, it does produce liphoteichoic acid
(LTA), which is similarly able to activate macrophages20,21. Thirty-five days after primary
systemic S. aureus infections, mice were given a second injection of S. aureus, and splenic
macrophages were isolated 3 days later.
After one week in vitro maturation, splenic macrophages were loaded with Fura-2AM for livecell Ca2+ imaging experiments. S. aureus supernatant (SAS) was used to stimulate Ca2+ flux at
the 2-min time point (Fig. 4a). Compared to the lack of a difference in naïve BMD macrophages,
it is particularly striking that peak Ca2+ response was significantly decreased (p = 0.0335) in
mutant splenic macrophages after secondary infection (Fig. 4b). Sustained Ca2+ levels as
measured by the area under the curve (AUC) from minutes 3–10 was also significantly decreased
(p = 0.0008) (Fig. 4c).
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BMD macrophages from uninfected nBmp2NLStm mutant mice and wild type mice show similar phagocytic
activity. To

test phagocytic activity of naïve BMD macrophages (meaning macrophages that were

isolated from uninfected mice) from nBmp2NLStm mutant compared to wild type mice, we
measured fluorescent bead engulfment by CD11b and F4/80 positive cells with flow cytometry
(Fig. 5a)22–28. We observed no differences in the phagocytic activity of naïve BMD macrophages
from nBmp2NLStm mutant compared to wild type mice (Fig. 5b–e).
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Figure 1. BMD macrophages and splenic macrophages express nBMP2, which is decreased in
the nuclei of nBmp2NLStm mutant macrophages. (a) BMD macrophages and (b) splenic
macrophages were stained with anti-BMP2 antibody (green) and counterstained with DAPI
(blue), demonstrating that nBMP2 is expressed and localized to the nucleus in wild type
macrophages, and that nuclear translocation of nBMP2 is inhibited in mutant macrophages.
BMP2 labeling within the cytoplasm is present in both wild type and mutant cells as expected,
because the targeted mutation allows translation of nBMP2 in the cytoplasm but inhibits
nuclear translocation, and it allows normal synthesis and secretion of conventional BMP2.
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Splenic macrophages from nBmp2NLStm mutant mice show impaired phagocytic activity. To

test

phagocytic activity in macrophages isolated from mice after secondary infection, splenic
macrophages were isolated from wild type and nBmp2NLStm mutant mice 3 days after mice
received a second systemic infection with S. aureus, and fluorescent bead engulfment was
measured as described above. While differences between wild type and mutant macrophages did
not reach significance when subgroups that engulfed 1, 2, or 3 or more beads were analyzed
individually (Fig. 6a–c), there was a significant reduction in overall mutant phagocytic activity
(p = 0.0176) when the subgroups were pooled (Fig. 6d). These data suggest a possible
relationship between the decreased Ca2+ response and reduced phagocytosis in nBmp2NLStm
mutant splenic macrophages.
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Figure 2. Quantification of nBMP2 nuclear staining intensity. Five images each were analyzed
for wild type and mutant BMD macrophages and for mutant splenic macrophages. Four images
were analyzed for wild type splenic macrophages. Each image contained between 10 and 93
cells, and the number of cells analyzed per group ranged from 100 to 337. ImageJ was used to
outline DAPI-stained regions and quantify BMP2 immunostaining as the sum of pixel
intensities within each nucleus. The mean density of BMP2 immunostaining was then
calculated for all nuclei in an image. An unpaired, two-tailed t-test was performed to compare
nuclear staining between wild type and mutant cells. For BMD wild type vs. mutant
macrophages, p = 0.0005. For splenic wild type vs mutant macrophages, p < 0.0001.

Figure 3. Naïve bone marrow derived (BMD) macrophages from nBmp2NLStm mutant mice and
wild type mice have a similar Ca2+ response. Naïve BMD macrophages from wild type (WT) and
nBmp2NLStm mutant
(MT) mice were loaded with Fura-2AM for live-cell Ca2+ imaging. During imaging, cells were
stimulated at 2 min with E. coli supernatant (ECS), then at 10 min with ionomycin as a positive
control. (a) Average curves showing intracellular Ca2+ response in wild type and nBmp2NLStm
mutant BMD macrophages. Fluorescence ratios (F340/F380) were measured at 3 sec intervals
from 0–12 min (n = 38 cells). Error bars (s.e.m.) are shown at one min intervals. (b) Average
(±s.e.m.) of peak Ca2+ influx (F340/F380) in wild type and nBmp2NLStm mutant BMD
macrophages (n = 38 cells). (c) Area under the curve (AUC) of F340/F380 ratios from minutes
3 to 10 min shows sustained intracellular Ca2+ levels (n = 38 cells). NS, not significant.

Figure 4. Splenic macrophages collected from nBmp2NLStm mutant mice after secondary
infection have an impaired Ca2+ response. Splenic macrophages from wild type (WT) and
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nBmp2NLStm mutant (MT) mice were loaded with Fura-2AM for live-cell Ca2+ imaging. During
imaging, cells were stimulated at 2 min with S. aureus supernatant (SAS), then at 10 min with
ionomycin as a positive control. (a) Average curves showing intracellular Ca2+ response in wild
type and nBmp2NLStm mutant splenic macrophages. Fluorescence ratios (F340/ F380) were
measured at 3 sec intervals from 0-12 min (n = 44 cells). Error bars (s.e.m.) are shown at one min
intervals. (b) Average ± s.e.m. of peak Ca2+ influx (F340/F380) in wild type and nBmp2NLStm
mutant splenic macrophages shows a significant difference (n = 44 cells). (c) AUC of F340/F380
ratios from minutes 3 to 10 min shows a significant difference in sustained intracellular Ca2+
levels (n = 44 cells). *p < 0.05, **p < 0.01, ***p < 0.0001.

Discussion
The role of BMP2 in macrophages is unknown and remains an area of active research. BMP2 has
been reported to be constitutively expressed in M1 (inflammatory) macrophages29. Other studies
have shown that BMP2 expression is upregulated as macrophages shift toward the prohealing/anti-inflammatory M2 phenotype30,31. BMP2 secretion by macrophages promotes
migration of vascular smooth muscle cells, and macrophages in the intestinal muscularis secrete
BMP2 to signal enteric neurons32,33. Reports of BMP2 expression by hematopoietic cells, in
particular macrophages, are relevant to this study because nBMP2 can be produced from the
same mRNA as the conventional secreted BMP2 growth factor—any time BMP2 mRNA or
BMP2 growth factor is detected, the potential for nBMP2 synthesis exists1. Accordingly, we
have demonstrated by immunofluorescence that both BMD macrophages and splenic
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macrophages express the nuclear variant of BMP2, nBMP2, and that nBMP2 is decreased in the
nuclei of macrophages from nBmp2NLStm mutant mice.
Previously, we demonstrated that deficiency of nBMP2 in the nucleus impairs secondary
immune response as evidenced by diminished spleen enlargement, poor clearance of S. aureus
from the bloodstream, and increased mortality after secondary infection11. We have also shown
that deficiency of nBMP2 in myonuclei is correlated with slowed skeletal muscle relaxation after
contraction, and deficiency of nBMP2 in the nuclei of hippocampal neurons is correlated with
learning/memory deficits2,3. Each of these phenotypes is consistent with deficiencies in
intracellular Ca2+ transport, but until now, no direct measurements of intracellular Ca2+ have been
performed in cells from nBmp2NLStm mutant mice. The discovery that macrophages express
nBMP2 (Fig. 1) provided an accessible cell type in which to directly address the question of
whether nBMP2 plays a role in intracellular Ca2+ response.
We found that intracellular Ca2+ response was impaired in mutant splenic macrophages after
secondary infection with S. aureus, but not in mutant BMD macrophages isolated from
uninfected mice, even though both macrophage types expressed nBMP2. Recent work has
revealed that innate immune cells can undergo memory-like adaptive responses to increasing
pathogen load, and the deficient Ca2+ response in splenic macrophages after secondary infection
might represent a failure of those adaptive responses34,35. Alternatively, it may be that the effects
of nBMP2 deficiency in the nucleus are simply cumulative, causing a Ca2+-handling phenotype
that becomes progressively more severe as cells differentiate and mature. A progressive
phenotype is consistent with our previously reported observation that hippocampal long-term
potentiation (LTP) was normal in 3-week-old nBmp2NLStm mutant mice but deficient in 3215

month-old mice3. Progressive impairment of intracellular Ca2+ response has received attention
recently as a potential mechanism for both brain and muscle aging36–38, suggesting that nBMP2
dysfunction could contribute to premature aging or aging-related diseases.
Deficiency of nBMP2 in the nucleus also produced a significant decrease in the total
phagocytic activity of splenic macrophages from nBmp2NLStm mutant mice, suggesting that
mutant cells may be less effective at clearing pathogens from the blood stream. This is consistent
with prior studies suggesting that intracellular Ca2+ mobilization plays a role in macrophage
phagocytic activity. For example, impaired Ca2+ response in macrophages from Trpm4(−/−)
mutant mice led to decreased phagocytic activity, resulting in bacterial overgrowth and
translocation to the bloodstream39. Intracellular Ca2+ levels increase during Fcɣ receptor (FcR)mediated phagocytosis40–42, and the loss of CaMKK2, a calcium-dependent kinase, left
macrophages unable to phagocytose bacteria or synthesize cytokines in response to bacterial
lipopolysaccharide (LPS)43.
Although evidence supports the involvement of Ca2+ response in macrophage phagocytic
activity, the scale of the decreased phagocytosis by splenic macrophages observed in our study
seems insufficient to account for the markedly increased mortality of nBmp2NLStm mutant mice
after secondary infection3. We cannot rule out the possibility that the bead engulfment assay did
not fully reflect the severity of phagocytosis impairment in splenic macrophages. Liver
macrophages also play a role in bacterial clearance, and it is possible that the absence of nBMP2
in the nucleus affects their function more severely44,45. In addition, the absence of nBMP2 in the
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Figure 5. Naïve bone marrow derived (BMD) macrophages from nBmp2NLStm mutant mice and
wild type mice show similar phagocytic activity. After incubation with fluorescent microspheres,
macrophages were analyzed by flow cytometry. (a) A representative analysis is shown. The
F4/80 and CD11b double positive population was selected, and from this gate a histogram was
produced to identify macrophages that had engulfed 1, 2, or 3 or more beads. The percentages of
total double positive cells represented within each peak are indicated. (b) Percent of cells
engulfing 1 bead, (c) percent of cells engulfing 2 beads, and (d) percent of cells engulfing 3 or
more beads. (e) Percent of cells engulfing one or more beads. N = 3 pairs of wild type and 3 pairs
of mutant mice. NS, not significant.

217

nucleus might affect other immune system cell types besides macrophages, and it is possible that
another cell type, or perhaps several cell types together, account for the increased mortality of
nBmp2NLStm mutant mice after secondary infection3. Indeed, BMP2 (and therefore potentially
nBMP2) is expressed by a specialized endothelial population in the early embryo, termed
hemogenic endothelium, that gives rise to hematopoietic stem cells46. The absence of nBMP2 at
the earliest stages of hemogenesis could therefore impact a wide range of immune cell types.
BMP2 is also expressed in human cord blood cells, including those that express CD34, a
hematopoietic progenitor cell antigen47, and acute bleeding triggers upregulation of BMP2
expression in hematopoietic stem cells48. BMP2 expression is also found in mature B cells,
where it is upregulated in response to infection with Aggregatibacter actinomycetemcomitans49.
It is possible, therefore, that nBMP2 impacts the activation or function of other immune cell
types in addition to macrophages, and the combined functional deficits account for the increased
mortality in nBmp2NLStm mutant mice after secondary infection.
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Figure 6. Splenic macrophages collected from nBmp2NLStm mutant mice after secondary
infection show impaired engulfment activity. After incubation with fluorescent microspheres,
macrophages were analyzed by flow cytometry as described in Fig. 3. (a) Percent of cells
engulfing 1 bead, (b) percent of cells engulfing 2 beads and, (c) percent of cells engulfing 3 or
more beads. (d) Percent of cells engulfing one or more beads. N = 3 pairs of wild type and 3
pairs of mutant mice. NS, not significant. *p < 0.05.

It will be important, in future work, to elucidate the molecular mechanisms underlying the
Ca2+ response differences between macrophages from wild type and nBMP2 mutant mice.
Differences may stem from impaired uptake or release of Ca2+ from endoplasmic reticulum
stores, as suggested by the decreased SERCA activity observed in skeletal muscle of nBMP2
mutant mice2. Alternatively, transport of Ca2+ could be impaired at the macrophage cell
membrane, consistent with observations that increasing extracellular Ca2+ levels can improve
phagocytosis50,51. Neurons and muscle cells are excitable cells and are therefore equipped with a
different set of ion channels and transporters than are macrophages, and so it will be important to
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examine molecular details of the Ca2+ handling defect in all three cell types. This work has thus
opened the way for future studies into the molecular interactions and activities of nBMP2.
Questions about how nBMP2 functions from inside the nucleus to affect Ca2+ response also
remain to be answered. The novel protein nBMP2 was first identified from among nuclear
proteins that had been isolated using DNA affinity chromatography, but subsequent experiments
failed to show direct binding of nBMP2 to DNA, and the amino acid sequence of nBMP2
contains no predicted DNA-binding domain1. It is possible that nBMP2 interacts indirectly with
DNA through a transcription factor, and future studies of nBMP2’s impact on the expression of
genes involved in Ca2+ signaling will be informative.
In summary, this study supports our working hypothesis that aberrant intracellular Ca2+
response is the mechanism that unites the otherwise disparate muscle, neurological, and immune
phenotypes observed in nBmp2NLStm mutant mice2,3,11,52–54. In doing so, this study has paved
the way for future work to elucidate the precise molecular nature of the Ca2+ signaling
disruptions in nBMP2 mutant cells and to understand how nBMP2’s interactions in the nucleus
impact Ca2+ signaling.
Materials and Methods
This study was carried out in strict accordance with recommendations in
the Guide for the Care and Use of Laboratory Animals55. The protocol was approved by the
Institutional Animal Care and Use Committee (IACUC) of Brigham Young University (protocol
numbers 15-0107 and 15-0603).
Mice were housed in a temperature-controlled (21–22 °C) room with a 12:12 hr light-dark
Research Animals.

cycle and fed standard rodent chow and water ad libitum. The nBmp2NLStm mice were
constructed on a Bl6/129 background, as described2. The homozygous wild type and mutant
mice used in this study were obtained by breeding heterozygotes, and genotyping was performed
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as previously described3. All experiments were performed with male mice at least 6 months of
age.
BMD and Splenic Macrophage Isolation. BMD macrophages

were obtained from femurs and tibias of

wild type and nBmp2NLStm mutant mice and were differentiated in culture at 37 °C with 5%
CO2 for 7 days in macrophage medium (DMEM (HyClone), 10% fetal bovine serum (FBS)
(HyClone), 20% supernatant from L929 mouse fibroblast as a source of macrophage colonystimulating factor (M-CSF), 5% heat inactivated horse serum (Sigma), 1 mM sodium pyruvate
(Gibco by Life Technologies), 1.5 mM L-glutamine (Thermofisher), 10 u/ml penicillin, 10 μg/ml
streptomycin (Gibco by Life Technologies)) prior to plating for immunocytochemistry, Ca2+
imaging or engulfment assays.
Spleens from wild type and nBmp2NLStm mutant mice were homogenized in phosphate
buffered saline (PBS). The homogenate was filtered, pelleted at 450 × g for 5 min, suspended in
lysis buffer (155 mM NH2Cl, 10 mM KHCO3, 0.1 mM EDTA) on ice for 3–5 min to lyse
erythrocytes, and then washed with 37 °C macrophage media and plated in macrophage medium
in 6-well plates. After 3 days of culture at 37 °C in 5% CO2, medium was replaced to remove
non-adherent cells56. On day 4, 100 ng/ml lipopolysaccharide (LPS) was added to the culture
medium to stimulate differentiation, and cells were incubated for 3–4 more days57. Differentiated
cells were then plated for immunocytochemistry, Ca2+ imaging, or engulfment assays.
Immunocytochemistry. Immunocytochemistry

was performed using BMD and splenic

macrophages. Following macrophage isolation and 7-day differentiation as described above,
cells were plated on coverslips that were pre-treated with 0.025% HCl in PBS for 20 min to
facilitate cell attachment. Cells were cultured for 1–2 days to reach 70–90% confluence, then
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fixed at 37 °C in 4% paraformaldehyde for 10 min. Epitopes were exposed through antigen
retrieval using 5% sodium citrate and 0.25% Tween-20 in ddH2O, pH 6.0, at 95 °C for 10 min.
Cells were permeabilized using 0.1% Triton X-100 then blocked for 1.5 hr at room temperature
(RT) using SEA BLOCK blocking buffer (ThermoFisher Scientific, 37527). The samples were
then probed with 1:50 anti-BMP2 antibody (Novus Biologicals, NBP1-19751) diluted in 10%
SEA BLOCK blocking buffer in 0.1% Tween-20/PBS (PBS-T), overnight at 4 °C. The probed
slides were then stained with anti-rabbit Alexa Fluor 488 (ThermoFisher Scientific, A-11034) for
1 hr at RT. Afterwards, nuclei were stained by incubating the slides in 1:5000 DAPI in PBS-T
for 15 min., then slides were mounted using ProlongTM Gold Antifade Mountant (Life
Technologies, P10144) and cured overnight prior to microscopic imaging. Cells were imaged
using a Leica TCS-SP8 confocal microscope with 63X magnification, using the same laser
intensities for all samples. Appropriate laser lines were used such as 405 nm for DAPI and 488
nm for BMP2-Alexa Fluor 488.
Comparison of nuclear BMP2 staining intensity between wild type and mutant cells was
performed on tiff versions of confocal microscope images using ImageJ to create tracings of
DAPI-stained regions and to calculate the mean pixel intensity of nBMP2 staining within each
nucleus. Mean nuclear staining intensity was calculated for each image, and groups were
compared using an unpaired, two-tailed t-test in GraphPad Prism.
S. aureus ATCC strain 12600 was cultured in tryptic soy broth
liquid culture alternating with standard streak plating on mannitol salt agar (Thermo Fisher
Scientific) for counting. To prepare bacteria for injections, 100 µl of overnight liquid culture was
transferred into a new 15 ml broth culture and grown until OD600 reached 1.0, then pelleted and
resuspended in 15 ml of PBS with 20% glycerol, aliquoted, and stored at −80 °C for 3 weeks
before injection. Frozen stock concentration was verified one day before the infection by thawing
a single aliquot and performing standard serial dilution plate counts. On the day of infection, S.
aureus was diluted from the frozen stock to the desired concentration in PBS, and mice received
S. aureus Bacterial Infections.
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a 200 μl retroorbital injection using a 1 ml syringe and 27-gauge needle. The injected volume
contained a priming dose of 1 × 104 CFU/g body weight on day 0 (primary infection), and a dose
of 3 × 105 CFU/g body weight on day 35 (secondary infection). Macrophages were harvested
three days later.
Bacterial Supernatant Preparation. Bacterial

supernatant obtained from E. coli K12 and S. aureus

12600 was used to stimulate Ca2+ fluxes in BMD and splenic macrophages19,58. A single colony
was picked from an agar plate and inoculated into liquid broth overnight culture. The next day, 1
ml of the overnight culture was inoculated into 15 ml liquid broth and incubated with shaking at
37 °C until culture reach an OD600 of 1–1.3. Cells were then pelleted by centrifugation at 1,800 ×
g for 12 min at 4 °C, and supernatant was collected.
Calcium Imaging. BMD and

splenic macrophages were isolated and differentiated in culture for 7

days as described above, then seeded on 8-chambered coverglasses (Nunc 155411, Thermo
Scientific) and incubated overnight in macrophage medium at 37 °C in 5% CO2. For BMD
macrophages, 10 ng/ml LPS from E. coli O55:B5 (Sigma) was included in the overnight
incubation to activate cells. The next day, cells were loaded with 3 μM Fura-2AM (Invitrogen) in
Ringers solution containing Ca2+ to be used as an extracellular source during the Ca2+ imaging
assay (150 mM NaCl, 10 mM glucose, 5 mM HEPES, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2,
pH 7.4) for 30 min at 37 °C in 5% CO2, washed with Ringers solution, then incubated for
another 30 minutes at 37 °C in Ringers solution. Calcium imaging was performed at room
temperature using an Olympus IX51 inverted microscope equipped with a xenon arc lamp. Fura2AM loaded macrophages were excited using 340 nm and 380 nm excitation filters, and images
of 340 nm, 380 nm, and transmitted light were capture using a florescence microscope camera
(Q Imaging Exi Blue) with a 20x objective (N.A. 0.75) at 3-sec intervals. At the 2-min time point
in each imaging protocol, 20 μl of bacterial supernatant was added to stimulate Ca2+ flux.
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Ionomycin (1 μM final concentration) was added at the 10-min time point as a positive control.
10–20 representative cells were selected as regions of interest in each frame, and F340:F380
ratios were calculated and analyzed using CellSens software from Olympus. Each individual
cell’s fluorescence was normalized to its first recorded value according to the equation (FFo)/Fo, where F is the fluorescence at the specific time point, and Fo is the fluorescence value at
time 019,59.
Engulfment Assay. BMD and

splenic macrophages were isolated and differentiated in culture for 7

days as described above, then seeded in 12-well culture plates for flow cytometry-based
engulfment assays22–28. 100% FBS was used to resuspend 2.0 μm phycoerythrin-conjugated
polychromatic red latex microspheres (Polysciences, Inc.) to prevent beads from sticking to the
cell membranes during engulfment23. The ~109 particles/ml concentration was chosen to ensure
that beads were not a limiting factor in phagocytosis rates23. Macrophages were then activated by
adding LPS from E. coli O55:B5 (Sigma) to a final concentration of 10 ng/ml and incubated for
1 hour at 37 °C and 5% CO2. Media was removed and cells were rinsed with cold PBS, then
collected and analyzed by flow cytometry using an Attune flow cytometer (Applied Biosystems
by Life technologies). Cells were pre-treated with anti-CD16/32 antibodies (14-0161-85
eBioscience) to prevent non-specific antibody binding, then surface stained with APCconjugated anti-CD11b antibodies (17-0112-82 eBioscience) and FITC-conjugated anti-F4/80
antibodies (11-4801-82 eBioscience). Doublets were removed based on forward scatter width
(FSC-W)/forward scatter area (FSC-A), and the F4/80 and CD11b double positive population
was selected. From within this gate, engulfing macrophages were distinguished from nonengulfing macrophages based on phycoerythrin fluorescence, and macrophages could be further
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distinguished based on the engulfment of one, two, or three or more beads. Results were
analyzed using FlowJo software (Tree Star).
Data Analysis. All

assays were performed as at least three independent repeats, each in triplicate.

Area under the curve (AUC) was determined using GraphPad Prism. Statistical significance was
assessed using unpaired two-tailed Students T test in GraphPad Prism.
Data Availability
All data generated or analyzed during this study are included in this published article. Biological
reagents will be made available on request.
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Abstract: Calcium influx is critical for T cell effector function and fate. T cells are activated when
T cell receptors (TCRs) engage peptides presented by antigen-presenting cells (APC), causing an increase of
intracellular calcium (Ca2+) concentration. Co-receptors stabilize interactions between the TCR and its ligand, the
peptide-major histocompatibility complex (pMHC), and enhance Ca2+ signaling and T cell activation. Conversely,
some co-receptors can dampen Ca2+ signaling and inhibit T cell activation. Immune checkpoint therapies block
inhibitory co-receptors, such as cytotoxic
T-lymphocyte associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), to increase T cell Ca2+ signaling and
promote T cell survival. Similar to CTLA-4 and PD-1, the co-receptor CD5 has been known to act as a negative
regulator of T cell activation and to alter Ca2+ signaling and T cell function. Though much is known about the role
of CD5 in B cells, recent research has expanded our understanding of CD5 function in T cells. Here we review these
recent findings and discuss how our improved understanding of CD5 Ca2+ signaling regulation could be useful for
basic and clinical research.
Keywords: calcium signaling; T cell receptor (TCR); co-receptors; CD-5; PD-1; CTL-4

1. Introduction
T cells are a critical component of the adaptive immune system. T cell responses are influenced by signals that
modulate the effects of the T cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) interaction
and initiate the transcription of genes involved in cytokine production, proliferation, and differentiation [1–3]. T cell
activation requires multiple signals. First, the TCR engages the pMHC leading to tyrosine phosphorylation of CD3 and
initiation of the Ca2+/Calcineurin/Nuclear factor of activated T cells (NFAT) or Protein kinase C-theta (PKCθ)/Nuclear
factor-κ-light chain enhancer of activated B cells (NF-κB) or Mitogen-activated protein kinase (MAP kinase)/AP-1
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pathways [4–6]. Second, cell surface costimulatory molecules, such as co-receptor CD28, amplify TCR-pMHC
complex signals and promote stronger intracellular interactions to prevent T cell anergy [7,8]. Finally, cytokines such
as interleukin-12 (IL-12), interferon α (INFα), and interleukin-1 (IL-1) promote T cell proliferation, differentiation,
and effector functions [6].
Co-receptors such as CD4 and CD8 interact with MHC molecules and additional co-receptors interact with
surface ligands present on antigen-presenting cells (APCs) to regulate T cell homeostasis, survival, and effector
functions with stimulatory or inhibitory signals [9]. Altering co-receptor levels, balance, or function dramatically
affects immune responses and their dysfunction is implicated in autoimmune diseases [10]. Stimulatory co-receptors
such as CD28, inducible T cell co-stimulator (ICOS), Tumor necrosis factor receptor superfamily member 9 (TNFRSF9
or 4-1BB), member of the TNR-superfamily receptor (CD134 or OX40), glucocorticoid-induced tumor necrosis factor
(TNF) receptor (GITR), CD137, and CD77 promote T cell activation and protective responses [11]. Co-receptor
Int. J. Mol. Sci. 2018, 19, 1295; doi:10.3390/ijms19051295

www.mdpi.com/journal/ijms

signaling is initiated by the phosphorylation of tyrosine residues located in immunoreceptor tyrosine-based
activation motifs (ITAMs) or immunoreceptor tyrosine-based inhibitory motifs (ITIMs) [7,12]. The phosphorylated
tyrosines serve as docking sites for spleen tyrosine kinase (Syk) family members such as zeta-chain-associated
protein kinase 10 (ZAP-70) and Syk which activate the phospholipase C γ (PLCγ), RAS, and extracellular signalregulated kinase (ERK) pathways in addition to mobilizing intracellular Ca2+ stores [13].
One of the best described T cell co-receptors, CD28, is a stimulatory T cell surface receptor from the Ig
superfamily with a single Ig variable-like domain which binds to B7-1 (CD80) and B7-2 (CD86) [2]. Ligand binding
phosphorylates CD28 cytoplasmic domain tyrosine motifs such as YMNM and PYAP and initiates binding and
activation of phosphatidylinositide 3 kinase (PI3K) which interacts with protein kinase B (Akt) and promotes T cell
proliferation and survival [1]. CD28 also activates the NFAT pathway and mobilizes intracellular Ca2+ stores through
association with growth factor receptor-bound protein 2 (GRB2) and the production of phosphatidylinositol 4,5bisphosphate (PIP2), the substrate of PLCγ1, respectively [2,14]. Blocking stimulatory co-receptors suppresses T cell
effector function. For example, blocking stimulatory CD28 with anti-CD28 antibodies promotes regulatory T cell
function and represses activation of auto- and allo-reactive T effector cells after organ transplantation [8,15].
T cells also have inhibitory co-receptors which regulate T cell responses [8]. The best characterized are
immunoglobulin (Ig) superfamily members cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed
cell death protein 1 (PD-1) [8,16]. CTLA-4 binds CD80 and CD86 with greater avidity than CD28, and its inhibitory
role refines early phase activation signals for proliferation and cytokine production [16–19]. PD-1, another CD28/B7
family member, regulates late phase effector and memory response [20]. Inhibitory co-receptors such as CTLA-4 and
PD-1, known as “immune checkpoints”, block the interaction between CD28 and its ligands altering downstream
secondary T cell activation signals [19]. Therefore, blocking CTLA-4 or PD-1 promotes effector T cell function in
immunosuppressive environments [19,21].
There are also a number of co-receptors that have differential modulatory properties. For example, CD5, a
lymphocyte glycoprotein expressed on thymocytes and all mature T cells, has contradictory roles at different time
points. CD5 expression is set during thymocyte development and decreases the perceived strength of TCR-pMHC
signaling in naïve T cells by clustering at the TCR-pMHC complex and reducing TCR downstream signals such as the
Ca2+ response when its cytoplasmic pseudo-ITAM domain is phosphorylated [22–25]. The CD5 cytoplasmic domain
has four tyrosine residues (Y378, Y429, Y411, and Y463), and residues Y429 and Y441 are found in a YSQP-(x8)-YPAL
pseudo ITAM motif while other tyrosine residues make up a pseudo-ITIM domain [23]. Phosphorylated tyrosines
recruit several effector molecules and may sequester activation kinases away from the TCR complex, effectively
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reducing activation signaling strength [23]. Recruited proteins include Src homology-2 protein phosphatase-1 (SHP1), Ras GTPase protein (rasGAP), CBL, casein kinase II (CK2), zeta-chain-associated protein kinase 70 (ZAP70), and
PI3K which are involved in regulating both positive and negative TCR-induced responses [26–28]. For example, ZAP70 phosphorylates other substrates and eventually recruits effector molecules such as PLC gamma and promotes
Ca2+ signaling and Ras activation which stimulates the ERK pathway and leads to cellular activation [13,29].
Conversely, SHP1 inhibits Ca2+ signaling and PKC activation via decreased tyrosine phosphorylation of PLCγ
[13,26,30,31]. Further, Y463 serves as a docking site for c-Cb1, a ubiquitin ligase, which is phosphorylated upon CD3–
CD5 ligation and leads to increased ubiquitylation and lysosomal/proteasomal degradation of TCR downstream
signaling effectors and CD5 itself [32]. Thus, CD5 has a mix of downstream effects that both promote and inhibit T
cell activation. Curiously, recent work suggests that in contrast to its initial inhibitory nature, CD5 also co-stimulates
resting and mature T cells by augmenting CD3-mediated signaling [25,33–35].
Ca2+ is an important second messenger in many cells types, including lymphocytes, and plays a key role in
shaping immune responses. In naïve T cells, intracellular Ca2+ is maintained at low levels, but when TCR-pMHC
complexes are formed, inositol triphosphate (IP3) initiates Ca2+ release from intracellular stores of the endoplasmic
reticulum (ER) which opens the Ca2+ release-activated Ca2+ channels (CRAC) and initiates influx of extracellular Ca2+
through store-operated Ca2+ entry (SOCE) [36–41]. The resulting elevation of intracellular Ca2+ levels activates
transcription factors involved in T cell proliferation, differentiation, and cytokine production (e.g., nuclear factor of
activated cells (NFAT)) [36,37]. Thus, impaired Ca2+ mobilization affects T cell development, activation,
differentiation, and function [42,43]. Examples of diseases with impaired Ca2+ signaling in T cells include systemic
lupus erythematosus, type 1 diabetes mellitus, and others [44,45].
In this review, we will focus on CD5 co-receptor signaling and its functional effects on T cell activation. First, we
will discuss how the inhibitory co-receptors CTLA-4 and PD-1 modulate T cell function. Then we will compare CTLA4 and PD-1 function to CD5 function, examine recent findings that expand our understanding of the role of CD5, and
assess how these findings apply to T cell Ca2+ signaling. Finally, we will consider CD5 Ca2+ signaling regulation in T
cells and its potential physiological impact on immunometabolism, cell differentiation, homeostasis, and behavior.

2. Roles of Negative Regulatory T Cell Co-Receptors
2.1. Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)
Cytotoxic T-lymphocyte antigen-4 (CTLA-4, CD152) inhibits early stages of T cell activation by recruiting
inhibitory proteins such as SHP-2 and type II serine/threonine phosphatase PP2A that interfere with T cell synapse
signaling [21,46–48]. CTLA-4 binds B7, a protein on activated APCs,
with higher affinity than the stimulatory co-receptor CD28; the resulting balance between inhibitory and stimulatory
signals controls T cell activation or anergy [19,49]. In naïve T cells, CTLA-4 is located in intracellular vesicles which
localize at TCR binding sites following antigen recognition and intracellular Ca2+ mobilization [19,50]. Like CD28,
CTLA-4 aggregates to the central supramolecular activation complex
(cSMAC) where it then extrinsically controls activation by decreasing immunological synapse contact time [51–53].
This suppresses proactivation signals by activating ligands (B7-1 and B7-2) and induces the enzyme Inoleamine 2,3dioxygenase (IDO) which impairs Ca2+ mobilization and suppresses T cell activation, ultimately altering IL-2
production and other effector functions in T cells [51,54,55]. CTLA-4 also stimulates production of regulatory
cytokines, such as transforming growth factor beta (TGF-β), which inhibit APC presentation and T cell effector
function [47,52,53]. Compared to effector T cells (Teff), CTLA-4 is highly expressed in regulatory T cells (Treg) and plays
a role in maintaining Treg homeostasis, proliferation, and immune responses [16,56,57]. Total or partial CTLA-4
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deficiency inhibits Treg’s ability to control cytokine production and can cause immune dysregulation [58–61]. Thus,
CTLA-4 has an important role in the Treg suppressive response [60]. Additionally, CTLA-4 mutations are associated
with autoimmune diseases as thoroughly reviewed by Kristiansen et al. [62].
The loss of CTLA-4 results in removal of CTLA-4 competition with CD28 for B7-1 and B7-2 and is implicated in
autoimmunity and cancer [15,63]. Because CTLA-4 inhibits TCR signaling, CTLA-4
deficiency leads to T cell overactivation as measured by increased CD3ζ phosphorylation and Ca2+ mobilization
[64]. Thus, modulating CTLA-4 signaling is an attractive target for immunotherapies that seek to boost or impair
early TCR signaling for cancer and autoinflammatory diseases [65,66]. For example, Ipilimunab, an IgG1 antibodybased melanoma treatment, is a T cell potentiator that blocks CTLA-4 to stimulate T cell proliferation and stem
malignant disease progression by delaying tumor progression and has been shown to significantly increase life
expectancy [19,67,68]. Additionally, Tremelimumab, a noncomplement fixing IgG2 antibody, has been tested alone
or in combination with other antibodies such as Durvalumab (a PD-1 inhibitor) and improves antitumor activity in
patients with non-small cell lung cancer (NSCLC), melanoma, colon cancer, gastric cancer, and mesothelioma
treatment [69–74].

2.2. Programmed Death 1 (PD-1)
Programmed cell death protein-1 (PD-1, CD279) is a 288-amino acid (50–55 KDa) type I transmembrane protein
and a member of the B7/CD28 immunoglobulin superfamily expressed on activated T cells, B cells, and myeloid cells
[19,75,76]. PD-1 has two known ligands, PD-L1 and PD-L2, which inhibit T cell activation signals [77]. Like CTLA-4,
PD-1 also inhibits T cell proliferation and cytokine production (INF-γ, TNF and IL-2) but is expressed at a later phase
of T cell activation [19]. PD-1 has an extracellular single immunoglobulin (Ig) superfamily domain and a cytoplasmic
domain containing an ITIM and an immunoreceptor tyrosine-based switch motif (ITSM) subunit critical for PD-1
inhibitory function [78]. Upon T cell activation, PD-1 is upregulated and initiates ITIM and ITSM tyrosine interaction
with SHP-2 which mediates TCR signaling inhibition by decreasing ERK phosphorylation and intracellular Ca2+
mobilization [79,80]. PD-1 can block the activation signaling pathways PI3K-Akt and Ras-Mek-ERK, which inhibit or
regulate T cell activation [79,81]. Thus, engagement of PD-1 by its ligand affects intracellular Ca2+ mobilization, IL-2
and TNF-α production, supporting PD-1’s inhibitory role in TCR strength-mediated signals [82].
PD-1 signaling also affects regulatory T cell (Treg) homeostasis, expansion, and function [83]. Treg activation and
proliferation are impacted by PD-1 expression which enhances their development and function while inhibiting T
effector cells [75,84]. PD-1, PD-L, and Tregs help terminate immune responses [85]. Thus, PD-1 deficiency results not
only in increased T cell activation, but in the breakdown of tolerance and the development of autoimmunity in
diseases such as multiple sclerosis and systemic lupus erythematosus [85–89]. PD-1 and its ligands protect tissues
from autoimmune attacks by regulating T cell activation and inducing and maintaining peripheral tolerance [90,91].
Studies done in PD-1-deficient mice observed the development of lupus-like glomerulonephritis and arthritis,
cardiomyopathy, autoimmune hydronephrosis, and Type I diabetes, among other ailments [92–94]. PD-1 protects
against autoimmunity and promotes Treg function. [85]. Enhancing Treg response with a PD-L1 agonist shows
therapeutic potential for asthma and other autoimmune disorders [85,95]. Because PD-1 specifically modulates
lymphocyte function, effective FDA-approved monoclonal antibodies targeting PD-1 are clinically available (i.e.,
Pembrolizumab and Nivolumab) to treat advanced malignancies [20]. Not only does blocking PD-1 decrease
immunotolerance of tumor cells, it also increases cytotoxic T lymphocyte antitumor activity [20].

3. CD5: A Contradictory Co-Receptor
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3.1. Overview of CD5 Signaling and Ca2+ Mobilization in T Cells
CD5, known as Ly-1 antigen in mice or as Leu-1 in humans, is a type I transmembrane glycoprotein (67 kDa)
expressed on the surface of thymocytes, mature T cells, and a subset of B cells (B-1a) [96,97]. Although CD5 was
discovered over 30 years ago, it was only in the last decade that CD5 gained attention as a key T cell activation
regulator [98,99]. CD5 expression is set in the thymus during positive selection and correlates with how tightly the
thymocyte TCR binds to self-peptide-MHC (self-pMHC); greater TCR affinity for self-peptide leads to increased CD5
expression in double positive (DP) thymocytes [100]. In other words, DP thymocytes that receive strong activation
signals through their TCR express more CD5 than those DP thymocytes that receive weak TCR signals [100]. CD5
knockout mice (CD5−/−) have a defective negative and positive selection process, and therefore their thymocytes are
hyper-responsive to TCR stimulation with increased Ca2+ mobilization, proliferation, and cytokine production [23,98].
On the other hand, because of the increased TCR avidity for self-pMHC, mature T cells with high CD5 expression
(CD5hi) (peripheral or postpositive selection T cells) respond to foreign peptide with increased survival and activation
compared to mature T cells with low CD5 expression (CD5lo) [34,101]. Therefore, CD5 is a negative regulator of TCR
signaling in the thymus and modulates mature T cell response in the periphery [23,34,100,102].
While CTLA-4 and PD-1 belong to the immunoglobulin (Ig) family, CD5 belongs to group B of the scavenger
receptor cysteine-rich (SRCR) superfamily and contains three extracellular SRCR domains [30,96,103]. The
cytoplasmic tail of CD5 contains several tyrosine residues which mediate the negative regulatory activity
independent of extracellular engagement [100,104,105]. As CD5 physically associates with TCRζ/CD3 complex upon
TCR and pMHC interaction, the tyrosine residues in both TCRζ and CD5 are phosphorylated by tyrosine kinases
associated with the complex [30,106–110]. This interaction is so intrinsic to T cell signaling that CD5 expression levels
are proportional to the degree of TCRζ phosphorylation, IL-2 production capacity, and ERK phosphorylation which
are critical for CD3-mediated signaling [33,111]. It is unknown whether posttranslational modifications, such as
conserved domain 1 and domain 2 glycosylations, impact CD5 signaling [112,113]. CD5 is present in membrane lipids
rafts of mature T cells where, upon activation, it helps augment TCR signaling, increases Ca2+ mobilization, and
upregulates ZAP-70/LAT (linker for activation of T cells) activation [114–116]. This suggests that CD5 is not only a
negative regulator in thymocytes, but also appears to positively influence T cell immune response to foreign antigens
[117,118]. See Figure 1.
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Figure 1. Effects of CD5 on different stages of T cell development. CD5 expression on thymocytes is directly
proportional to the signaling intensity of the TCR:self-pMHC interaction. In the periphery, T cells with higher CD5
levels (CD5hi) are better responders to foreign-peptide. Long-lived memory cells populations are enriched for CD5hi T
cells [34,102,119].

CD5 has three known ligands: CD72, a glycoprotein expressed by B cells, CD5 ligand or CD5L, an activation
antigen expressed on splenocytes, and CD5 itself [120–122]. Crosslinking CD5L to CD5 increases intracellular Ca2+
concentrations [30,120,121,123,124]. Early studies with anti-CD5 monoclonal antibodies also demonstrated
enhanced Ca2+ mobilization and proliferation, suggesting that CD5 co-stimulates and increases the T cell activation
signal [125,126]. Following TCR:pMHC interaction, CD5 cytoplasmic ITAM and ITIM like-domains are phosphorylated
by p56lck and bound by Src homology 2 (SH2) domain-containing protein tyrosine phosphatase (SHP-1)
[108,127,128]. However, while SHP-1 affects Ca2+ mobilization and is a purported down-regulator of thymocyte
activation, recent findings suggest that SHP-1 is not necessary for CD5 signaling as T cells deficient in SHP-1 have
normal CD5 expression and continue to signal normally [26,129]. Thus, while CD5 is not a SHP-1 substrate and SHP1 is likely unnecessary for CD5 signaling, CD5 signaling results in increased Ca2+ mobilization. It has yet to be resolved
how CD5 can act as an inhibiting co-receptor in the thymus and as an activating co-receptor in the periphery.

3.2. CD5 as a Ca2+ Signaling Modulator
As previously mentioned, CD5 expression levels are set in the thymus during T cell development and are
maintained on peripheral lymphocytes [117]. CD5 expression in T cells plays an important role during development
and primes naïve T cells for responsiveness in the periphery [35,111,130]. CD5hi T cells have the highest affinity for
self-peptides and respond with increased cytokine production and proliferation to infection [101,131,132].
Our laboratory works with two TCR transgenic mouse lines with different levels of CD5 expression: LLO56
(CD5hi) and LLO118 (CD5lo) [111,117,130]. While LLO56 (CD5hi) and LLO118 (CD5lo) have similar affinity for the same
immunodominant epitope (listeriolysin O amino acids 190–205 or LLO190–205) from Listeria monocytogenes, on day 7
of primary response, LLO118 (CD5lo) has approximately three times the number of responding cells compared to
LLO56 (CD5hi), and conversely, on day 4 during secondary infection, LLO56 (CD5hi) has approximately fifteen times
more cells than LLO118 (CD5lo) [130]. This difference is not due to differential proliferative capacity, rather LLO56
(CD5hi) has higher levels of apoptosis during the primary response [130]. Thus, LLO56 CD5hi and LLO118 CD5lo’s
capacity to respond to infection appears to be regulated by their CD5 expression levels [117]. LLO56 (CD5hi)
thymocytes have greater affinity for self-peptide, which primes them to be highly apoptotic [130].
Recently we reported that in response to foreign peptide, LLO56 (CD5hi) naïve T cells have higher intracellular
2+
Ca mobilization than LLO118 (CD5lo), which correlates with increased rate of apoptosis of LLO56 (CD5hi), as Ca2+
overloaded mitochondria release cytochrome c which activates caspase and nuclease enzymes, thus initiating the
apoptotic pathways [35,133,134]. LLO56 (CD5hi) naïve T cell increased Ca2+ mobilization also provides additional
support to the idea that CD5hi T cells have an enhanced response to foreign peptide [35,134]. This supports previous
research that found that upon T cell activation, increased CD5 expression is correlated with greater basal TCRζ
phosphorylation, increased ERK phosphorylation, and more IL-2 production [101,111].
Thus, unlike CTLA-4 and PD-1 which are expressed only on activated T cells in the periphery during early and
late phases of immune response, respectively, CD5 is set during T cell development, and influences T cells both
during thymic development and during postthymic immune responses [19, 101,111] (see Figure 2). CD5 not only has
an important inhibitory role in the thymus, but also appears to positively influence the T cell population response;
for example, more CD5hi T cells populate the memory T cell repertoire because CD5hi naïve T cells have a stronger
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primary response [34,135]. CD5 finetunes the sensitivity of TCR signaling to pMHC, altering intracellular Ca2+
mobilization and NFAT transcription, key players in T cell effector function [19,64,126]. As Ca2+ signaling plays a key
role in T cell activation and function, controlling Ca2+ mobilization in T cells through CD5 expression could influence
diverse areas of clinical research including metabolism, cancer treatments, and even cognitive behavior.

Figure 2. Inhibiting co-receptors modulate T cell activation by increasing (green arrows) or decreasing activity (red
arrows). CD5 is present in naïve T cells and localizes to the TCR:pMHC complex during activation. Initial activation
cascades signal for the release of CTLA-4 from vesicles to the cell surface
while the transcription factor NFAT transcribes PD-1. CTLA-4 provides inhibitory signals during early activation while PD-1 is
expressed later and inhibits later stages of T cell activation. The initial Ca2+ mobilization is decreased by CTLA-4 and PD-1
downstream signals. A more detailed illustration of the calcium signaling pathway (i.e., IP3, STIM 1/2, CRAC channel,
calmodulin, etc.) is outlined in Figure 3.

4. Physiological Impact of CD5 Expression in T Cells
4.1. Metabolism
Naive T cells are in a quiescent state and rely on oxidative phosphorylation (OXPHOS) to generate
ATP for survival [136,137]. Upon TCR-pMHC interaction, T cells undergo metabolic reprograming to meet energetic
demands by switching from OXPHOS to glycolysis [138]. Glycolysis is a rapid source of ATP and regulates
posttranscriptional production of INF-γ, a critical effector cytokine [139]. Following the immune response, most
effector T cells undergo apoptosis while a subset become quiescent memory T cells. Memory T cells have lower
energetic requirements and rely on OXPHOS and Fatty Acid Oxidation (FAO) to enhance mitochondrial capacity for
maintenance and survival [140].
Ca2+ signaling is a key second messenger in T cell activation and Ca2+ ions also modulate T cell metabolism
through CRAC channel activity and NFAT activation [3,141]. During TCR-pMHC binding Ca2+ is released from the
endoplasmic reticulum (ER) where it is absorbed by the mitochondria and initiates an influx of extracellular Ca2+ [3].
First, the rise of cytoplasmic Ca2+ activates stromal interaction molecule 1 (STIM1) located on the ER membrane to
interact with the CRAC channel located on the cell membrane [142]. The release of the ER store and resulting
extracellular Ca2+ influx increases the intracellular Ca2+ concentration and promotes AMPK (adenosine
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monophosphates activated protein kinase) expression and CaMKK (calmodulin-dependent protein kinase kinase)
activity [3,142,143]. AMPK senses cellular energy levels through the ratio of AMP to ATP and generates ATP by
inhibiting ATP-dependent pathways and stimulating catabolic pathways [144]. This indirectly controls T cell fate as
AMPK indirectly inhibits mTOR (mammalian target of rapamycin complex) [145]. Because mTOR coordinates the
metabolic cues that control T cell homeostasis, it plays a critical role in T cell fate [146]. T cells that are TSC1
(Tuberous sclerosis complex 1)-deficient show metabolic alterations through increased glucose uptake and glycolytic
flux [147].
The rise of cytoplasmic Ca2+ also encourages mitochondria to uptake cytoplasmic Ca2+ through the
mitochondrial Ca2+ uniporter (MCU) [148]. This MCU uptake increases Ca2+ influx by depleting Ca2+ near the ER which
further activates the CRAC channels and promotes STIM1 oligomerization [3,149–151]. Ca2+ uptake in the
mitochondria also enhances the function of the tricarboxylic acid cycle (TAC), which generates more ATP through
OXPHOS [152,153]. OXPHOS is maintained by a glycolysis product, phosphoenolpyruvate (PEP), which sustains TCRmediated Ca2+-NFAT signaling by inhibiting the sarcoendoplasmic reticulum (SR) calcium transport ATPase (SERCA)
pump, thus promoting T cell effector function [154,155]. Downregulation of calmodulin kinase, CaMKK2, which
controls NFAT signaling, decreases glycolytic flux, glucose uptake, and lactate and citrate metabolic processes [156].
Ca2+ may also orchestrate the metabolic reprogramming of naïve T cells by promoting glycolysis and OXPHOS through
the SOCE/calcineurin pathway which controls the expression of glucose transporters GLUT1/GLUT3 and
transcriptional co-regulator proteins important for the expression of electron transport chain complexes required
for mitochondria respiration [141].
Co-receptor stimulation plays a pivotal role in T cell metabolism and function. A decrease in T cell Ca2+ signaling
represses glycolysis and affects T cell effector function [152]. PD-1 and CTLA-4 depress Ca2+ signaling and glycolysis
while promoting FAO and antibodies against CTLA-4 and PD-1 increase Ca2+ mobilization and glycolysis during T cell
activation [157,158]. Like CTLA-4 and PD-1, CD5 modulatory function has the potential to influence T cell
metabolism. Analysis of gene families modulated by CD5 in B cells found that CD5 upregulates metabolic-related
genes including VEFG, Wnt signaling pathways genes, MAPK cascade genes, I-kB/NF-kB cascade genes, TGF β
signaling genes, and adipogenesis process genes [159]. Therefore, proliferation differences correlated with CD5
expression in T cells may be caused by improved metabolic function as CD5lo T cells seem to be more quiescent than
CD5hi T cells [160]. Although not much is known about how CD5 alters metabolic function in T cells, signaling strength
differences of CD5hi and CD5lo T cell populations correlate with intracellular Ca2+ mobilization during activation and
influence their immune response [35,111,130]. This implies that different metabolic processes may be initiated
which would influence proliferation, memory cell generation, and cytokine production. Figure 3 summarizes how
Ca2+ may be mobilized in CD5hi and CD5lo naïve T cells and the role Ca2+ may play on metabolism.
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Figure 3. CD5 expression levels in naïve T cells may influence T cell metabolism and function. Differential levels of
CD5 result in differences in Ca2+ mobilization in naïve T cells. CD5hi naïve T cells have higher Ca2+ influx than CD5lo naïve
T cells upon TCR:pMHC interaction [35]. Ca2+ signaling plays a significant role in T cell activation and influences
metabolism and T cell function. Differential Ca2+ mobilization and expression of calcineurin and NFAT affect glycolysis
and mitochondrial respiration (hypothetical levels of metabolic activation are shown with dashed (low) or solid (high)
arrows), suggesting CD5 expression may affect metabolic reprograming during T cell activation [141].

4.2. Neuroimmunology
The field of neuroimmunology examines the interplay between the immune system and the central nervous
system (CNS) [161]. The adaptive immune system does influence the CNS as cognition is impaired by the absence of
mature T cells [162]. In wild type mice, there is an increase in the number of T cells present in the meninges during
the learning process, in stark contrast to mice with T helper 2 cytokine deficiencies (such as IL-4 and IL-13) who have
decreased T cell recruitment and impaired learning [163]. Furthermore, regulation of T cell activation and cytokine
production critically assists neuronal function and behavior, suggesting that manipulation of T cells could be a
potential therapeutic target in treating neuroimmunological diseases [164,165].
T cells go through several microenvironments before reaching the CNS [166]. Many of the signal interactions
present in these microenvironments affect T cell function and involve changes in intracellular Ca2+ levels [166,167].
In experimental autoimmune encephalitis (EAE), a model for human multiple sclerosis, autoreactive T cells have Ca2+
fluctuations throughout their journey to the CNS [166]. Prior to reaching the CNS, T cells interact with splenic stroma
cells that do not display the cognate auto-antigen and this interaction produces short-lived low Ca2+ mobilization
spikes [166]. Following entrance into the CNS, T cells encounter autoantigen-presenting cells and have sustained
Ca2+ mobilization which results in NFAT translocation and T cell activation [166,168]. EAE mice display reduced social
interaction and cognition demonstrating that autoimmune response impairs neuronal function and organismal
behavior [169].
Inhibitory T cell co-receptors are implicated in CNS dysregulation and disease. Varicella zoster virus (VZV)
infection is characterized by lifelong persistence in neurons. VZV increases the expression of CTLA-4 and PD-1 in
infected T cells which reduces IL-2 production and increases T cell anergy [170,171]. PD-1-deficient mice (Pdcd1−/−)
have increased T cell activation, leading to greater intracellular Ca2+ mobilization, and as previously discussed,
increased glycolysis [86]. PD-1 deficiency causes elevated concentration of aromatic amino acids in the serum,
specifically tryptophan and tyrosine, which decreases their availability in the brain where they are important for the
synthesis of neurotransmitters such as dopamine and serotonin; consequently, there is an increase in anxiety-like
behavior and fear in Pdcd1−/− mice [86]. Therefore, increased T cell activation caused by PD-1 deficiency can affect
brain function and thus, affects cognitive behavior [86].

4.3. Cancer
T cells are critical components of the immune response to cancer. Helper T cells directly activate killer T cells
to eradicate tumors and are essential in generating a strong antitumor response alone or in concert with killer T cells
by promoting killer T cell activation, infiltration, persistence, and memory formation [172–177]. Tumor-specific T
cells may not mount a robust response towards cancerous cells because the tumor microenvironment has numerous
immunosuppressive factors; cancerous cells also downregulate cell surface co-stimulatory and MHC proteins which
suppresses T cell activation [178–182]. Potent antitumor immune checkpoint blockade therapies using CTLA-4 and
PD-1 monoclonal antibodies augment T cell response by suppressing the co-receptors’ inhibitory signals, thereby
promoting increased Ca2+ mobilization, glycolysis, and activation [183,184]. CTLA-4
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monoclonal antibodies such as ipilimumab (Yervoy) and tremelimumab block B7-interaction and have been
used to treat melanoma [47,185,186]. The monoclonal antibody pembrolizumab is highly selective for PD-1 and
prevents PD-1 from engaging PD-L1 and PD-L2, thus enhancing T cell immune response [19,187,188]. Further
research will address whether combining anti-CTLA-4 and anti-PD-1 antibodies will improve cancer treatments [19].
As previously mentioned, Ca2+ is critical for T cell activation and immune response. Manipulating Ca2+ signaling
to enhance T cell-directed immune response against cancer is an intriguing notion, yet the means to target the Ca2+
response of specific cells without tampering with the metabolic processes of other cells remains elusive [189].
Antitumor activity of tumor-infiltrating lymphocytes (TIL) is inversely related to CD5 expression [99]. CD5 levels in
naïve T cells are constantly tuned in the periphery by interactions with self pMHC complexes to maintain
homeostasis; therefore, CD5 expression on TILs can be downregulated in response to low affinity for cancer antigens
[190–192]. Thus, the majority of TILs are CD5lo which increase their reactivity while CD5hi TILs do not elicit a Ca2+
response and become anergic and are unable to eliminate malignant cells [99,192]. While downregulation of CD5
on TILs enhances antitumor T cell activity, CD5lo T cells are also more likely to experience activation-induced cell
death (AICD) as CD5 protects T cells from overstimulation [23]. To maximize TIL effectiveness, the inhibitory effects
of CD5 could be blocked by neutralizing monoclonal antibodies or soluble CD5-Fc molecules combined with soluble
FAS-Fc molecules to reduce the inherent AICD [23,193,194]. Soluble human CD5 (shCD5) may have a similar effect
but avoids targeting issues by blocking CD5-mediated interaction via a “decoy receptor” effect. Mice constitutively
expressing shCD5 had reduced melanoma and thyoma tumor cell growth and increased numbers of CD4+ and CD8+
T cells [195]. Wild type mice treated with an injection of recombinant shCD5 also had reduced tumor growth [195].
Finally, CD5-deficient mice engrafted with B16-F10 melanoma cells had slower tumor growth compared to wild type
C57BL/6 mice [196]. This evidence suggests that CD5, along with PD-1 and CTLA-4, may be a potential target to
specifically modulate T cell Ca2+ mobilization in an immunosuppressive tumor setting.

4.4. Microbiome
The gut microbiome, including the bacteria and their products, forms a dynamic beneficial symbiosis with the
immune system influencing host genes and cellular response. The gut microbiome shapes and directs immune
responses while the immune system dictates the bacterial composition of the gut microbiome [197]. As the gut is
the major symbiotic system intersecting the immune system and microbiota, understanding their connection has
implications for immune system development and function as the gut microbiome is involved in protecting against
pathogens, influencing states of inflammation, and even affecting cancer patient outcomes [198,199].
The gut microbiome primes immune responses [200]. Alteration in the microbial composition can induce
changes in T cell function in infectious disease, autoimmunity, and cancer [201]. For example, mice treated with
antibiotics which restrict or reduce the microbial environment exhibit impaired immune response because their T
cells have altered TCR signaling and compromised intracellular Ca2+ mobilization in infectious disease and cystic
fibrosis models [202–204]. In contrast, administering oral antibiotics to mice with EAE increases the frequency of
CD5+ B cell subpopulations in distal lymphoid sites and confers disease protection [205]. In cancer, the microbiome
also influences patient response to immune checkpoint inhibitors such as CTLA-4 and PD-1 [206,207]. Mice and
melanoma patients immunized or populated with Bacteriodes fragilis respond better to treatment with
Ipilimumab, a monoclonal antibody against CTLA-4 [198]. Similarly, tumor-specific immunity improved when antiPD-1/PD-L1 monoclonal antibodies where used in the presence of Bifidobacterium [208].
Though little is known about how CD5 influences T cell interaction with the microbiome, some tantalizing
details are available. As specific bacterium promotes cancer regression during CTLA-4 and PD-1 checkpoint
blockades, a CD5 blockade in conjunction with bacterial selection may also improve immune response. Such studies
would lead to novel immunotherapeutic treatments for cancer and autoimmune diseases.
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5. Conclusions
CD5, widely known as an inhibitory co-receptor in the thymus, appears to modulate the signaling intensity of
peripheral T cells by increasing Ca2+ signaling activity and efficacy of CD5hi T cells. CD5 expression levels in the
periphery correlates with intracellular Ca2+ mobilization, suggesting that CD5 promotes peripheral T cell activation
and immune response. As such, CD5 may be a novel checkpoint therapy to regulate T cell activation and metabolism
through altering Ca2+ mobilization, and could be used to affect neurological behavior, alter microbiome interactions,
and treat cancer and autoinflammatory diseases. While this paper focuses on the role of co-receptor CD5 effects on
calcium signaling and activation of T cells, CD5 itself may be regulated through posttranslational modifications, such
as N-glycosylation, which may affect Ca2+ mobilization, T cell metabolism, activation, and function. In the future it
would be interesting to determine the role of other posttranslational modifications (e.g., N-glycosylation, Sglutathionylation, lipidation) in CD5 signaling.
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Abstract

Flavonoids are dietary compounds with potential anti-diabetes activities. Many
flavonoids have poor bioavailability and thus low circulating concentrations. Unabsorbed
flavonoids are metabolized by the gut microbiota to smaller metabolites, which are more
bioavailable than their precursors. The activities of these metabolites may be partly
responsible for associations between flavonoids and health. However, these activities
remain poorly understood. We investigated bioactivities of flavonoid microbial
metabolites [hippuric acid (HA), homovanillic acid (HVA), and 5-phenylvaleric acid
(5PVA)] in primary skeletal muscle and β-cells compared to a native flavonoid ([(−)epicatechin, EC]. In muscle, EC was the most potent stimulator of glucose oxidation,
while 5PVA and HA simulated glucose metabolism at 25 μM, and all compounds
preserved mitochondrial function after insult. However, EC and the metabolites did not
uncouple mitochonndrial respiration, with the exception of 5PVA at10 μM. In β-cells, all
metabolites more potently enhanced glucose-stimulated insulin secretion (GSIS)
compared to EC. Unlike EC, the metabolites appear to enhance GSIS without enhancing
β-cell mitochondrial respiration or increasing expression of mitochondrial electron
transport chain components, and with varying effects on β-cell insulin content. The
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present results demonstrate the activities of flavonoid microbial metabolites for
preservation of β-cell function and glucose utilization. Additionally, our data suggest that
metabolites and native compounds may act by distinct mechanisms, suggesting
complementary and synergistic activities in vivo which warrant further investigation. This
raises the intriguing prospect that bioavailability of native dietary flavonoids may not be
as critical of a limiting factor to bioactivity as previously thought.

Keywords
hippuric acid; homovanillic acid; 5-phenylvaleric acid; (−)-epicatechin; insulin; respiration

1. INTRODUCTION
Incidence rates of type-2 diabetes and obesity are rising worldwide. In adition to
traditional medical interventions, complementary lifestyle strategies such as diet and
exercise are needed to blunt this epidemic. Flavonoids from cocoa, fruit, tea and
other sources have been identified as dietary bioactive compounds with potential
anti-obesity and anti-diabetes activities. Many of these flavonoids, such as quercetin
[1] and procyanidins [2], have poor oral bioavailability and thus low circulating
concentrations. Non-extractable/bound flavonoids (from cocoa, etc.) and oxidized
flavonoids, such as theaflavins and thearubigins from oolong and black teas, have
extremely limited oral bioavailability [3,4] and vanishing low circulating
concentrations. As an extreme example, consumption of 700 mg theaflavins
(equivalent to ~30 cups of black tea), produced maximal blood concentrations of
only 1 μg/L (~1.8 nM) in humans [3]. Therefore, circulating concentrations of the
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native species may represent a very small fraction of the ingested dose, whereas the
majority reaches the colon unabsorbed. Unabsorbed flavonoids are extensively
metabolized by the gut microbiota to a series of smaller metabolites such as
valerolactones, phenylalkyl acids, and smaller aromatics (Figure 1A) [4–9]. While
some metabolites are unique to individual flavonoid compounds or subclasses,
dozens of metabolites are common to most flavonoids [10,11]. These metabolites are
comparatively more bioavailable than their native flavonoid precursors, and in many
cases represent the predominant circulating forms following flavonoid consumption
[10]. For example, a recent study of pharmacokinetics following consumption of
grape pomace demonstrated that anthocyanins and procyanidins were not detected in
blood and catechins and their phase-II conjugates exhibited maximum blood levels
of 7–136 nM (with only 1 compound reaching at least 100 nM), while microbial
metabolites exhibited maximum blood levels of 3–1170 nM (with 8 compounds
reaching at least 100 nM) [12]. In an extreme example, consumption of 6 cups of
green or black tea resulted in circulating metabolite levels in the mM range (hippuric
acid, HA, reached 2.3 mM) [13]. This highlights the comparative importance of
these metabolites as potential bioactives in circulation following the consumption of
flavonoids.
Even flavonoids with comparatively high bioavailability (monomeric catechins, etc.)
are only present in the bloodstream at nM to very low μM levels following
consumption of typical doses in foods and supplements [14,15]. These doses are
generally lower than the range of concentrations typically used to study mechanisms
in cell culture models (1–100 μM, or sometimes higher). Despite poor
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bioavailability and low circulating concentrations, many of these compounds (and
foods rich in them) appear to effectively prevent or ameliorate metabolic syndrome
even at low dietary doses in animals [16] and humans [17]. Dietary efficacy, despite
poor bioavailability and/or low circulating concentrations of the native forms,
suggests three mechanisms by which ingested flavonoids exert their activities: 1)
native flavonoids primarily exert their activities in the gut lumen (inhibition of
digestive enzymes, alteration of microbiome composition and function, etc.) [18,19]
and/or epithelium (improving barrier function, immune development, etc.) [20]
where they are at highest concentrations (μM-mM range), 2) native flavonoids
primarily exert their activity in peripheral tissues even at the very low (pM-low μM
range) circulating levels achieved, or 3) microbial metabolites of flavonoids
generated by commensal microbiota in the lower gut exert activities locally in the
gut and systemically [21,22].
Considering the relatively high concentrations of microbial metabolites documented
in plasma compared to the native compounds, it is plausible that these metabolites
may be responsible, at least in part, for observed associations between dietary
flavonoids and health outcomes. While all of the three possible scenarios identified
above likely occur simultaneously, the potential anti-diabetic and anti-obesity
activities of microbial metabolites formed from unabsorbed flavonoids remain
poorly understood.
Recent provocative evidence has strengthened the argument that native flavonoids
may exert their effects independent of systemic bioavailability: either directly on the
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microbiota, or by formation of bioavailable microbial metabolites that then act in
peripheral tissues [23]. In
vitro, 3-(3-hydroxyphenyl)propionoic acid (a microbial metabolite common to many

flavonoids) prevented loss of insulin-stimulated nitric oxide synthesis and activity
under high glucose concentrations in human aortic endothelial cells [24]. In human
skeletal muscle myotubes, various microbial metabolites stimulated glucose and
oleic acid uptake [25]. Recent studies demonstrated that phenylacetic and
phenylpropionic acid have protective activities in pancreatic β-cells and islets
[26,27] and protect hepatocytes from acetaminophen injury [28]. Two recent studies
demonstrated that valerolactones inhibited monocyte adhesion to endothelial cells
[29]. A key animal study demonstrated that administration of antibiotics (depletion
of gut microbiota and their associated metabolites) abolished the ability of
procyanidin-rich grape seed extract to prevent inflammation, insulin resistance,
hyperglycemia and weight gain in a high-fat feeding mouse model [30].
Furthermore, antibiotic administration reversed the ability of blackcurrant
anthocyanins to ameliorate diet-induced obesity in mice [31]. Finally, digestion and
microbial metabolism of berry flavonoids did not diminish their protective activities
against colon cancer [32]. While the in vivo studies did not measure metabolite
production, they strongly suggest that these effects are mediated by the microbiota
and/or their metabolites produced from the native dietary flavonoids. Perhaps the
most well-known microbial metabolites, the phenylalkyl acids (phenylacetic, phenyl
propionic, and phenylvaleric acids) have not been well studied, and the
phenylvaleric acids have not been studied at all to our knowledge. Some compounds
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that are microbial metabolites have been studied, but only because they also exist as
native compounds in foods, such as the cinnamic acids and small aromatics such as
vanillic acid. These compounds have been shown to possess anti-diabetic and antiobesity activities in βcell, skeletal muscle, hepatocyte and adipose models (see
Supplementary Information). Finally, some microbial metabolites of flavonoids
have been shown to possess enhanced anti-tumor and anti-platelet agreggation
activities compared to the native forms [33].
Despite these promising findings, relatively little work has been done to characterize
the effects of these metabolites in cell or animal models, in comparison to the
exhaustive body of literature on the bioactivities of native flavonoids. The majority
of research that does exist on these metabolites has focused on their formation, but
not their activities nor mechanisms of action. Our objectives were therefore to 1)
investigate the anti-diabetic activities of microbial flavonoid metabolites (including
a poorly-studied class, phenylvaleric acids) in βcells and primary skeletal muscle
cells, 2) compare these activities to those of a control native flavonoid, and 3)
suggest potential mechanisms by which these activities may occur. Our findings
demonstrate that these metabolites possess potent bioactivities, and may contribute
to the observed peripheral tissue effects of dietary flavonoids.
2. MATERIALS AND METHODS
2.1 Materials
Three representative metabolites representative of three distinct classes of
metabolites common to a variety of dietary flavonoids were selected for
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investigation: hippuric acid (HA, 98%), homovanillic acid (HVA), and 5phenylvaleric acid (5PVA, 99%) were obtained from Sigma (St. Louis, MO). A
native flavanol, (−)-epicatechin (EC, Sigma), was used as a positive control; note
that the three selected metabolites can be obtained by metabolism of EC and related
compounds [9]. Structures of these compounds are shown in Figure 1B. All
compounds were tested over a range of 0–100 μM (depending upon the specific
assay) in water or DMSO, with equal final concentrations of DMSO in cell media
for all treatments. Generally, doses of 5–25 μM were employed, which are easily
obtainable in circulation for metabolites but which represent the extreme upper end
of what is attainable for native flavonoids [13,34]. Microbial metabolites, similar to
those of native flavonoids, exhibit pharmacokinetic curves that depend on a variety
of factors and circulating concentrations necessarily fluctuate over time based on
consumption frequency. The levels employed herein are attainable following
flavonoid consumption but are not continuously present, similar to those of native
dietary flavonoids. Furthermore, while compounds and doses were uniform across
experiments, differences in some aspects (treatment times, etc.) were necessary due
to the use of established, robust experimental protocols for each model system.
2.2 Skeletal muscle experiments
Skeletal muscle metabolism experiments were conducted per previously published
methods [35,36], with modifications. Primary human muscle cells were cultured for
measuring palmitate and glucose oxidation. Cultures of primary human muscle cells
were obtained from a singler subject who provided written informed consent under
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an approved protocol by Virginia Polytechnic Institute and State University
Institutional Review Board (approval #11–770). The subject was a healthy
Caucasian male, age 22 years, with a BMI of 23.6 and 20.9% body fat.
2.2.1 Skeletal muscle substrate metabolism—Cells were grown in low glucose
DMEM supplemented with 10% fetal bovine serum and SkGM SingleQuots (Lonza,
Walkersville, MD). Upon reaching ~80% confluence in standard 12-well plates,
cells were differentiated for 7 days in 2% horse serum. All experiments were
performed on day 7 of differentiation following overnight serum deprivation. The
compounds tested were treated for 24 hours prior to assessment of substrate
metabolism. Fatty acid oxidation was assessed by measuring and summing 14CO2
production (complete) and 14C-labeled acid-soluble metabolites (incomplete) from
the oxidation of [1-14C] palmitic acid (American Radiolabeled Chemicals, St. Louis,
MO). Briefly, cells were incubated in media containing radiolabeled substrate along
with the compound at 5 or 10 μM, or vehicle only (0 μM, 0.1% DMSO) for 3 hours
at 37ºC, 5% CO2. Following incubation media was removed and acidified with 45%
perchloric acid to elute gaseous 14CO2. 14CO2 was trapped in 1M NaOH over the
course of 1 hour. The NaOH was then placed in a liquid scintillation counter and
counted. Data were expressed as means ± SEM and is normalized to total protein
content. Glucose oxidation was assessed by measuring 14CO2 production from the
oxidation of [U-14C] glucose (American Radiolabeled Chemicals, St. Louis, MO) in
a manner similar to fatty acid oxidation expect for the substitution of glucose in
place of palmitic acid. Compounds were tested at 10 and 25 μM.
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2.2.2 Skeletal muscle cell respiration—Oxygen consumption rate (OCR) was
measured with our established protocols [37] using a XF96 Seahorse Extracellular
Flux Analyzer (Agilent Technologies, Santa Clara, California, USA). C2C12
myoblast studies are commonly used by our groups as a fast and practical model to
screen for compound efficacy. Because differentiating cells into myotubes takes 7
days continuously in the SeaHorse plate, we utilized the myoblasts as a more
feasible approach. Cultured C2C12 muscle cells were seeded at a density of 1.5 ×
104 per well in supplemented DMEM media [4.5 g/L DGlucose, L-Glutamine, and
110 mg/L Sodium Pyruvate supplemented with 10% Fetal
Bovine Serum (FBS) and 1% Penicillin Streptomycin (PSA)] on a Seahorse XF96
Cell Culture Microplate. Cells were then incubated overnight at 37ºC in 5% CO2 to
allow for adherence. Following adherence, cells were pretreated for 4 hours with
10% FBS/1% PSA DMEM containing the test compounds (5 and 10 μM) or vehicle
only (≤0.1 % DMSO). After the 4-hour pretreatment, 500 μM H2O2 was added to
injure the cells, and the microplate was subsequently incubated for an additional 4
hours. Following incubation, the cells were washed with supplemented XF media
(XF base media plus 1 mM pyruvate, 2 mM glutamine, 10 mM glucose) twice
before adding a final volume of 180 μL per well. A XF Cell Mitochondrial Stress
Test was completed to assess the bioenergetic status of the cells by injecting ATP
synthase inhibitor oligomycin (1 μg/mL), inner membrane uncoupler fluorocarbonyl
cyanide (FCCP, 2 μM), and complex III inhibitor antimycin A (2 μM). Oxygen
consumption rate data were normalized by subtracting non-mitochondrial rates of
respiration (after antimycin A), and are expressed as pmol O2 per minute per 1.5 ×
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104 cells. Mitochondrial coupling efficiency was calculated by taking the ATPdependent respiration (baseline-oligomycin) and dividing by the basal rates for
internal normalization.
2.3 β-cell experiments
β-cell metabolism experiments were conducted per previously published methods,
with modifications [38,39].
2.3.1 INS-1 832/13 β-cell culture—Cell culture was performed per our
established protocols [40–44] The INS-1 derived 832/13 rat β-cell line was
maintained in complete RPMI 1640 medium with L-glutamine and 11.2 mM glucose
supplemented with 50 U/ml penicillin, 50 μg/ml streptomycin, 10 mM HEPES, 10%
fetal bovine serum, and INS-1 supplement, as previously described. For all glucosestimulated insulin secretion and respiration assays using the 832/13 β-cells, cells
were plated at 0 hours, treated with test compounds at 24 hours, and harvested at 48
hours. Stock solutions of test compounds were made at 100mM, and diluted in
media for assays at final concentrations of 0100 μM (0.1% DMSO in all treatments).
2.3.2 Glucose-stimulated insulin secretion—Glucose-stimulated insulin
secretion (GSIS) was performed as previously described [40]. Briefly, INS-1 832/13
β-cells were plated and grown to confluency in standard 24-well plates. Upon
reaching confluency, cell were cultured with test compounds at 0 −100 μM in
complete media for 24 hours. Following the 24 hour treatment, cells were washed
with PBS and preincubated in secretion assay buffer (SAB) for 1.5 hours (114 mM
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NaCl, 4.7 mM KCl, 1.2 mM KH2PO4 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM
CaCl2, 0.2% BSA, pH 7.2) containing 2.5 mM glucose. GSIS was performed by
incubating quadruplicate replicate wells of cells previously cultured with test
compounds in SAB containing 2.5 mM glucose for 1 hour (basal), followed by 1
hour in SAB with 16.7 mM glucose (glucose stimulation), followed by collection of
the respective buffers, as previously described. For total insulin content, β-cells
stimulated with
16.7 mM glucose for 1 hour were lysed in RIPA buffer with protease inhibitors (Life
Technologies). Secreted insulin and total insulin was measured in SAB using a rat
insulin RIA kit (MP Biomedicals), and normalized to total cellular protein
concentration (determined by BCA assay), as previously described.
2.3.3 INS-1 832/13 β-Cell Oxygen Consumption Rate—Oxygen consumption rate
(OCR) was measured using an XFp Extracellular Flux Analyzer (Agilent
Technologies). INS-1 832/13 β-cells were seeded at 2.0 × 104 cells/well in complete
832/13 RPMI 1640 medium (L-glutamine, 11.2 mM glucose supplemented, 50 U/ml
penicillin, 50 μg/ml streptomycin, 10 mM HEPES, 10% fetal bovine serum, and
INS-1 supplement) on a Seahorse XFp Cell Culture Microplate. Cells were
incubated overnight and then treated with test compounds at 10 μM, 5 μM or 0 μM
in complete RPMI 1640 media. Following 24 hours of culture with the compounds,
cells were incubated in 2.5mM glucose SAB for 3 hours. Following incubation,
buffer was exchanged for 180 μL fresh pre-warmed 2.5mM glucose SAB per well.
A XF Cell Mitochondrial Stress Test was completed to assess the bioenergetic status
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of the cells by injecting glucose (16.7mM, in order to examine respiration under
glucose stimulation), oligomycin (4 μM), FCCP (2.5 μM), and antimycin A with
rotenone (2.5 μM). Residual oxygen consumption was determined following
inhibition of complex III with the addition of rotenone and antimycin A. This state
of residual oxygen consumption served as a baseline correction for all of the other
states. All data were normalized to protein content of each well, determined by BCA
assay.
2.3.4 Western blotting—832/13 beta cells were plated in standard 6-welll plates,
grown to confluency, and cultured overnight in media containing each test
compound at 10 μM or vehicle control (0.1% DMSO in both). Cells were washed in
PBS and harvested in RIPA buffer followed by sonication. Protein concentration
was quantified by BCA, and 30 μg was run per sample. Western blotting and
transfer was performed as previously described
[38,40,41]. Blot were probed using the Anti Rt/Ms Total OxPhos Complex Kit
(1:250, Life Technologies, Carlsbad, CA) which contains a cocktail of antibodies for
the electron transport chain (ETC) components ATP5A (Complex V), UQCR2
(Complex III), MTCO1 (Complex IV), SDHB (Complex II) and NDUFB8
(Complex I). Blot was imaged in the linear range using a LI-COR Odyssey CLx (LICOR Biotechnology, Lincoln, NE). Blotting was performed on triplicate samples.
2.4 Statistics
All results are expressed as mean ± SEM. For activity assays, data were analyzed by
1- or 2way ANOVA as appropriate. For 2-way ANOVAs, if a significant main effect
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of treatment compound dose was detected, Dunnett’s post hoc test was performed
within the highglucose treatments to compare each dose to the vehicle (0 μM)
control. For 1-way ANOVAs, if a significant treatment effect was detected,
Dunnett’s post hoc test was performed within each compound to compare each dose
to the vehicle controls. Significance was defined a priori as P < 0.05. Statistical
anslyses were performed on Prism v6.0f (GraphPad, La Jolla, CA).
3. RESULTS AND DISCUSSION
3.1 Skeletal muscle
3.1.1 Skeletal muscle metabolism—The ability of EC (+ control, native
flavonoid) and 3 representative metabolites (HA, HVA and 5PVA) to influence fatty
acid or glucose uptake and metabolism was examined in primary human skeletal
muscle cells. As shown in Figure 2, these compounds exhibited minimal ability to
alter fatty acid oxidation. The only statistically significant findings were that HA
was able to increase complete fatty acid oxidation at 25 μM (Figure 2D) and
increase the ratio of complete: incomplete oxidation at 10 μM (Figure 2P). While
these results suggest that HA has more potent activities than EC, overall the
enhancement of fatty acid oxidation does not seem to be a significant mechanism of
action for these metabolites. These results suggest that, despite a reported finding
that metabolites increased oleic acid uptake in human skeletal muscle myotubes
[25], alteration of fatty acid oxidation in skeletal muscle may not be a primary
mechanism by which flavonoid microbial metabolites exert anti-diabetic and antiobesity activities.
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Glucose oxidation results (Figure 3) were more promising than fatty acid oxidation.
EC appeared to be the most potent stimulator of glucose utilization, increasing
activity at both 10 and 25 μM (Figure 3A). While HVA had no apparent activity,
both 5PVA and HA were able to simulate glucose metabolism at 25 μM (Figures
3B-D). While the EC activity at lower concentrations suggests that it is more potent
than the metabolites on an equal concentration basis, it is important to keep in mind
that the metabolites tend to exist in circulation at higher levels than the native forms.
Thus, the observed increase in glucose oxidation for 5PVA and HA, combined with
previous reports that microbial metabolites stimulate glucose uptake [25], suggest
promise for the ability of these metabolites to exert significant benefits on blood
glucose levels in vivo.
3.1.2 Skeletal muscle cell respiration—The effects of EC and the three
metabolites on respiration in normal, uninjured C2C12 cells are shown in Figure 4.
We utilized a peroxide stress paradigm since heightened mitochondrial ROS burdens
are observed in skeletal muscle from humans and animal models of diabetes, often
before the onset of overt systemic hyperglycemia [45]. Respiration curves for
controls and each dose, including basal, leak (oligomycin) and maximal (FCCP)
respiration, are shown in Figure 4A-B. None of the compounds tested significantly
enhanced basal respiration (Figure 4C), ATP-dependent respiration (Figure 4E),
maximal respiration (Figure 4F), or respiratory reserve (the difference between
basal and maximal respiration, which reflects reserve bioenergetic capacity available
to the cell, Figure 4G) compared to the control at either 5 or 10 μM compared to
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vehicle control. Coupling efficiency was not influenced by any of the compounds at
any concentration, with the exception of 5PVA at 10 μM (Figure 4H). HA and
5PVA both modestly enhanced ‘leak’ respiration at 10 μM (Figure 4D), suggesting
either slight mitochondrial injury (potentially due to minor pro-oxidant effects at
these higher doses) or mitochondrial uncoupling. The data in uninjured cells
generally suggest that EC and the metabolites do not alter skeletal muscle repiration
under normal conditions at low doses, and indicate that do not appear to acutely
uncouple mitochondria or partially inhibit the respiratory chain (both of which have
been postulated as a strategy to treat obesity/diabetes for decades) with the possible
exception of HA and 5PVA at high doses [46,47].
The effects of EC and the metabolites on C2C12 cells exposed to peroxide challenge
(i.e. injured) are presented in Figure 5. Peroxide treatment induced mitochondrial
injury as assessed by increased ‘leak’ respiration (respiration after oligomycin
roughly doubled) (Figure 5D) and lower rates of maximal respiration (FCCP), ATPdependent respiration (Figure 5E), respiratory reserve capacity (Figure 5G), and
coupling efficiency (Figure 5H) for H2O2 treated cells (red bars) compared to
control (blue bars). While there were some differences in basal respiration, this can
be due to slight respiratory uncoupling due to the injury and should be interpreted
with caution. Each of the compounds studied significantly protected against
peroxide-mediated injury at 5 μM, reflected by reduced leak respiration, and
preserved maximal respiration respiratory reserve and/or coupling efficiency at the
same level as the uninjured control despite peroxide challenge (Figures 5D-H). As
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observed for uninjured cells, one metabolite actually worsed cell injury as measured
by leak respiration, although in this case it was 10 μM HVA (as opposed to HA and
PVA in uninjured cells), again suggesting either cellular injury or uncoupling.
Interestingly, while HA and 5PVA increased leak respiration in the absence of H2O2,
there was only a slight additional increase in leak respiration with H2O2 treatment.
These data indicate that HA and 5PVA may have pro-oxidant effects similar to
H2O2, but that these metabolites did not exacerbate leak respiration when combined
with H2O2 stress. Future studies that further examine the effects of HA and 5PVA
will advance our understanding of these compounds on mitochondrial bioenergetics.
The 10 μM dose was generally ineffective for all compounds except HA, which
partly preserved respiratory reserve (Figure 5E). These results suggest that EC and
the flavonoid microbial metabolites preserve skeletal mitochondrial function after
oxidative insult, notably at lower micromolar concentrations.
3.2 β-cells
3.2.1 β-cell glucose-stimulated insulin secretion—In addition to substrate
utilization in skeletal muscle, β-cell function is a critical target at all stages of
diabetes development. We sought to examine the impact of EC and representative
flavonoid metabolites on GSIS in a β-cell model (Figure 6). We have previously
demonstrated that the epicatechin-rich fraction from cocoa enhances β-cell GSIS at
25 μg/ml [38]. In the present experiment, EC was able to enhance GSIS in INS-1
832/13 β-cells but only at 100 μM (Figure 6A), which is not physiologically
relevant, suggesting minimal relevance for activity in vivo. Interestingly, all three
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microbial metabolites demonstrated significant induction of GSIS at concentrations
from 5–100 μM (Figure 6B-D) except HA, which induced GSIS at 5–50 μM but not
100 μM). These data demonstrate that the metabolites increase GSIS at much lower
(and physiologically relevant) concentrations compared to EC, suggesting that the
metabolites are more potent stimulators of GSIS than native EC. This fact, combined
with the greater bioavailability of microbial metabolites than the parent compound,
point towards the potential contribution of microbial metabolites to the observed
effects of dietary flavanoids.
To further investigate the effects of these compounds on INS-1 832/13 β-cells, we
examined the cellular insulin content under stimulatory conditions (16.7 mM
glucose) to determine if treatment impacted insulin expression (Figure 7). An
increase in insulin content, concomitant with an increase in insulin secretion would
indicate greater insulin expression, while a decrease in insulin content with no
change in insulin secretion would indicate an impediment in insulin production. EC
exhibited small increases in insulin content (Figure 7A), but the effect was
inconsistent across doses. Interestingly, increases in insulin content were vastly
different across the metabolites (Figure 7B-D), despite similarities observed in
GSIS. 5PVA and HVA stimulated greater insulin content, particularly at lower
doses. HA exhibited a slight increase in insulin content at 50 μM. These results are
intriguing, as they suggest distinct mechanism at play that impinges on β-cell insulin
secretion. The results for EC are consistent with our previous results demonstrating
increased insulin secretion at high doses, without concurrent increase in insulin
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content [38]. For 5PVA and HVA we observed increased GSIS and increased
cellular insulin content. The increased insulin content could be due to greater insulin
gene expression, enhanced insulin processing, or improved insulin stability. As has
been previously shown, increased cellular insulin content can be sufficient to
enhance GSIS [48]. Therefore, the enhanced insulin secretion from β-cells treated
with these metabolites, particularly at lower doses, may be due to an increased
insulin load, rather than modulation of the β-cell glucose sensing machinery. The
GSIS observed by HA occurs with minimal changes to insulin content. The data
suggest that flavonoid microbial metabolites may exert significant effects on β-cell
function by increasing both β-cell insulin production and insulin secretion. These
distinct mechanisms suggest complementary and synergistic activities of various
metabolites present simultaneously following flavonoid consumption, and thus
warrant further investigation in vitro and in vivo.
3.2.2 β-cell respiration—Given our previous data demonstrating enhanced β-cell
mitochondrial respiration due to exposure to EC from cocoa [38,39], we sought to
define the effect of culture in the presence of EC and microbial metabolites on β-cell
mitochondrial respiration under basal conditions (low glucose) and glucose
stimulation (Figure 8). Basal respiration rate was significantly increased by 10 μM
EC, and appeared to be somewhat reduced (albeit not statistically significantly) by 5
and 10 μM HA (Figure 8C). The same results were also observed under glucose
stimulation and maximal respiration (although the level of glucose induced
respiration is surprisingly less that what has been observed in other studies) (Figure
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8D-E). None of the compounds tested significantly affected respiratory reserve
(Figure 8F). It is important to note that the low means and comparatively high
SEMs for respiratory reserve in this case are indicative of the fact that these cells
were essentially already operating near maximal respiration in the basal state
(Figure 8A-B, F). Note that uncoupling and ATP-dependent respiration were not
plotted individually from these data due to differences in the question being asked
between the β-cells (do these compounds enhance respiration as a means to improve
β-cell function?) vs. the skeletal muscle cells (do these compounds enhance
respiration via uncoupling as a means to improve energy expenditure, and do they
protect from injury?). The finding that EC enhances respiration is consistent with
our previous data [38,39]. Coupled with the GSIS data (Figure 6), these respiration
data suggest several novel findings. First, EC does not enhance GSIS except at
extremely high doses despite enhacing β-cell respiration at lower doses. Second, HA
enhances GSIS despite inhibition of β-cell respiration (although these reductions
were not statistically significant, this trend appears to be of practical significance as
suggested by Figures 8C-E). Third, HVA and 5PVA enhance GSIS despite not
affecting β-cell respiration. Thus, these data demonstrate that while each of the
epicatechin metabolites enhance GSIS; their individual mechanisms do not all
increase insulin release through modulating mitochondrial respiration. Therefore, the
mechanisms by which these compounds exert their effects are likely distinct and
thus warrant further investigation.
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3.2.3 Expression of ETC components—To validate the changes that we
observed in β-cell respiration after treatment with EC or the gut metabolites, we
measured protein levels of select ETC components (Figure 9). Similar to what was
observed in our mitochondrial respiration studies, only treatment with EC changed
protein levels of ETC components. These data validate our previous findings that
while the metabolites do enhance glucose stimulated insulin secretion, it appears to
be through extra mitochondrial modifications.
3.3 Discussion
The premise of this study was to explore the possibility that the unique activities of
microbial flavonoid metabolites on peripheral tissues may contribute to the observed
bioactivities of native dietary flavonoids. In other words, can dietary flavonoids
exert significant bioactivities despite poor bioavailability, or is bioavailability of the
native dietary species at peripheral target tissues indeed the primary limiting factor
for bioactivity in vivo?
Our central hypothesis, spanning this study and others in progress, is that the
systemic, peripheral tissue activities of microbial metabolites may account for a
significant portion of observed bioactivity following dietary flavonoid exposure in
vivo.

The present results demonstrate the potent activities of flavonoid microbial
metabolites, particularly for preservation of β-cell function, enhancement of skeletal
muscle glucose utilization and protection of skeletal muscle respiratory function
from oxidative injury, Therefore, these data suggest that further investigation of the
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anti-diabetic activities of flavonoid microbial metabolites is warranted. Additionally,
our data suggest that metabolites and native compounds may act by distinct
mechanisms, suggesting complementary and synergistic activities in vivo.
Specifically, our data demonstrate that the gut metabolites enhance β-cell glucose
stimulated insulin secretion more effectively than EC. Furthermore, unlike EC, these
metabolites appear to do this without enhancing mitochondrial respiration or
increasing expression of mitochondrial electron transport chain components, and
with varying effects on β-cellinsulin content. Insulin secretion is dependent on ATP
production in the β-cell due to glycolysis, TCA cycle and the ETC. In addition, the
increases in ATP closes K+ channels which cause membrane depolarization and
opening of Ca2+ channels which allow Ca2+ influx. The modulation of these two
channels is an area of future interest in determine how the metabolites enhance
glucose stimulated insulin secretion. In skeletal muscle, these compounds appear to
enhance glucose utilization, but do not appear to enhance respiration under normal
conditions. Therefore, mitochondrial uncoupling does not appear to be a mechanism
by which these compounds can prevent obesity and glucose intolerance, with the
exception of HA and 5PVA at high doses. However, they do appear to
significantlyprotect respiratory function against oxidative injury. The objective of
these respiration experiments was to evaluate the impacts of the selected compounds
on overall respiration. Future mechanistic experiments, including use of ETC
complex inhibitors as well as comparing intact cells, permeabilized cells and
isolated mitochondria, will be useful to elucidate the specific mechanisms by which
the microbial metabolites exert these effects on respiration. Future work will also
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provide new insight that address some of the current study limitations, such as
examining compound efficacy in differentiated muscle myotubes from mouse and
human (to compliment myoblast studies that were conducted herein).
The results presented here make significant additions to the small, yet growing, body
of published data indicating that flavonoid microbial metabolites likely account for a
significant fraction of many observed bioactivities of dietary flavonoids, particularly
those with poor oral bioavailability of the native forms. These data help to explain
epidemiological and experimental data suggesting that some dietary flavonoids (and
potentially other classes of compounds, such as curcuminoids)possess potent
bioactivities despite poor oral bioavailability. These results also suggest that the
metabolites may be equally important to, if not more important than (in some cases),
the native forms for in vitro mechanistic studies in cell culture models that attempt to
recapitulate effects in peripheral tissues (hepatic, adipose, pancreatic, skeletal
muscle, endothelial and other cell models). This is particularly true at compound
doses in the mid to high μM range, which are commonly used for bioactives in cell
culture but which are much more likely to be obtained by the microbial metabolites
than the native dietary forms
Moving forward, there is a need to further identify the most active individual
metabolites (or metabolite profiles) that confer systemic benefits, to understand the
characteristics of the microbiome that facilitate generation of these profiles, and to
understand how interindividual variability in microbial metabolism affects
subsequent metabolite profiles and bioactivities [49]. This knowledge will be critical
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for development of strategies to fully exploit the potential health benefits of dietary
flavonoids. While initial studies have used antibiotics to eliminate the effect of the
microbiome and microbiome-derived metabolites [30,31], germ-free and other
gnotobiotic models will be instrumental in elucidation of the role of the microbiome
in mediating the beneficial effects of poorly-bioavailable flavonoids. Furthermore,
large-scale screening of several dozen (if not libraries of several hundred) microbial
metabolites in peripheral tissue cell culture models will need to be performed in
order to understand the tissue-specific mechanisms by which these compounds exert
their activities. This will require advances in commercial availability of some
metabolites, specifically the valerolactones, which to our knowledge are not
currently available. It will also be important to conduct full dose-dependence studies
of these metabolites. Furthermore,
in vitro anaerobic fecal fermentations of flavonoids, with assessment of the

bioactivity before and after fermentation in vitro and in vivo (via i.p. administration of
filter-sterilized supernatants) will be useful to identify broad effects of microbial
transformation.
It is important to note that we did not study valerolactones, which are among the
early microbial metabolites of flavonoids. These compounds are present in high
concentrations in circulation following flavonoid intake, and represent important
compounds that may possess significant bioactivities. We did not study these
compounds due to the lack of commercial availability, which is a significant
obstacle for understanding their activities. Due to the provocative data in the present
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work, future work is needed to generate, isolate, and elucidate the activity of
valerolactones. Two possible approaches include isolation from in vivo or ex vivo
fecal fermentation mixtures, as well as synthetic approaches. These will need to be
performed in order to complete our understanding of the potential bioactivities of
flavonoid microbial metabolites.
It is also important to note that these microbial metabolites exist in circulation in the
unconjugated forms studied, as well as Phase-II conjugates (sulfate, O-methyl and
glucuronide forms) produced in enterocytes and hepatocytes following their
absorption [50]. While the present work focused on the unconjugated forms, future
work needs to be performed to elucidate the bioactivities of the conjugated forms.
Such transformations can be performed using enterocytes, hepatocytes, liver
microsomes, or isolated conjugating enzymes. Such studies will further advance the
overall objective of the present work which is to understand the bioactivities of the
actual circulating profile of compounds
(unconjugated and phase-II conjugates of both native dietary flavonoids and their
microbial metabolites) as opposed to just the native, unconjugated forms (i.e. the
majority of existing studies).
4. CONCLUSION
In summary, our data demonstrate that flavonoid microbial metabolites stimulate βcell function, as well as glucose utilization and mitochondrial respiration in skeletal
muscle.
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These data support the hypothesis that dietary flavonoids may exert significant
activity despite poor bioavailability via their microbial metabolites. This raises the
intriguing prospect that bioavailability of native flavonoids may not be as critical of
a limiting factor to bioactivity as previously thought. If, in fact, bioavailability of
native flavonoids is not as crucial as currently thought, this would represent a
paradigm shift in the thinking regarding how to exploit the activities of flavonoids in
the diet. While development of strategies to enhance bioavailability of native
compounds should not be discontinued, exploration of strategies that do not require
bioavailability should receive extensive consideration as a parallel complementary
approach to solving the same problem. Our overall logic for the proposed
experiments moving forward is that we are quickly approaching an asymptote
(diminishing novel returns) in terms of what we can learn from further studies
focusing on the activities of native flavonoids. New approaches are now needed to
answer the complex questions remaining.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

5. ACKNOWLEDGEMENT
Funding for this work was provided, in part, by the Virginia Agricultural Experiment Station and the Hatch
Program of the National Institute of Food and Agriculture, U.S. Department of Agriculture (APN and DAB), American
Diabetes Association (1-JF-05–24 to MWH), the National Institutes of Health-NIDDK (2RO1
DK-078765), R01 HL123647 to DAB), BYU mentoring environment grant (JST), BYU ORCA Grant (BFB), American
Diabetes Association (1–17-IBS-101 to JST), and a grant from the Diabetes Action Research and Education Foundation (Grant
#461 to JST).
Grants, sponsors, and funding sources: Funding for this work was provided, in part, by the Virginia Agricultural Experiment
Station and the Hatch Program of the National Institute of Food and Agriculture, U.S. Department of
Agriculture (APN and DAB), American Diabetes Association (1-JF-05–24 to MWH), the National Institutes of
Health-NIDDK (2RO1 DK078765), R01 HL123647 to DAB), BYU mentoring environment grant (JST), BYU ORCA Grant
(BFB), American Diabetes Association (1–17-IBS-101 to JST), and a grant from the Diabetes Action Research and Education
Foundation (Grant #461 to JST).

276

REFERENCES
[1]. Guo Y, Bruno RS. Endogenous and exogenous mediators of quercetin bioavailability. J Nutr Biochem
2015;26:201–10. doi:10.1016/j.jnutbio.2014.10.008. [PubMed: 25468612]
[2]. Stefanie Wiese, Tuba Esatbeyoglu, Peter Winterhalter, Peter Kruse Hans, Stephanie Winkler, Achim Bub, et
al. Comparative biokinetics and metabolism of pure monomeric, dimeric, and polymeric flavan-3-ols: A
randomized cross-over study in humans. Mol Nutr Food Res
2015;59:610–21. doi:10.1002/mnfr.201400422. [PubMed: 25546356]
[3]. Mulder TPJ, van Platerink CJ, Wijnand Schuyl PJ, van Amelsvoort JMM. Analysis of theaflavins in
biological fluids using liquid chromatography–electrospray mass spectrometry. J Chromatogr B Biomed
Sci App 2001;760:271–9. doi:10.1016/S03784347(01)00285-7.
[4]. González-Sarrías A, Espín JC, Tomás-Barberán FA. Non-extractable polyphenols produce gut microbiota
metabolites that persist in circulation and show anti-inflammatory and free radicalscavenging effects.
Trends Food Sci Technol 2017;69:281–8. doi:10.1016/j.tifs.2017.07.010.
[5]. Ulaszewska MM, Trost K, Stanstrup J, Tuohy KM, Franceschi P, Chong MF-F, et al. Urinary metabolomic
profiling to identify biomarkers of a flavonoid-rich and flavonoid-poor fruits and vegetables diet in adults:
the FLAVURS trial. Metabolomics 2016;12:32. doi:10.1007/ s11306-015-0935-z.
[6]. Mulder TP, Rietveld AG, van Amelsvoort JM. Consumption of both black tea and green tea results in an
increase in the excretion of hippuric acid into urine. Am J Clin Nutr 2005;81:256S–260S. [PubMed:
15640488]
[7]. Pereira-Caro G, Moreno-Rojas JM, Brindani N, Del Rio D, Lean MEJ, Hara Y, et al. Bioavailability of
Black Tea Theaflavins: Absorption, Metabolism, and Colonic Catabolism. J Agric Food Chem
2017;65:5365–74. doi:10.1021/acs.jafc.7b01707. [PubMed: 28595385]
[8]. Chen H, Hayek S, Guzman JR, Gillitt ND, Ibrahim SA, Jobin C, et al. The Microbiota Is Essential for the
Generation of Black Tea Theaflavins-Derived Metabolites. PLOS ONE 2012;7:e51001.
doi:10.1371/journal.pone.0051001. [PubMed: 23227227]
[9]. Goodrich KM, Smithson AT, Ickes AK, Neilson AP. Pan-colonic pharmacokinetics of catechins and
procyanidins in male Sprague–Dawley rats. J Nutr Biochem 2015;26:1007–14. [PubMed: 26026837]
[10]. Lin W, Wang W, Yang H, Wang D, Ling W. Influence of Intestinal Microbiota on the Catabolism of
Flavonoids in Mice. J Food Sci n.d;81:H3026–34. doi:10.1111/17503841.13544.
[11]. Serra A, Macià A, Romero M-P, Reguant J, Ortega N, Motilva M-J. Metabolic pathways of the colonic
metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem
2012;130:383–93. doi:10.1016/j.foodchem.2011.07.055.
[12]. Castello F, Costabile G, Bresciani L, Tassotti M, Naviglio D, Luongo D, et al. Bioavailability and
pharmacokinetic profile of grape pomace phenolic compounds in humans. Arch Biochem Biophys
2018;646:1–9. doi:10.1016/j.abb.2018.03.021. [PubMed: 29580945]
[13]. Henning Susanne M., Piwen Wang, Narine Abgaryan, Roberto Vicinanza, de Oliveira Daniela Moura,
Yanjun Zhang, et al. Phenolic acid concentrations in plasma and urine from men consuming green or black
tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res 2013;57:483–93.
doi:10.1002/mnfr.201200646. [PubMed: 23319439]
[14]. Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, et al. Population nutrikinetics of green
tea extract. PLOS ONE 2018;13:e0193074. doi:10.1371/journal.pone. 0193074. [PubMed: 29466429]
[15]. Clifford MN, Hooft VD, Jj J, Crozier A. Human studies on the absorption, distribution, metabolism, and
excretion of tea polyphenols. Am J Clin Nutr 2013;98:1619S–1630S. doi:
10.3945/ajcn.113.058958. [PubMed: 24172307]
[16]. Kawser Hossain M, Abdal Dayem A, Han J, Yin Y, Kim K, Kumar Saha S, et al. Molecular
Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids. Int J Mol Sci
2016;17:569. doi:10.3390/ijms17040569. [PubMed: 27092490]
[17]. Amiot MJ, Riva C, Vinet A Effects of dietary polyphenols on metabolic syndrome features in humans: a
systematic review. Obes Rev 2016;17:573–86. doi:10.1111/obr.12409. [PubMed: 27079631]
[18]. Gu Y, Hurst WJ, Stuart DA, Lambert JD. Inhibition of Key Digestive Enzymes by Cocoa Extracts and
Procyanidins. J Agric Food Chem 2011;59:5305–11. doi:10.1021/jf200180n. [PubMed: 21495725]

277

[19]. Ryan CM, Khoo W, Ye L, Lambert JD, O’Keefe SF, Neilson AP. Loss of Native Flavanols during
Fermentation and Roasting Does Not Necessarily Reduce Digestive EnzymeInhibiting Bioactivities of
Cocoa. J Agric Food Chem 2016;64:3616–25. doi:10.1021/acs.jafc.6b01725. [PubMed: 27094258]
[20]. Bitzer ZT, Glisan SL, Dorenkott MR, Goodrich KM, Ye L, O’Keefe SF, et al. Cocoa procyanidins with
different degrees of polymerization possess distinct activities in models of colonic inflammation. J Nutr
Biochem 2015. doi:10.1016/j.jnutbio.2015.02.007.
[21]. Masumoto S, Terao A, Yamamoto Y, Mukai T, Miura T, Shoji T. Non-absorbable apple procyanidins
prevent obesity associated with gut microbial and metabolomic changes. Sci Rep
2016;6:31208. doi:10.1038/srep31208. [PubMed: 27506289]
[22]. Dorenkott MR, Griffin LE, Goodrich KM, Thompson-Witrick KA, Fundaro G, Ye L, et al. Oligomeric
cocoa procyanidins possess enhanced bioactivity compared to monomeric and polymeric cocoa
procyanidins for preventing the development of obesity, insulin resistance, and impaired glucose tolerance
during high-fat feeding. J Agric Food Chem 2014;62:2216–27.
[PubMed: 24559282]
[23]. Larrosa M, Luceri C, Vivoli E, Pagliuca C, Lodovici M, Moneti G, et al. Polyphenol metabolites from
colonic microbiota exert anti-inflammatory activity on different inflammation models. Mol Nutr Food Res
2009;53:1044–54. doi:10.1002/mnfr.200800446. [PubMed: 19557820]
[24]. Qian Y, Babu PVA, Symons JD, Jalili T. Metabolites of flavonoid compounds preserve indices of
endothelial cell nitric oxide bioavailability under glucotoxic conditions. Nutr Diabetes
2017;7:e286. doi:10.1038/nutd.2017.34. [PubMed: 28892039]
[25]. Ho GTT, Kase ET, Wangensteen H, Barsett H. Phenolic Elderberry Extracts, Anthocyanins, Procyanidins,
and Metabolites Influence Glucose and Fatty Acid Uptake in Human Skeletal Muscle Cells. J Agric Food
Chem 2017;65:2677–85. doi:10.1021/acs.jafc.6b05582. [PubMed: 28303711]
[26]. Carrasco-Pozo C, Gotteland M, Castillo RL, Chen C. 3,4-dihydroxyphenylacetic acid, a microbiota-derived
metabolite of quercetin, protects against pancreatic β-cells dysfunction induced by high cholesterol. Exp
Cell Res 2015;334:270–82. doi:10.1016/j.yexcr.2015.03.021. [PubMed: 25845496]
[27]. Fernández-Millán E, Ramos S, Alvarez C, Bravo L, Goya L, Martín MÁ. Microbial phenolic metabolites
improve glucose-stimulated insulin secretion and protect pancreatic beta cells against tert-butyl
hydroperoxide-induced toxicity via ERKs and PKC pathways. Food Chem Toxicol
2014;66:245–53. doi:10.1016/j.fct.2014.01.044. [PubMed: 24491264]
[28]. Xue H, Xie W, Jiang Z, Wang M, Wang J, Zhao H, et al. 3,4-Dihydroxyphenylacetic acid, a microbiotaderived metabolite of quercetin, attenuates acetaminophen (APAP)-induced liver injury through activation
of Nrf-2. Xenobiotica 2016;46:931–9. doi:
10.3109/00498254.2016.1140847. [PubMed: 26931552]
[29]. Lee CC, Kim JH, Kim JS, Oh YS, Han SM, Park JHY, et al. 5-(3′,4′-Dihydroxyphenylγvalerolactone), a
Major Microbial Metabolite of Proanthocyanidin, Attenuates THP-1 Monocyte-Endothelial Adhesion. Int J
Mol Sci 2017;18:1363. doi:10.3390/ijms18071363.
[30]. Wen Liu, Shaoqian Zhao, Jiqiu Wang, Juan Shi, Yingkai Sun, Weiqing Wang, et al. Grape seed
proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high‐fat
diet mice. Mol Nutr Food Res 2017;61:1601082. doi:10.1002/mnfr.201601082.
[31]. Esposito D, Damsud T, Wilson M, Grace MH, Strauch R, Li X, et al. Black Currant Anthocyanins
Attenuate Weight Gain and Improve Glucose Metabolism in Diet-Induced Obese Mice with Intact, but Not
Disrupted, Gut Microbiome. J Agric Food Chem 2015;63:6172–80.
doi:10.1021/acs.jafc.5b00963. [PubMed: 26066489]
[32]. Brown EM, McDougall GJ, Stewart D, Pereira-Caro G, González-Barrio R, Allsopp P, et al. Persistence of
Anticancer Activity in Berry Extracts after Simulated Gastrointestinal Digestion and Colonic Fermentation.
PLOS ONE 2012;7:e49740. doi:10.1371/journal.pone.0049740. [PubMed: 23185422]
[33]. Kim D-H, Jung E-A, Sohng I-S, Han J-A, Kim T-H, Han MJ. Intestinal bacterial metabolism of flavonoids
and its relation to some biological activities. Arch Pharm Res 1998;21:17–23. doi:
10.1007/BF03216747. [PubMed: 9875509]
[34]. van der Pijl PC, Foltz M, Glube ND, Peters S, Duchateau G. Pharmacokinetics of black teaderived phenolic
acids in plasma. J Funct Foods 2015;17:667–75. doi:10.1016/j.jff. 2015.06.020.
[35]. Frisard MI, McMillan RP, Marchand J, Wahlberg KA, Wu Y, Voelker KA, et al. Toll-like receptor

278

4 modulates skeletal muscle substrate metabolism. Am J Physiol - Endocrinol Metab
2010;298:E988–98. doi:10.1152/ajpendo.00307.2009. [PubMed: 20179247]
[36]. Anderson AS, Roberts PC, Frisard MI, McMillan RP, Brown TJ, Lawless MH, et al. Metabolic changes
during ovarian cancer progression as targets for sphingosine treatment. Exp Cell Res
2013;319:1431–42. doi:10.1016/j.yexcr.2013.02.017. [PubMed: 23518387]
[37]. Dai W, Cheung E, Alleman RJ, Perry JB, Allen ME, Brown DA, et al. Cardioprotective Effects of
Mitochondria-Targeted Peptide SBT-20 in two Different Models of Rat Ischemia/Reperfusion.
Cardiovasc Drugs Ther 2016;30:559–66. doi:10.1007/s10557-0166695-9. [PubMed: 27747447]
[38]. Rowley TJ, Bitner BF, Ray JD, Lathen DR, Smithson AT, Dallon BW, et al. Monomeric cocoa catechins
enhance β-cell function by increasing mitochondrial respiration. J Nutr Biochem
2017;49:30–41. doi:10.1016/j.jnutbio.2017.07.015. [PubMed: 28863367]
[39]. Kener KB, Munk DJ, Hancock CR, Tessem JS. High-resolution Respirometry to Measure Mitochondrial
Function of Intact Beta Cells in the Presence of Natural Compounds. J Vis Exp JoVE 2018.
doi:10.3791/57053.
[40]. Hobson A, Draney C, Stratford A, Becker TC, Lu D, Arlotto M, et al. Aurora Kinase A is critical for the
Nkx6.1 mediated β-cell proliferation pathway. Islets 2015;7:e1027854. doi:
10.1080/19382014.2015.1027854. [PubMed: 26030060]
[41]. Tessem JS, Moss LG, Chao LC, Arlotto M, Lu D, Jensen MV, et al. Nkx6.1 regulates islet βcell
proliferation via Nr4a1 and Nr4a3 nuclear receptors. Proc Natl Acad Sci 2014;111:5242–7. doi:
10.1073/pnas.1320953111. [PubMed: 24706823]
[42]. Draney C, Hobson AE, Grover SG, Jack BO, Tessem JS. Cdk5r1 Overexpression Induces Primary β-Cell
Proliferation. J Diabetes Res 2016. doi:10.1155/2016/6375804.
[43]. Reynolds MS, Hancock CR, Ray JD, Kener KB, Draney C, Garland K, et al. β-Cell deletion of
Nr4a1 and Nr4a3 nuclear receptors impedes mitochondrial respiration and insulin secretion. Am J PhysiolEndocrinol Metab 2016;311:E186–201. doi:10.1152/ajpendo.00022.2016. [PubMed: 27221116]
[44]. Ray Jason D, Kener Kyle B, Bitner Benjamin F, Wright Brent J, Ballard Matthew S, Barrett Emily J, et al.
Nkx6.1‐mediated insulin secretion and β‐cell proliferation is dependent on upregulation of c‐Fos. FEBS
Lett 2016;590:1791–803. doi:10.1002/18733468.12208. [PubMed: 27164028]
[45]. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin C-T, et al. Mitochondrial H2O2 emission
and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest
2009;119:573–81. doi:10.1172/JCI37048. [PubMed: 19188683]
[46]. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348 Pt 3:607–14.
[PubMed: 10839993]
[47]. Childress ES, Alexopoulos SJ, Hoehn KL, Santos WL. Small Molecule Mitochondrial Uncouplers and
Their Therapeutic Potential. J Med Chem 2017. doi:10.1021/acs.jmedchem. 7b01182.
[48]. García-Ocaña A, Vasavada RC, Cebrian A, Reddy V, Takane KK, López-Talavera J-C, et al. Transgenic
Overexpression of Hepatocyte Growth Factor in the β-Cell Markedly Improves Islet Function and Islet
Transplant Outcomes in Mice. Diabetes 2001;50:2752–62. doi:10.2337/ diabetes.50.12.2752. [PubMed:
11723058]
[49]. Bolca S, Van de Wiele T, Possemiers S. Gut metabotypes govern health effects of dietary polyphenols.
Curr Opin Biotechnol 2013;24:220–5. doi:10.1016/j.copbio.2012.09.009. [PubMed: 23040410]
[50]. Feliciano RP, Mills CE, Istas G, Heiss C, Rodriguez-Mateos A. Absorption, Metabolism and Excretion of
Cranberry (Poly)phenols in Humans: A Dose Response Study and Assessment of Inter-Individual
Variability. Nutrients 2017;9. doi:10.3390/nu9030268.

279

HIGHLIGHTS
•

Microbial metabolites of flavonoids possess potent activities

•

Metabolites stimulated glucose-stimulated insulin secretion

•

Metabolites stimulated beta-cell respiration

•

Metabolites protected skeletal muscle from oxidative injury

•

Metabolites did not generally uncouple mitochondrial respiration
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Figure 1.

A) Schematic showing representative sequential metabolism of representative
flavonoids [a dimeric procyanidin, and (−)-epicatechin monomer] by the gut
microbiota. B) Structures of (−)-epicatechin and the three representative flavonoid
microbial metabolites employed in this present study.

281

Figure 2.

Fatty acid oxidation in primary human skeletal muscle cells treated with either
hippuric acid, homovanillic acid, 5-phenylvaleric acid, or epicatechin. Complete

oxidation represents evolution of 14CO2 from 14C-labeled palmitate. Incomplete
oxidation represents production of 14C-labeled acid-soluble metabolites (ASM) from
14

C-labeled palmitate. Total oxidation represents the sum of complete and

incomplete oxidation. Values represent mean ± SEM from n=4 replicates,
normalized to vehicle (vehicle expressed as 1). Data were analyzed by 1-way
ANOVA. If a significant treatment effect was detected, Dunnett’s post hoc test was
performed within each compound to compare each dose to the vehicle control.
Significance vs. vehicle control is indicated by: *P ≤ 0.05, **P ≤ 0.01.
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Figure 3.

Glucose oxidation in primary human skeletal muscle cells treated with either
hippuric acid, homovanillic acid, 5-phenylvaleric acid, or epicatechin. Oxidation
represents evolution of 14CO2 from 14C-labeled glucose. Values represent mean ±
SEM from n=4 replicates, normalized to vehicle (vehicle expressed as 1). Data were
analyzed by 1-way ANOVA. If a significant treatment effect was detected,

Dunnett’s post hoc test was performed within each
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Figure 4.

Corrected mitochondrial respiration data for C2C12 cells cells cultured acutely (4h)
in the presence of hippuric acid (HA), homovanillic acid (HVA), 5-phenylvaleric
acid (5PVA), or epicatechin (EC): oxygen consumption rate (OCR) curves for
treatments at 5 μM (A) and 10 μM (B), basal respiration (C), leak respiration (after
oligomycin, D), ATP-dependent respiration (E),maximal respiration (after FCCP, F)
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respiratory reserve (maximal − basal, G), and coupling efficiency (ATP-dependent
respiration/basal respiration, H). Oxygen consumption rate data were normalized by
subtracting non-mitochondrial rates of respiration (after antimycin A, not shown),
and are expressed as pmol O2 per minute per 1.5 × 104 cells. Values represent mean
± SEM from n=8 replicates. Data were analyzed by 1-way ANOVA.
If a significant treatment effect was detected, Dunnett’s post hoc test was performed
within each compound to compare each dose to the vehicle control (H2O).
Significance vs. vehicle control is indicated by: *P ≤ 0.05, **P ≤ 0.01, ***P ≤
0.001, ****P ≤ 0.0001.
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Figure 5.

Corrected mitochondrial respiration data for H2O2-injured C2C12 cells cultured
acutely (4h) in the presence of hippuric acid (HA), homovanillic acid (HVA), 5phenylvaleric acid
(5PVA), or epicatechin (EC): oxygen consumption rate (OCR) curves for treatments
at 5 μM (A) and 10 μM (B), basal respiration (C), leak respiration (after oligomycin,
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D), ATPdependent respiration (E), maximal respiration (after FCCP, F) respiratory
reserve (maximal – basal, G), and coupling efficiency (ATP-dependent
respiration/basal respiration, H). Oxygen consumption rate data were normalized by
subtracting non-mitochondrial rates of respiration (after antimycin A, not shown),
and are expressed as pmol O2 per minute per 1.5 × 104 cells. Values represent mean
± SEM from n=8 replicates. Data were analyzed by 1way ANOVA. If a significant
treatment effect was detected, Dunnett’s post hoc test was performed within each
compound to compare each dose to the vehicle control (H2O) as well

O+H
O ). Significance vs. vehicle control is indicated by: *P ≤ 0.05,
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Figure 6.

Glucose-stimulated insulin secretion in INS-1 derived 832/13 rat β-cells treated with
either hippuric acid, homovanillic acid, 5-phenylvaleric acid, or epicatechin. Values
represent mean ± SEM from n=6 replicates. Data were analyzed by 2-way ANOVA.
If a significant main effect of treatment compound dose was detected, Dunnett’s post
hoc test was performed
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Figure 7.

Total insulin content of INS-1 derived 832/13 rat β-cells cultured in 16.7 mM
glucose treated with either hippuric acid, homovanillic acid, 5-phenylvaleric acid, or
epicatechin. Values represent mean ± SEM from n=6 replicates. Data were analyzed
by 1-way ANOVA. If a significant treatment effect was detected, Dunnett’s post hoc
test was performed to compare each dose to the untreated (0 μM) control.
Significance vs. untreated control is indicated by: *P ≤ 0.05, **P ≤ 0.01, ***P ≤
0.001, ****P ≤ 0.0001.
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Figure 8.

Corrected mitochondrial respiration measured after culturing INS-1 832/13 β-cells
for 24 h in the presence of 0, 5 or 10 μM hippuric acid (HA), homovanillic acid
(HVA), 5phenylvaleric acid (5PVA), or epicatechin (EC): A) 0 (Ctrl) and 5 μM, B)
0 (Ctrl) and 10 μM, C) Basal respiration (2 min), D) glucose-stimulated respiration
(21 min), E) maximal respiration (61 min) and F) respiratory reserve (maxmal −
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basal). Oxygen consumption rate data were normalized by subtracting nonmitochondrial rates of respiration (after antimycin A, not shown), and are expressed
as pmol O2 per minute, normalizer per μg protein. Values represent mean ± SEM
from n=5 replicates. Significance vs. untreated control is indicated by: *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Figure 9.
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A) Expression levels of electron transport chain components ATP5A (Complex V),
UQCR2 (Complex III), MTCO1 (Complex IV), SDHB (Complex II) and NDUFB8
(Complex I) as quantified by Western blotting. Values are presented as mean ± SEM
from n=3 replicates per condition. Data were analyzed by 1-way ANOVA. If a
significant treatment effect was detected, Dunnett’s post hoc test was performed to
compare each dose to the untreated (0 μM) control. Significance vs. untreated
control is indicated by: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. B)
Representative Western blot.
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